

# CITATION REPORT

List of articles citing

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer

DOI: 10.1016/0002-9343(94)90321-2  
American Journal of Medicine, 1994, 97, 418-28.

**Source:** <https://exaly.com/paper-pdf/25301962/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2227	Long-term impact of initial and surgical therapy on papillary and follicular thyroid cancer. <i>American Journal of Medicine</i> , <b>1994</b> , 97, 499-500	2.4	33
2226	Follicular lesions of the thyroid. Does frozen section evaluation alter operative management?. <b>1995</b> , 222, 101-6		115
2225	Surgical management of the patient with papillary cancer. <b>1995</b> , 75, 449-64		17
2224	Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. <b>1995</b> , 76, 1643-54		75
2223	Diagnosis and Management of Thyroid Cancer. <b>1995</b> , 2, 107327489500200		
2222	Radioiodine Therapy for Thyroid Cancer. <b>1995</b> , 24, 803-839		49
2221	Follicular Thyroid Cancer. <b>1995</b> , 24, 761-801		139
2220	Papillary Thyroid Carcinoma. <b>1995</b> , 24, 711-760		95
2219	Thyroglobulin Measurement. <b>1995</b> , 24, 841-863		127
2218	Advances in the management of patients with thyroid disease. <b>1995</b> , 25, 205-20		22
2217	Surgical considerations and approach to thyroid cancer. <b>1996</b> , 25, 115-39		67
2216	Thyroid cancer in children, pregnant women, and patients with Graves' disease. <b>1996</b> , 25, 27-48		55
2215	Prevalence of activating ras mutations in morphologically characterized thyroid nodules. <b>1996</b> , 6, 409-16		90
2214	Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. <b>1996</b> , 172, 692-4		210
2213	Cloning of the human sodium iodide symporter. <b>1996</b> , 226, 339-45		417
2212	Adenoviral infection of thyroid cells: a rationale for gene therapy for metastatic thyroid carcinoma. <b>1996</b> , 120, 921-5		19
2211	Thyroid cancer: differentiated carcinoma. <b>1996</b> , 22, 161-77		24

2210	External radiation and thyroid neoplasia. <b>1996</b> , 25, 181-95	42
2209	Unusual types of thyroid neoplasms. <b>1996</b> , 25, 49-68	68
2208	Thyroid Cancer Nodal Metastases: Biologic Significance and Therapeutic Considerations. <b>1996</b> , 5, 43-63	292
2207	Thyroid cancer and pregnancy. <b>1996</b> , 147-156	0
2206	Changing concepts in the pathogenesis and management of thyroid carcinoma. <b>1996</b> , 46, 261-83	33
2205	Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. <b>1996</b> , 77, 2574-80	123
2204	Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. <b>1996</b> , 78, 493-501	71
2203	Management of thyroid carcinoma with radioactive 131I. <b>1996</b> , 36, 83-6	11
2202	Role of radioiodine in the treatment of local thyroid cancer. <b>1996</b> , 36, 263-5	4
2201	Well differentiated thyroid carcinoma. <b>1996</b> , 8, 281-8	29
2200	Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. <b>1996</b> , 81, 1724-5	40
2199	Treatment Guidelines for Patients With Thyroid Nodules and Well-Differentiated Thyroid Cancer. <b>1996</b> , 156, 2165	247
2198	Follicular thyroid cancer. <b>1996</b> , 8, 969-76	1
2197	Epithelial cell thyroid cancer and thyroid stimulating hormone--when less is more. <b>1997</b> , 82, 9-10	7
2196	Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. <b>1997</b> , 138, 3133-40	66
2195	Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. <b>1997</b> , 82, 3553-62	296
2194	Follow-up of patients with thyroid carcinoma. <b>1997</b> , 337, 928-30	44
2193	Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy. <b>1997</b> , 7, 63-6	26

2192	Validity of risk group definition in differentiated thyroid carcinoma. <b>1997</b> , 4, 459-464	2
2191	131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?. <b>1997</b> , 7, 669-72	57
2190	The role of surgery in the management of differentiated thyroid cancer. <b>1997</b> , 20, 32-5	11
2189	Papillary thyroid carcinoma: the last steps for an optimal treatment?. <b>1997</b> , 44, 199-202	
2188	The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. <b>1997</b> , 24, 722-7	39
2187	Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. <b>1997</b> , 337, 888-96	357
2186	Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. <b>1997</b> , 7, 265-71	184
2185	Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. <b>1997</b> , 174, 462-8	85
2184	Prognostic Factors in Thyroid Carcinoma. <b>1997</b> , 6, 555-598	35
2183	Evaluation and management of common thyroid disorders in women. <b>1997</b> , 176, 507-14	32
2182	Chemotherapie bei Schilddrüsenkarzinomen: Indikation und Ergebnisse. <b>1997</b> , 3, 55-58	10
2181	[Prognostic factors in differentiated thyroid gland carcinoma]. <b>1997</b> , 18, 275-85	3
2180	The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. <b>1997</b> , 47, 713-20	26
2179	Papillary thyroid carcinoma: demographics, treatment, and outcome in eleven pediatric patients treated at a single institution. <b>1997</b> , 28, 433-40	17
2178	A comparison of different staging systems predictability of patient outcome. <b>1997</b> , 79, 2414-2423	204
2177	Perspective: National Cancer Institute summary report about estimated exposures and thyroid doses received from iodine 131 in fallout after Nevada atmospheric nuclear bomb tests. <b>1998</b> , 48, 285-98	20
2176	The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. <b>1998</b> , 82, 375-388	302
2175	Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. <b>1998</b> , 83, 553-9	284

2174	Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. <b>1998</b> , 83, 1012-21	296
2173	Staging in thyroid carcinoma. <b>1998</b> , 83, 844-7	42
2172	Staging of thyroid carcinoma--reply. <b>1998</b> , 83, 848-50	34
2171	A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. <b>1998</b> , 83, 2638-48	1294
2170	Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. <b>1998</b> , 20, 549-55	62
2169	Therapeutic strategies and long-term results in differentiated thyroid cancer. <b>1998</b> , 67, 52-9	9
2168	Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. <b>1998</b> , 383, 160-3	52
2167	Lymph node dissection in patients with differentiated thyroid carcinoma--who benefits?. <b>1998</b> , 383, 355-8	34
2166	Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131)I therapy. <b>1998</b> , 5, 329-37	24
2165	The risks of thyroidectomy: words of caution for referring physicians. <b>1998</b> , 13, 60-1	6
2164	An audit of the management of thyroid cancer in a district general hospital. <b>1998</b> , 48, 419-24	15
2163	Trends in treatment and long-term survival of thyroid cancer in southeastern Netherlands, 1960-1992. <b>1998</b> , 34, 1235-41	18
2162	The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer. <b>1998</b> , 33, 1134-8; discussion 1139-40	40
2161	Overexpression of TTF-1 and PAX-8 restores thyroglobulin gene promoter activity in ARO and WRO cell lines. <b>1998</b> , 124, 1100-5	26
2160	Management of the neck in thyroid cancer. <b>1998</b> , 31, 823-31	100
2159	Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports. <b>1998</b> , 21, 392-8	9
2158	Papillary and follicular thyroid carcinoma. <b>1998</b> , 338, 297-306	1204
2157	Drug therapy alternatives in the treatment of thyroid cancer. <b>1998</b> , 55, 801-12	16

2156	Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. <b>1998</b> , 47, 325-30	35
2155	[Differentiated thyroid gland carcinoma in children and adolescents]. <b>1998</b> , 210, 373-8	9
2154	Effect of early referral to an endocrinologist on efficiency and cost of evaluation and development of treatment plan in patients with thyroid nodules. <b>1998</b> , 83, 3803-7	37
2153	Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. <b>1998</b> , 83, 2675-80	109
2152	The use of radioactive iodine in patients with papillary and follicular thyroid cancer. <b>1998</b> , 83, 4195-203	120
2151	Outcome of differentiated thyroid cancer in Graves' patients. <b>1998</b> , 83, 2805-9	95
2150	Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. <b>1998</b> , 8, 737-44	239
2149	Solitary cerebellar metastasis from papillary thyroid carcinoma: a case report. <b>1998</b> , 8, 327-35	30
2148	Sentinel Lymphadenectomy in Thyroid Malignant Neoplasms—Invited Commentary. <b>1998</b> , 133, 292	
2147	Sentinel lymphadenectomy in thyroid malignant neoplasms. <b>1998</b> , 133, 288-92	147
2146	Thyroid nodules: malignant or benign?. <b>1998</b> , 33, 143-4, 147-8, 153-6	0
2145	Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. <b>1998</b> , 133, 89-93	57
2144	Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer: Towards A Selective Approach. <b>1998</b> , 83, 4201-4203	8
2143	Changing trends and prognoses for patients with papillary thyroid cancer. <b>1998</b> , 133, 1058-65	20
2142	Hormone Replacement Therapy and Cancer (Part 2). <b>1998</b> , 20, 1353-1354	
2141	Postoperative prognosis of intrathyroidal papillary thyroid carcinoma: long-term (35-45 year) follow-up study. <b>1998</b> , 45, 475-84	13
2140	Management of Follicular and Hürthle Cell Neoplasms of the Thyroid Gland. <b>1998</b> , 7, 893-910	31
2139	Papillary Thyroid Carcinoma. <b>1998</b> , 7, 645-663	21

2138	Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. <b>1998</b> , 129, 622-7	132
2137	[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. <b>1999</b> , 84, 2291-302	210
2136	Thyroid microcarcinoma: prevalence, prognosis, and management. <b>1999</b> , 5, 148-56	32
2135	Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. <b>1999</b> , 9, 105-11	132
2134	A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. <b>1999</b> , 84, 3877-85	378
2133	Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. <b>1999</b> , 84, 4037-42	57
2132	Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. <b>1999</b> , 84, 4549-53	27
2131	Immunohistochemical study of thrombospondin and its receptors alpha root of beta 3 and CD36 in normal thyroid and in thyroid tumours. <b>1999</b> , 52, 895-900	10
2130	Cervicomedial magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits. <b>1999</b> , 9, 591-7	15
2129	Analyses of the outcome of locally invasive papillary thyroid carcinomas. <b>1999</b> , 9, 1017-22	10
2128	Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases. <b>1999</b> , 6, 109-15	40
2127	Differentiated thyroid cancer: a retrospective analysis of 832 cases from Greece. <b>1999</b> , 50, 643-54	19
2126	The management of the solitary thyroid nodule: a review. <b>1999</b> , 24, 388-97	25
2125	Complications associated with different surgical approaches to differentiated thyroid carcinoma. <b>1999</b> , 384, 50-3	35
2124	Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. <b>1999</b> , 16, 12-5	21
2123	Surgical management of laryngotracheal and esophageal involvement by locally advanced thyroid cancer. <b>1999</b> , 16, 19-29	41
2122	Adjuvant therapy and long-term management of differentiated thyroid carcinoma. <b>1999</b> , 16, 30-3	2
2121	Surveillance of patients to detect recurrent thyroid carcinoma. <b>1999</b> , 85, 945-51	31

2120	Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. <b>1999</b> , 18, 1627-40	78
2119	An overview of the management of papillary and follicular thyroid carcinoma. <b>1999</b> , 9, 421-7	287
2118	Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. <b>1999</b> , 126, 1195-8; discussion 1198-9	50
2117	Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. <b>1999</b> , 126, 1173-81; discussion 1181-2	71
2116	Predictive factors for node involvement in papillary thyroid carcinoma. Univariate and multivariate analyses. <b>1999</b> , 35, 420-3	39
2115	Oncogene profile of papillary thyroid carcinoma. <b>1999</b> , 125, 46-52	73
2114	Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma. <b>1999</b> , 34, 1799-804	53
2113	Thyroid cancer with concurrent hyperthyroidism. <b>1999</b> , 134, 130-4	24
2112	Prognostic indicators in differentiated thyroid carcinoma. <b>2000</b> , 7, 229-39	128
2111	Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. <b>2000</b> , 21, 521-8	23
2110	Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. <b>2000</b> , 21, 529-32	44
2109	Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic tests. <b>2000</b> , 21, 991-1000	15
2108	Prognostic importance of vascular invasion in papillary thyroid carcinoma. <b>2000</b> , 126, 309-12	77
2107	Comparative analysis of thyroid carcinoma in Germany and the U.S. <b>2000</b> , 89, 1-4	3
2106	Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. <b>2000</b> , 89, 202-17	397
2105	Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma. <b>2000</b> , 90, 357-363	177
2104	Metalloproteinase-9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. <b>2000</b> , 22, 373-9	12
2103	Ablation of the thyroid remnant and I dose in differentiated thyroid cancer. <b>2000</b> , 52, 765-773	72



2102	Subclinical thyroid disease after radiation therapy detected by radionuclide scanning. <b>2000</b> , 48, 181-8	6
2101	Long-standing lateral neck mass as the initial manifestation of well-differentiated thyroid carcinoma. <b>2000</b> , 110, 204-9	15
2100	Systemic radiation therapy with unsealed radionuclides. <b>2000</b> , 10, 94-102	10
2099	Death from thyroid cancer of follicular cell origin. <b>2000</b> , 191, 600-6	34
2098	Follicular thyroid cancer: an update. <b>2000</b> , 57, 566-570	
2097	The use of recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. <b>2000</b> , 1, 147-54	2
2096	Thyroid cancer surgery. <b>2000</b> , 1, 155-63	6
2095	Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. <b>2000</b> , 1, 173-81	12
2094	Initial treatment of differentiated thyroid carcinoma. <b>2000</b> , 1, 139-45	10
2093	Solitary brain metastasis from papillary thyroid carcinoma in a patient with depression: report of a case. <b>2000</b> , 30, 827-30	9
2092	Optimizing the management of differentiated thyroid cancer. <b>2000</b> , 12, 363-4	1
2091	Radioiodine treatment for differentiated thyroid cancer. <b>2000</b> , 12, 365-72	22
2090	Northern Cancer Network Guidelines for Management of Thyroid Cancer. <b>2000</b> , 12, 373-391	
2089	Prognostic factors in patients with differentiated thyroid carcinoma. <b>2000</b> , 166, 29-33	53
2088	Multiple brain metastases from a diffuse sclerosing variant of papillary carcinoma of the thyroid. <b>2000</b> , 11, 97-108	14
2087	Papillary thyroid cancer. <b>2000</b> , 1, 329-38	4
2086	Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. <b>2000</b> , 27, 833-41	110
2085	Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. <b>2000</b> , 27, 1465-72	16

2084	The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. <b>2000</b> , 27, 431-40	49
2083	Thyroid cancer: 1999 update. <b>2000</b> , 7, 376-98	35
2082	Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. <b>2000</b> , 6, 469-76	135
2081	Surgical management of thyroid cancer. <b>2000</b> , 6, 465-8	3
2080	Management of thyroid cancer: radioiodine ablation, "stunning," and treatment of thyroglobulin-positive, (131)I scan-negative patients. <b>2000</b> , 6, 401-6	17
2079	Analysis of the results of phase III controlled clinical trials with recombinant human thyrotropin: developing a clinical guide. <b>2000</b> , 6, 391-5	1
2078	Lymphatic Metastasis and Sentinel Lymphonodectomy. <b>2000</b> ,	3
2077	Tall cell variant: An aggressive form of papillary thyroid carcinoma. <b>2000</b> , 122, 352-357	8
2076	Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy. <b>2000</b> , 10, 975-9	25
2075	Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. <b>2000</b> , 13, 861-5	138
2074	[Pro and contra lymphadenectomy in papillary and follicular thyroid gland carcinoma]. <b>2000</b> , 125, 835-40; discussion 840-1	2
2073	Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. <b>2000</b> , 85, 175-8	266
2072	Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. <b>2000</b> , 85, 1107-13	205
2071	[The significance of lymph node status in papillary and follicular thyroid gland carcinoma for the nuclear medicine physician]. <b>2000</b> , 125, 830-4	3
2070	Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?. <b>2000</b> , 10, 573-7	108
2069	Upper retropharyngeal node involvement in differentiated thyroid carcinoma demonstrated by 131I scintigraphy. <b>2000</b> , 73, 1260-4	16
2068	Local control in differentiated thyroid carcinoma with extrathyroidal invasion. <b>2000</b> , 179, 86-91	26
2067	Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. <b>2000</b> , 179, 457-61	61

2066	Tall cell variant: an aggressive form of papillary thyroid carcinoma. <b>2000</b> , 122, 352-7	83
2065	[A swelling of the sternum during respiration]. <b>2000</b> , 21, 1126-7	
2064	Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. <b>2000</b> , 30, 98-106	28
2063	Thyroid cancer in children: the Royal Marsden Hospital experience. <b>2000</b> , 36, 214-20	86
2062	Serum thyroglobulin levels after thyroxine withdrawal in patients with low risk papillary thyroid carcinoma. <b>2000</b> , 10, 165-9	6
2061	Incidentally discovered papillary carcinoma of the thyroid: value of ultrasonographic follow-up. A case-report. <b>2000</b> , 23, 251-4	9
2060	Surgical approach to thyroid nodules and cancer. <b>2000</b> , 14, 651-66	8
2059	Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. <b>2001</b> , 28, 198-202	37
2058	Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. <b>2001</b> , 129, 552-8	133
2057	Conservative management of patients with intrathyroidal well-differentiated follicular thyroid carcinoma. <b>2001</b> , 130, 30-5	21
2056	Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. <b>2001</b> , 130, 921-30	91
2055	Accuracy of sentinel lymph node in papillary thyroid carcinoma. <b>2001</b> , 130, 907-13	47
2054	Propuesta 2000 para el tratamiento y seguimiento del carcinoma diferenciado de tiroides. <b>2001</b> , 48, 70-77	1
2053	Serum thyroglobulin measurement. Utility in clinical practice. <b>2001</b> , 30, 429-67	75
2052	[Evidence based medicine. Generalizations on the application to nuclear medicine. Part I]. <b>2001</b> , 20, 313-28; quiz 329-31	3
2051	The sentinel node procedure with Patent Blue V dye in the surgical treatment of papillary thyroid carcinoma. <b>2001</b> , 121, 421-4	39
2050	Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. <b>2001</b> , 11, 1025-30	39
2049	Management of thyroglobulin positive/whole-body scan negative: is Tg positive/ <sup>131</sup> I therapy useful?. <b>2001</b> , 24, 194-8	11

2048	Surgical management of the neck in thyroid cancer. <b>2001</b> , 63, 63-5	3
2047	Predictive Value of Thyroglobulin Changes for the Efficacy of Thyroid Remnant Ablation. <b>2001</b> , 87, 42-46	1
2046	Carcinoma folicular de tireóide: estudo retrospectivo. <b>2001</b> , 28, 319-322	
2045	Authors' Response: Metabolic Abnormalities in Patients with Adrenal Incidentaloma. <b>2001</b> , 86, 951-952	
2044	Practical application of recombinant thyrotropin testing in clinical practice. <b>2001</b> , 7, 195-201	9
2043	Histologic variants of papillary thyroid carcinoma. <b>2001</b> , 7, 139-42	10
2042	Authors' Response: Dietary Protein and Fiber Intake and Sex Hormone-Binding Globulin. <b>2001</b> , 86, 950-950	
2041	Recovery-test or immunoradiometric measurement of anti-thyroglobulin autoantibodies. <b>2001</b> , 40, 155-163	13
2040	Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma. <b>2001</b> , 22, 1021-7	31
2039	Recombinant human thyrotropin in the management of thyroid cancer. <b>2001</b> , 13, 39-43	29
2038	Management of the N0 neck in thyroid malignancy. <b>2001</b> , 9, 85-89	
2037	Human telomerase reverse transcriptase expression in Diff-Quik-stained FNA samples from thyroid nodules. <b>2001</b> , 10, 123-9	22
2036	Distant metastases from thyroid and parathyroid cancer. <b>2001</b> , 63, 243-9	58
2035	Scoring patients' risk in differentiated thyroid cancer. <b>2001</b> , 24, 561-8	3
2034	An audit of management of differentiated thyroid cancer in specialist and non-specialist clinic settings. <b>2001</b> , 54, 719-23	27
2033	Thyroid cancer in the UK: can we do it better?. <b>2001</b> , 54, 705-6	4
2032	Differentiated thyroid carcinoma in the elderly. <b>2001</b> , 38, 79-91	15
2031	Minimal residual disease in thyroid carcinoma. <b>2001</b> , 20, 272-7	11

2030	A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. <b>2001</b> , 91, 505-24	173
2029	Sentinel lymph node biopsy in patients with papillary thyroid carcinoma. <b>2001</b> , 92, 2868-74	76
2028	[Thyroid cancers: the Geneva experience]. <b>2001</b> , 126, 969-76	
2027	Cause of death in patients with well-differentiated thyroid carcinoma. <b>2001</b> , 111, 989-91	20
2026	CCN proteins are distinct from, and should not be considered members of, the insulin-like growth factor-binding protein superfamily. <b>2001</b> , 86, 944-5	11
2025	An unusual presentation of follicular carcinoma of the thyroid. <b>2001</b> , 11, 591-3	3
2024	Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. <b>2001</b> , 11, 953-7	59
2023	Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. <b>2001</b> , 11, 637-45	45
2022	Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. <b>2001</b> , 86, 1568-73	205
2021	Paraneoplastic hypercortisolism as a risk factor for severe infections in patients with malignant diseases. <b>2001</b> , 86, 947-8	3
2020	Hashimoto's encephalitis. <b>2001</b> , 86, 947	7
2019	Dietary protein and fiber intake and sex hormone-binding globulin. <b>2001</b> , 86, 950	1
2018	nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. <b>2001</b> , 86, 3975-80	25
2017	Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. <b>2001</b> , 86, 1447-63	975
2016	Behavior of small thyroid cancers found by screening radiation-exposed individuals. <b>2001</b> , 86, 3711-6	18
2015	Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. <b>2001</b> , 86, 5686-90	142
2014	Metabolic abnormalities in patients with adrenal incidentaloma. <b>2001</b> , 86, 950-2	3
2013	Usefulness of the diagnostic total body scan in differentiated thyroid cancer. <b>2001</b> , 86, 949-50	2

2012	Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. <b>2001</b> , 86, 3327-35	102
2011	Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. <b>2001</b> , 86, 619-25	119
2010	Nomenclature of the insulin-like growth factor-binding protein superfamily. <b>2001</b> , 86, 946	3
2009	Is hydrocortisone clearance 50% slower in the evening than in the morning?. <b>2001</b> , 86, 948-9	1
2008	Leptin actions on the reproductive axis. <b>2001</b> , 86, 946-7	5
2007	Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. <b>2001</b> , 11, 877-81	118
2006	Increasing incidence and characteristics of differentiated thyroid cancer in Huntington, West Virginia. <b>2001</b> , 11, 1063-9	10
2005	Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. <b>2002</b> , 17, 71-82	23
2004	Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. <b>2002</b> , 12, 683-702	157
2003	Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. <b>2002</b> , 12, 37-43	80
2002	Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. <b>2002</b> , 12, 583-90	68
2001	Death from differentiated thyroid carcinoma: retrospective study of a 40-year investigation. <b>2002</b> , 17, 507-14	10
2000	Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?. <b>2002</b> , 57, 117-24	21
1999	Cytotoxic effects of carboplatin and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. <b>2002</b> , 87, 4160-5	80
1998	Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. <b>2002</b> , 9, 227-47	124
1997	Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma. <b>2002</b> , 87, 4059-62	11
1996	Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. <b>2002</b> , 87, 1499-501	223
1995	Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. <b>2002</b> , 128, 825-8	104

1994	Bedeutung der Lymphknoten- und Fernmetastasen für das Ausmaß der chirurgischen Therapie von papillären und follikulären Schilddrüsenkarzinomen. <b>2002</b> , 37, 404-409		
1993	Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission. <b>2002</b> , 87, 3201-8		38
1992	Thyroid cancer: a unique human neoplasm. <b>2002</b> , 122, 343-7		4
1991	Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. <b>2002</b> , 87, 1247-53		51
1990	Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. <b>2002</b> , 26, 1007-15		48
1989	Outcome and toxicity associated with maximum safe dose radioiodine treatment of metastatic thyroid cancer. <b>2002</b> , 27, 556-66		11
1988	Tumor above the spinal accessory nerve in papillary thyroid cancer that involves lateral neck nodes: a common occurrence. <b>2002</b> , 128, 1275-8		63
1987	Thyroid suppression therapy: risks and indications. <b>2002</b> , 10, 188-193		1
1986	Differentiated thyroid cancer in children and adolescents. <b>2002</b> , 25, 18-24		64
1985	Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. <b>2002</b> , 87, 1490-8		195
1984	Differentiation between healthy thyroid remnants and tumor tissue after radioiodine therapy in patients with differentiated thyroid carcinoma using in vitro phosphorus-31 magnetic resonance spectroscopy. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 634-41	2.4	3
1983	The use of recombinant thyrotropin in the follow-up of patients with differentiated thyroid cancer. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 721-5	2.4	5
1982	The clinicopathological significance of histologic vascular invasion in differentiated thyroid carcinoma. <b>2002</b> , 183, 80-6		29
1981	Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. <b>2002</b> , 12, 989-96		60
1980	Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. <b>2002</b> , 132, 1070-3; discussion 1073-4		170
1979	Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. <b>2002</b> , 34, 554-64		188
1978	Recurrent and/or metastatic thyroid cancer: therapeutic options. <b>2002</b> , 3, 939-47		6
1977	Recombinant human TSH testing for recurrent thyroid cancer: a re-appraisal. <b>2002</b> , 12, 599-602		1

1976	Sentinel lymph node biopsy in patients with thyroid carcinoma. <b>2002</b> , 56 Suppl 1, 83s-87s	5
1975	Management of thyroid cancer. <b>2002</b> , 3, 407-14	63
1974	Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. <b>2002</b> , 514, 77-85	33
1973	Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. <b>2002</b> , 131, 249-56	209
1972	Bases anatômicas del vaciamiento ganglionar cervical central. <b>2002</b> , 71, 163-168	1
1971	Frequency and predictive factors of malignancy in residual thyroid tissue and cervical lymph nodes after partial thyroidectomy for differentiated thyroid cancer. <b>2002</b> , 131, 443-9	25
1970	Management of Papillary and Follicular Thyroid Cancer. <b>2002</b> , 95, 325-326	5
1969	Prognostic Factors in Mortality and Morbidity in Patients with differentiated Thyroid Cancer. <b>2002</b> , 81, 856-863	11
1968	Managing differentiated thyroid cancer. <b>2002</b> , 324, 988-9	5
1967	Prognostic factors for well-differentiated thyroid cancer in an endemic area. <b>2002</b> , 25, 325-9	4
1966	Sentinel lymph node biopsy in staging of differentiated thyroid cancer: a critical review. <b>2002</b> , 11, 137-42	32
1965	Diagnosis and management of patients with thyroid nodules. <b>2002</b> , 80, 157-70	41
1964	Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. <b>2002</b> , 24, 670-7	43
1963	Follicular thyroid carcinoma: prognostic factors and the role of radioiodine. <b>2002</b> , 95, 488-98	70
1962	Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis. <b>2002</b> , 95, 2076-85	67
1961	Follicular thyroid carcinoma. <b>2002</b> , 3, 349-54	9
1960	Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. <b>2002</b> , 26, 879-85	566
1959	Importance of lymph node metastases in follicular thyroid cancer. <b>2002</b> , 26, 1017-22	57



1958 Kommentar auf Anforderung der Schriftleitung. **2002**, 73, 43-45

1957 The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. **2002**, 56, 247-52 41

1956 Gonadal damage from 131I therapy for thyroid cancer. **2002**, 57, 313-4 25

1955 The sodium iodide symporter: its pathophysiological and therapeutic implications. **2002**, 57, 559-74 128

1954 Testicular dose and fertility in men following I(131) therapy for thyroid cancer. **2002**, 56, 755-8 116

1953 Basal TSH levels compared with TRH-stimulated TSH levels to diagnose different degrees of TSH suppression: diagnostic and therapeutic impact of assay performance. **2002**, 32, 931-7 11

1952 Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. **2002**, 52, 784-95 97

1951 Incidental metastatic papillary thyroid carcinoma in microvascular reconstruction. **2002**, 112, 2170-7 3

1950 Current therapy for childhood thyroid cancer: optimal surgery and the legacy of king pyrrhus. **2003**, 10, 4-6 4

1949 Differentiated thyroid cancer. **2003**, 70, 707-13 23

1948 Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?. **2003**, 30, 974-81 75

1947 Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. **2003**, 30, 1371-7 78

1946 Sentinel lymph node biopsy in thyroid tumors: a pilot study. **2003**, 260, 364-8 35

1945 Signifikanz der prophylaktischen systematischen Lymphadenektomie bei papillären Mikrokarzinomen der Schilddrüse. **2003**, 9, 768-770

1944 Detection of sentinel lymph nodes in patients with papillary thyroid cancer. **2003**, 26, 145-8 23

1943 The treatment of well-differentiated thyroid cancer. **2003**, 14, 80-85

1942 Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. **2003**, 97, 90-6 226

1941 Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. **2003**, 97, 1181-5 138

1940	Long-term results in elderly patients with differentiated thyroid carcinoma. <b>2003</b> , 97, 2736-42	72
1939	Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. <b>2003</b> , 98, 31-40	553
1938	Papillary thyroid cancer: high inter-(simple sequence repeat) genomic instability in a typically indolent cancer. <b>2003</b> , 25, 825-32	7
1937	Incidence and survival of Swedish patients with differentiated thyroid cancer. <b>2003</b> , 106, 569-573	62
1936	Value of external irradiation for locally advanced papillary thyroid cancer. <b>2003</b> , 55, 1006-12	61
1935	Pituitary tumour transforming gene in endocrine cancer. <b>2003</b> , 58, 673-82	6
1934	Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. <b>2003</b> , 58, 428-35	93
1933	Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer. <b>2003</b> , 58, 451-5	7
1932	The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. <b>2003</b> , 58, 556-61	24
1931	Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. <b>2003</b> , 58, 513-8	24
1930	Guidelines for the management of thyroid cancer. <b>2003</b> , 58, 400-2	18
1929	Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. <b>2003</b> , 113, 77-81	43
1928	Clinical course of thyroid carcinoma after neck dissection. <b>2003</b> , 113, 2102-7	74
1927	Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000. <b>2003</b> , 15, 329-36	51
1926	The impact of clinical guidelines on surgical management in patients with thyroid cancer. <b>2003</b> , 15, 485-9	6
1925	Timing and special concerns regarding endocrine surgery during pregnancy. <b>2003</b> , 32, 337-54	45
1924	[Diagnosis and treatment of differentiated thyroid carcinoma]. <b>2003</b> , 22, 349-59; quiz 360-2	
1923	Well-differentiated carcinoma of the thyroid. <b>2003</b> , 36, 73-90, viii	12

1922	Controversias en el tratamiento del c�ncer diferenciado de tiroides. Encuesta a endocrin�logos. <b>2003</b> , 50, 128-132	2
1921	TSH recombinante y determinaci�n de tiroglobulina en el seguimiento del carcinoma diferenciado de tiroides. <b>2003</b> , 50, 261-265	0
1920	Detection and prognostic relevance of cytokeratin 20 in differentiated and anaplastic thyroid carcinomas by RT-PCR. <b>2003</b> , 134, 964-71; discussion 971-2	11
1919	The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. <b>2003</b> , 134, 1005-12; discussion 1012	89
1918	The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. <b>2003</b> , 24, 48-77	629
1917	Thyroid carcinoma. <b>2003</b> , 361, 501-11	766
1916	Low expression of sodium iodide symporter identifies aggressive thyroid tumors. <b>2003</b> , 200, 85-91	35
1915	Diffuse sclerosing variant of papillary thyroid carcinoma--clinical features and outcome. <b>2003</b> , 29, 446-9	81
1914	Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. <b>2003</b> , 13, 491-5	50
1913	Postoperative management of differentiated thyroid cancer. <b>2003</b> , 36, 129-57	16
1912	Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses. <b>2003</b> , 17, 19-38	19
1911	"Bacteriology of Acute and Chronic Frontal Sinusitis": A Reply�Reply. <b>2003</b> , 129, 497	
1910	Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. <b>2003</b> , 13, 949-58	78
1909	The Impact of Nodal Metastases on Prognosis of Well-Differentiated Thyroid Cancer Suggests the Practice of Prophylactic Neck Dissection�Reply. <b>2003</b> , 129, 496	0
1908	Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. <b>2003</b> , 13, 479-84	83
1907	Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. <b>2003</b> , 18, 231-7	6
1906	Modern management of differentiated thyroid cancer. <b>2003</b> , 18, 689-705	6
1905	Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in children and adolescents. <b>2003</b> , 16, 693-702	17

1904	Treatment of recurrent papillary thyroid carcinoma in children and adolescents. <b>2003</b> , 16, 1033-40	8
1903	Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. <b>2003</b> , 129, 716-9	87
1902	Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer. <b>2003</b> , 88, 211-4	10
1901	Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. <b>2003</b> , 88, 4110-5	119
1900	Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. <b>2003</b> , 237, 227-34	39
1899	. <b>2003</b> , 237, 227-234	23
1898	. <b>2003</b> , 237, 399-407	61
1897	Parapharyngeal lymph node involvement in papillary thyroid carcinoma. <b>2003</b> , 28, 947-8	3
1896	In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging. <b>2003</b> , 28, 208-17	19
1895	Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. <b>2003</b> , 237, 399-407	580
1894	Thyroid. <b>2003</b> , 379-387	
1893	Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. <b>2003</b> , 10, 845	
1892	Thyroid Cancer. <b>2003</b> , 405-431	
1891	[Thyroid cancer: prognostic factors and treatment]. <b>2004</b> , 48, 126-36	3
1890	[Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer]. <b>2004</b> , 48, 310-4	7
1889	[Usefulness of radioiodine scanning in patients with moderate/high risk differentiated thyroid carcinoma in whom thyroglobulin after thyroxin withdrawal is undetectable after initial treatment]. <b>2004</b> , 48, 384-8	3
1888	Management and outcome of recurrent well-differentiated thyroid carcinoma. <b>2004</b> , 130, 819-24	72
1887	Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. <b>2004</b> , 89, 3285-9	47

1886 Szintigraphie beim Schilddrüsenkarzinom. **2004**, 27, 123-132

1885 Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. **2004**, 89, 1666-73 125

1884 Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors. **2004**, 10, 5762-8 27

1883 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. **2004**, 64, 2898-903 124

1882 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. **2004**, 89, 3713-20 265

1881 Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. **2004**, 11, 571-9 98

1880 Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. **2004**, 11, 131-9 100

1879 The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. **2004**, 89, 114-20 303

1878 Controversies in the follow-up and management of well-differentiated thyroid cancer. **2004**, 11, 97-116 46

1877 Comparison of the effectiveness between a single low dose and fractionated doses of radioiodine in ablation of post-operative thyroid remnants. **2004**, 34, 469-71 5

1876 Well differentiated thyroid cancer. **2004**, 93, 261-71 38

1875 Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. **2004**, 89, 585-90 33

1874 Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. **2004**, 41, 161-70 145

1873 Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. **2004**, 14, 133-40 55

1872 False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. **2004**, 14, 207-15 141

1871 Practice, efficacy, and costs of thyroid nodule evaluation: a retrospective study in a Dutch university hospital. **2004**, 14, 287-93 36

1870 Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. **2004**, 14, 453-8 78

1869 The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. **2004**, 17, 339-43 20

1868	Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. <b>2004</b> , 89, 5362-8	89
1867	Patterns of lateral neck metastasis in papillary thyroid carcinoma. <b>2004</b> , 130, 857-60	148
1866	Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. <b>2004</b> , 61, 163-73	26
1865	Octanoylated and nonoctanoylated ghrelin levels in cord blood. <b>2004</b> , 61, 649; author reply 649-50	1
1864	Response to the letter: "Octanoylated and nonoctanoylated ghrelin levels in cord blood" by S. Ferrero. <b>2004</b> , 61, 649-650	
1863	Decrease in thyroid autoantibodies after eradication of Helicobacter pylori infection. <b>2004</b> , 61, 650-2	36
1862	Completion thyroidectomy in patients with thyroid carcinoma initially submitted to lobectomy. <b>2004</b> , 61, 652-3	5
1861	Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?. <b>2004</b> , 91, 200-4	20
1860	BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. <b>2004</b> , 17, 1359-63	139
1859	Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. <b>2004</b> , 114, 393-402	146
1858	Safety of modified radical neck dissection for differentiated thyroid carcinoma. <b>2004</b> , 114, 403-6	70
1857	Prognostic factors in well-differentiated thyroid carcinoma. <b>2004</b> , 114, 2110-5	54
1856	AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States. <b>2004</b> , 136, 609-16	31
1855	Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. <b>2004</b> , 136, 1183-91	71
1854	Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer. <b>2004</b> , 136, 1275-80	9
1853	Thyroid lobectomy: Operative anatomy, technique, and morbidity. <b>2004</b> , 15, 210-219	5
1852	RET oncogene expression of papillary thyroid carcinoma in Korea. <b>2004</b> , 34, 485-92	8
1851	Surgical treatment of thyroid cancers with concurrent Graves disease. <b>2004</b> , 11, 407-12	21

1850	Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer. <b>2004</b> , 59, 1330-6	28
1849	Recurrent laryngeal nerve palsy in well-differentiated thyroid carcinoma: clinicopathologic features and outcome study. <b>2004</b> , 28, 1093-8	29
1848	Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. <b>2004</b> , 28, 1103-9	21
1847	Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer. <b>2004</b> , 28, 1110-4	27
1846	Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. <b>2004</b> , 42, 176-83	111
1845	Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. <b>2004</b> , 40, 355-64	94
1844	New fields of application of the sentinel lymph node biopsy in the pathologic staging of solid neoplasms: review of literature and surgical perspectives. <b>2004</b> , 85, 171-9	21
1843	The management of advanced thyroid cancer. <b>2004</b> , 16, 561-8	33
1842	Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. <b>2004</b> , 89, 3668-76	328
1841	Iodine 131 ( <sup>131</sup> I) as adjuvant therapy of differentiated thyroid cancer. <b>2004</b> , 13, 129-49	2
1840	Male reproductive function in relation with thyroid alterations. <b>2004</b> , 18, 183-95	70
1839	Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. <b>2004</b> , 89, 91-5	134
1838	Extent of surgery for differentiated thyroid cancer. <b>2004</b> , 84, 817-32	28
1837	Differentiated thyroid cancer and outcome in iodine deficiency. <b>2004</b> , 30, 325-31	7
1836	Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients 2004, 39, 1500-5	77
1835	Incidence of occult thyroid carcinoma metastases in lateral cervical cysts. <b>2004</b> , 25, 11-7	54
1834	Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. <b>2004</b> , 25, 547-52	95
1833	Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation. <b>2004</b> , 25, 793-7	17

1832	Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. <b>2004</b> , 25, 799-805	20
1831	Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma. <b>2004</b> , 29, 358-61	19
1830	Radiofrequency Ablation for Skeletal Metastasis of Papillary Carcinoma of the Thyroid. <b>2004</b> , 14, 5-11	5
1829	Current issues in the management of differentiated thyroid cancer. <b>2004</b> , 25, 873-81	11
1828	Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study. <b>2004</b> , 25, 245-51	15
1827	Thyroid cancer: an overview. <b>2004</b> , 25, 861-7	9
1826	Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning". <b>2004</b> , 25, 883-9	12
1825	Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. <b>2004</b> , 130, 110-3	82
1824	Sonography in the diagnosis of cervical recurrence in patients with differentiated thyroid carcinoma. <b>2004</b> , 23, 915-20; quiz 921-2	38
1823	Sonography of thyroid nodules: a "classic pattern" diagnostic approach. <b>2005</b> , 21, 157-65	113
1822	Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. <b>2005</b> , 241, 640-6	69
1821	Nationwide survey on the treatment policy for well-differentiated thyroid cancer -- results of a questionnaire distributed at the 37th meeting of the Japanese Society of Thyroid Surgery. <b>2005</b> , 52, 479-91	28
1820	High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. <b>2005</b> , 63, 449-55	45
1819	[Low-risk papillary thyroid cancer. What is the procedure of choice for thyroidectomy and lymph node resection?]. <b>2005</b> , 130, 411-3	1
1818	Cancers de la thyroïde. <b>2005</b> , 2, 1-38	10
1817	The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. <b>2005</b> , 16, 295-309	49
1816	Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma. <b>2005</b> , 35, 714-9	20
1815	Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. <b>2005</b> , 62, 376-9	42



1814	Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. <b>2005</b> , 63, 87-93	133
1813	Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. <b>2005</b> , 63, 418-27	128
1812	No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. <b>2005</b> , 63, 461-6	115
1811	Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers - are they different diseases?. <b>2005</b> , 63, 577-81	49
1810	A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. <b>2005</b> , 200, 378-92	38
1809	Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. <b>2005</b> , 138, 1176-82; discussion 1182	38
1808	Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. <b>2005</b> , 138, 1095-100, discussion 1100-1	263
1807	Thyroid surgery in an area of iodine deficiency. <b>2005</b> , 27, 383-9	1
1806	Implications of mediastinal uptake of 131I with regard to surgery in patients with differentiated thyroid carcinoma. <b>2005</b> , 103, 59-67	19
1805	The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. <b>2005</b> , 103, 2269-73	282
1804	Importance of tumour size in papillary and follicular thyroid cancer. <b>2005</b> , 92, 184-9	36
1803	Role of 131I in the treatment of well differentiated thyroid cancer. <b>2005</b> , 89, 114-21	26
1802	Follicular thyroid lesions, elements that affect both diagnosis and prognosis. <b>2005</b> , 89, 108-13	36
1801	Optimal timing of surgery in well-differentiated thyroid carcinoma detected during pregnancy. <b>2005</b> , 91, 199-203	38
1800	Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. <b>2005</b> , 32, 1144-51	20
1799	Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. <b>2005</b> , 29, 917-20	148
1798	[Reoperation for thyroid cancer]. <b>2005</b> , 76, 238-49	1
1797	Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. <b>2005</b> , 12, 81-9	165

1796	A less invasive, selective, functional neck dissection for papillary thyroid carcinoma. <b>2005</b> , 390, 381-4	8
1795	Chirurgie der Schilddrüsenkarzinome. <b>2005</b> , 11, 58-69	8
1794	Radiojodtherapie des Schilddrüsenkarzinoms. <b>2005</b> , 11, 70-77	2
1793	Papillary thyroid cancer: medical management and follow-up. <b>2005</b> , 6, 323-38	31
1792	Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma. <b>2005</b> , 60, 233-40	19
1791	Choosing the Activity of I-131 for Therapy. <b>2005</b> , 169-175	0
1790	Diagnostic accuracy of high-resolution neck ultrasonography in the follow-up of differentiated thyroid cancer: a prospective study. <b>2005</b> , 11, 165-71	9
1789	Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. <b>2005</b> , 11, 2525-31	39
1788	Radioiodine Therapy for Thyroid Cancer. <b>2005</b> , 95-126	2
1787	Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. <b>2005</b> , 152, 33-7	74
1786	High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. <b>2005</b> , 90, 5265-9	101
1785	Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow. <b>2005</b> , 5, 573-84	25
1784	Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na <sup>+</sup> /I <sup>-</sup> symporter. <b>2005</b> , 19, 2847-58	49
1783	Molecular Basis of Thyroid Cancer. <b>2005</b> ,	1
1782	Follicular neoplasms of the thyroid: what to recommend. <b>2005</b> , 15, 583-7	57
1781	Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. <b>2005</b> , 15, 158-64	6
1780	The pathology of thyroid cancer. <b>2004</b> , 122, 23-67	4
1779	Essentials of Thyroid Cancer Management. <b>2005</b> ,	7

1778	Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. <b>2005</b> , 26, 57-64	67
1777	Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer?. <b>2005</b> , 6, 529-31	37
1776	Advances in the management of thyroid cancer. <b>2005</b> , 3, 213-20	15
1775	Changing concepts in the management of differentiated thyroid cancer. <b>2005</b> , 35, 257-65	15
1774	Contemporary management of differentiated thyroid carcinoma. <b>2005</b> , 38, 161-78, x	15
1773	[Papillary and/or vesicular thyroid cancer: before and during surgery]. <b>2005</b> , 66, 81-3	
1772	Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. <b>2005</b> , 15, 267-73	31
1771	Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. <b>2005</b> , 28, 540-6	34
1770	Gamma probe-guided surgery for revision thyroidectomy: in comparison with conventional technique. <b>2005</b> , 28, 583-8	9
1769	Thyroid-hormone therapy and thyroid cancer: a reassessment. <b>2005</b> , 1, 32-40	145
1768	Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. <b>2005</b> , 237, 794-800	881
1767	The role of a more extensive surgical approach in the initial multimodality management of papillary thyroid cancer in children. <b>2005</b> , 40, 1696-700	39
1766	Thyroid cancer in pregnancy. <b>2005</b> , 91, 15-20	91
1765	Papillary thyroid microcarcinoma: a surgical perspective. <b>2005</b> , 31, 423-38	93
1764	Risk for recurrence and death from preexisting cancers after transplantation. <b>2005</b> , 19, 151-163	10
1763	Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. <b>2005</b> , 133, 391-6	46
1762	Contemporary management of thyroid cancer. <b>2005</b> , 26, 249-60	23
1761	[Epidemiological and clinicopathological study of thyroid cancer in east Madrid]. <b>2005</b> , 205, 307-10	3

1760	Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. <b>2005</b> , 352, 2406-12	199
1759	Tiroglobulina en el seguimiento del c�ncer diferenciado de tiroides. <b>2005</b> , 52, 82-87	1
1758	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. <b>2005</b> , 90, 6373-9	775
1757	Outcomes of patients with differentiated thyroid carcinoma following initial therapy. <b>2006</b> , 16, 1229-42	483
1756	Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer. <b>2006</b> , 6, 167-76	1
1755	Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline. <b>2006</b> , 16, 461-9	28
1754	Non-surgical Management of Thyroid Cancer. <b>2006</b> , 171-191	8
1753	[Diferenciado thyroid carcinomas with laryngo-tracheal invasion]. <b>2006</b> , 123, 34-40	
1752	Follicular and H�rtle cell carcinoma of the thyroid gland. <b>2006</b> , 15, 603-23, ix-x	31
1751	Utilidad de la tiroglobulina plasm�tica tras TSH humana recombinante en el c�ncer diferenciado de tiroides libre de enfermedad. <b>2006</b> , 53, 168-173	
1750	La prueba de tiroglobulina tras hormona estimulante de la tiroides recombinante modifica la estrategia del seguimiento del c�ncer diferenciado de tiroides. <b>2006</b> , 53, 543-549	
1749	External beam radiotherapy for differentiated thyroid cancer. <b>2006</b> , 27, 24-8	41
1748	Sentinel node mapping and biopsy in thyroid cancer: a surgical perspective. <b>2006</b> , 60, 405-8	27
1747	Predictors of outcome in patients with papillary thyroid carcinoma. <b>2006</b> , 32, 345-52	18
1746	Lymphadenectomy for papillary thyroid cancer: changes in practice over four decades. <b>2006</b> , 32, 340-4	44
1745	Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. <b>2006</b> , 32, 1144-8	103
1744	What is the biology and optimal treatment for papillary microcarcinoma of the thyroid?. <b>2006</b> , 134, 160-2	32
1743	Thyroid cancer in children: management and outcome experience of a referral center. <b>2006</b> , 135, 581-4	57

1742 Emerging Therapies for Thyroid Cancer. **2006**, 423-428

1741 An Overview of the Management of Thyroid Cancer. **2006**, 1-28 8

1740 Workup of well-differentiated thyroid carcinoma. **2006**, 13, 99-105 24

1739 Role of [18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. **2006**, 12, 152-8 13

1738 [Low-risk differentiated thyroid carcinoma--literature review and management guidelines]. **2006**, 50, 550-7 2

1737 Thyroglobulin. **2006**, 211-228

1736 Thyroid Cancer and the Endocrinologist. **2006**, 109-117

1735 Total thyroidectomy for the treatment of thyroid diseases in an endemic area. **2006**, 99, 1224-9 5

1734 Differentiated Thyroid Carcinoma in Pediatric Age. **2006**, 11, 210-224

1733 Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH. **2006**, 53, 723-8 3

1732 When fine-needle aspiration biopsy cannot exclude papillary thyroid cancer: a therapeutic dilemma. **2006**, 141, 961-6; discussion 966 20

1731 Chapter 5 Thyroglobulin measurements in thyroid cancer evaluation and surveillance. **2006**, 4, 83-105

1730 Chapter 4 Controversies in the use of radioiodine for remnant ablation and therapy of thyroid carcinoma. **2006**, 49-82

1729 Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. **2006**, 27, 627-32 37

1728 Importance of Tumour Size in Papillary and Follicular Thyroid Cancer. **2006**, 2006, 274-277

1727 A Single Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Measurement Predicts Differentiated Thyroid Carcinoma Metastases Three to Five Years Later. **2006**, 2006, 293-297

1726 Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up. **2006**, 12, 275-82 31

1725 Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. **2006**, 22, 231-8; discussion 239-40 115

1724	Late Disease Recurrence in Patients Diagnosed With and Treated for Differentiated Thyroid Carcinoma. <b>2006</b> , 16, 329-334	1
1723	Completion thyroidectomy for malignancy after initial minimal access thyroid surgery. <b>2006</b> , 76, 332-4	13
1722	Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. <b>2006</b> , 65, 402-7	127
1721	Disparities between male and female patients with thyroid cancers: sex difference or gender divide?. <b>2006</b> , 65, 500-5	48
1720	Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. <b>2006</b> , 16, 109-42	1553
1719	Fine-needle aspiration optimizes surgical management in patients with thyroid cancer. <b>2006</b> , 13, 859-63	42
1718	Is tumor size the best predictor of outcome for papillary thyroid cancer?. <b>2006</b> , 13, 1524-8	32
1717	Expression of MAGE tumor-associated antigen in thyroid carcinomas. <b>2006</b> , 17, 45-52	16
1716	Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. <b>2006</b> , 106, 524-31	494
1715	2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. <b>2006</b> , 8, 309-14	17
1714	Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. <b>2006</b> , 118, 601-9	18
1713	Skull metastasis from papillary thyroid carcinoma accompanied by neurofibromatosis type 1 and pheochromocytoma: report of a case. <b>2006</b> , 23, 97-100	18
1712	Radio-guided surgery for persistent differentiated papillary thyroid cancer: case presentations and review of the literature. <b>2006</b> , 391, 178-86	20
1711	Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. <b>2006</b> , 30, 1821-8	151
1710	Papillary thyroid cancer. <b>2006</b> , 7, 309-19	23
1709	Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. <b>2006</b> , 599, 26-35	28
1708	Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. <b>2006</b> , 107, 1831-8	107
1707	Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma. <b>2006</b> , 28, 1032-9	8

1706	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. <b>2006</b> , 119, 2322-9	140
1705	Specific features of differentiated thyroid carcinoma in patients over 70 years of age. <b>2006</b> , 93, 194-8	20
1704	Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. <b>2006</b> , 94, 692-700	72
1703	Treatment of thyroid cancer based on risk groups. <b>2006</b> , 94, 683-91	55
1702	Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer. <b>2006</b> , 94, 678-82	23
1701	Contemporary diagnostic approach to the thyroid nodule. <b>2006</b> , 94, 649-61	32
1700	Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. <b>2006</b> , 91, 1404-9	38
1699	Micropapillary thyroid cancer: should we aspirate all nodules regardless of size?. <b>2006</b> , 91, 2043-6	18
1698	Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. <b>2006</b> , 141, 489-94; discussion 494-6	300
1697	A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. <b>2006</b> , 91, 878-84	145
1696	Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. <b>2006</b> , 91, 98-104	38
1695	A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy. <b>2006</b> , 45, 1067-72	12
1694	VEGF-C and COX-2 expression in papillary thyroid cancer. <b>2006</b> , 13, 465-73	33
1693	Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. <b>2006</b> , 115, 607-10	41
1692	Survival and death causes in differentiated thyroid carcinoma. <b>2006</b> , 91, 313-9	204
1691	Geriatric Otolaryngology. <b>2006</b> ,	6
1690	Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis. <b>2006</b> , 16, 1273-8	18
1689	The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. <b>2006</b> , 16, 583-91	90

1688	Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. <b>2006</b> , 16, 1033-40	40
1687	Surgery of lymph nodes in papillary thyroid cancer. <b>2006</b> , 6, 1217-29	17
1686	Sodium iodide I 131 treatment of dogs with nonresectable thyroid tumors: 39 cases (1990-2003). <b>2006</b> , 229, 542-8	48
1685	Differentiated Thyroid Cancer. <b>2006</b> , 163-281	
1684	Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. <b>2006</b> , 19, 1377-93	47
1683	Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. <b>2007</b> , 17, 655-61	100
1682	Treatment of micropapillary carcinoma of the thyroid: where do we draw the line?. <b>2007</b> , 17, 1093-6	24
1681	Isotretinoin as a diagnostic tool for localization of thyroid tissue in a thyroid cancer patient: a case report. <b>2007</b> , 17, 893-6	1
1680	Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. <b>2007</b> , 28, 2451-8	90
1679	Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. <b>2007</b> , 92, 2487-95	152
1678	Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. <b>2007</b> , 92, 4686-95	61
1677	Use of radiopharmaceuticals for diagnosis, treatment, and follow-up of differentiated thyroid carcinoma. <b>2007</b> , 7, 399-409	5
1676	Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. <b>2007</b> , 92, 2610-5	111
1675	Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. <b>2007</b> , 5, 87-90	39
1674	Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. <b>2007</b> , 14, 29-42	37
1673	Management of low-risk differentiated thyroid cancer. <b>2007</b> , 13, 498-512	181
1672	Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. <b>2007</b> , 13, 1341-9	141
1671	Role of radioactive iodine for adjuvant therapy and treatment of metastases. <b>2007</b> , 5, 631-40	7



1670	Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given. <b>2007</b> , 133, 870-3	11
1669	Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. <b>2007</b> , 32, 440-4	58
1668	Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation <sup>131</sup> I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. <b>2007</b> , 30, 63-8	18
1667	Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. <b>2007</b> , 246, 114-21	45
1666	Circulating thyroid cancer markers. <b>2007</b> , 14, 383-8	27
1665	Is thyroglobulin the stronger indicator for progressive disease than the other conventional factors in same age patient groups with differentiated thyroid cancer?. <b>2007</b> , 28, 907-13	7
1664	Routine <sup>201</sup> Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact. <b>2007</b> , 28, 681-7	1
1663	Staging systems for papillary thyroid carcinoma: a review and comparison. <b>2007</b> , 245, 366-78	177
1662	Extent of surgery affects survival for papillary thyroid cancer. <b>2007</b> , 246, 375-81; discussion 381-4	494
1661	Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. <b>2007</b> , 19, 11-7	55
1660	Hormonoth�rapie thyro�dienne freinatrice. Principes et modalit�s pratiques. <b>2007</b> , 4, 1-7	
1659	Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. <b>2007</b> ,	1
1658	Is the type of dissection in lateral neck metastasis for differentiated thyroid carcinoma important?. <b>2007</b> , 136, 957-60	27
1657	Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. <b>2007</b> , 28, 31-6	24
1656	US diagnosis of cervical recurrence in patients operated on thyroid cancer: sonographic features and clinical significance. <b>2007</b> , 34, 213-9	5
1655	Use of preoperative lymphoscintigraphy and intraoperative gamma-probe detection for identification of the sentinel lymph node in patients with papillary thyroid carcinoma. <b>2007</b> , 33, 1075-80	41
1654	Sonographically guided fine-needle biopsy of thyroid nodules: the effects of nodule characteristics, sampling technique, and needle size on the adequacy of cytological material. <b>2007</b> , 62, 798-803	105
1653	Postmenopause is associated with recurrence of differentiated papillary thyroid carcinoma. <b>2007</b> , 69, 209-13	7

1652	Differentiated pediatric thyroid cancer: correlates with adult disease, controversies in treatment. <b>2007</b> , 37, 340-56	44
1651	Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. <b>2007</b> , 92, S1-47	576
1650	BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. <b>2007</b> , 28, 742-62	755
1649	Differentiated thyroid cancer. <b>2007</b> , 4, 197-204	1
1648	Branchial cleft cyst as the initial impression of a metastatic thyroid papillary carcinoma: two case reports. <b>2007</b> , 23, 634-8	20
1647	Clinical features and therapeutic implication of papillary thyroid microcarcinoma. <b>2007</b> , 17, 1085-92	90
1646	Appropriate treatment for asymptomatic papillary microcarcinoma of the thyroid. <b>2007</b> , 8, 3205-15	17
1645	[Guidelines for the management of differentiated thyroid cancers]. <b>2007</b> , 68 Suppl 2, S57-72	0
1644	Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. <b>2007</b> , 5, 367-73	106
1643	Papillary thyroid cancer: monitoring and therapy. <b>2007</b> , 36, 753-78, vii	55
1642	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. <b>2007</b> , 54, 390.e1-390.e16	
1641	The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. <b>2007</b> , 92, 3511-6	82
1640	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. <b>2007</b> , 92, 4085-90	329
1639	[Thyroid nodules and differentiated thyroid cancer: Brazilian consensus]. <b>2007</b> , 51, 867-93	34
1638	The importance of sodium/iodide symporter (NIS) for thyroid cancer management. <b>2007</b> , 51, 672-82	39
1637	[Thyroid microcarcinoma: experience and management in private clinic]. <b>2007</b> , 51, 774-82	2
1636	[Cervical lymph nodes metastases in patients with differentiated thyroid cancer]. <b>2007</b> , 51, 813-7	1
1635	Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. <b>2007</b> , 94, 571-7	44

1634	Transoral resection of thyroid cancer metastasis to lateral retropharyngeal nodes. <b>2007</b> , 29, 258-66	41
1633	Retropharyngeal node metastasis from papillary thyroid carcinoma. <b>2007</b> , 29, 508-11	45
1632	Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. <b>2007</b> , 110, 1451-6	198
1631	Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. <b>2007</b> , 111, 508-16	493
1630	Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. <b>2007</b> , 96, 3-7	63
1629	Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. <b>2007</b> , 95, 555-60	91
1628	Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. <b>2007</b> , 26, 4018-24	30
1627	Routine level VI lymph node dissection for papillary thyroid cancer: surgical technique. <b>2007</b> , 77, 203-8	72
1626	Clinicopathological correlations of Bcl-xL and Bax expression in differentiated thyroid carcinoma. <b>2008</b> , 68, 190-7	6
1625	Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. <b>2007</b> , 14, 730-8	103
1624	Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability. <b>2007</b> , 14, 1551-9	37
1623	Reproducibility of whole-body <sup>131</sup> I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin. <b>2007</b> , 34, 363-7	3
1622	Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". <b>2007</b> , 34, 772-786	107
1621	Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. <b>2007</b> , 31, 838-48	105
1620	Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts. <b>2007</b> , 31, 888-94	32
1619	TNM classification of thyroid carcinoma. <b>2007</b> , 31, 879-87	83
1618	Central lymph node dissection in differentiated thyroid cancer. <b>2007</b> , 31, 895-904	280
1617	Role of surgeons in clinical trials for thyroid cancer. <b>2007</b> , 31, 987-95	7

1616	Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation. <b>2007</b> , 31, 2309-14	6
1615	Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. <b>2007</b> , 9, 72-7	33
1614	Incidental papillary microcarcinoma of the thyroid--factors affecting lymph node metastasis. <b>2008</b> , 393, 25-9	41
1613	Anthropometric factors at age 20 years and risk of thyroid cancer. <b>2008</b> , 19, 1233-42	47
1612	Guidelines for radioiodine therapy of differentiated thyroid cancer. <b>2008</b> , 35, 1941-59	445
1611	Risk-stratified management of well-differentiated thyroid cancers: a review of experience from a single institution, 1990-2003. <b>2008</b> , 32, 386-94	3
1610	Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. <b>2008</b> , 32, 1552-8	176
1609	Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. <b>2008</b> , 32, 2494-502	96
1608	<sup>99</sup> Tc Nanocolloid sentinel node procedure in thyroid carcinoma. <b>2008</b> , 393, 705-8	18
1607	Papillary thyroid microcarcinoma: prognostic factors and treatment. <b>2008</b> , 97, 221-5	65
1606	Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. <b>2008</b> , 113, 936-44	32
1605	Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer. <b>2008</b> , 122, 785-90	23
1604	Predictors of level V metastasis in well-differentiated thyroid cancer. <b>2008</b> , 30, 1469-74	58
1603	Thyroid cancer guidelines--what's new?. <b>2008</b> , 20, 264-6	3
1602	Papillary thyroid carcinoma: factors influencing recurrence and survival. <b>2008</b> , 15, 1518-22	110
1601	Selective surgical management of well-differentiated thyroid cancer. <b>2008</b> , 1138, 58-64	17
1600	Regional metastases in well-differentiated thyroid carcinoma: pattern of spread. <b>2008</b> , 118, 433-6	35
1599	Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer. <b>2008</b> , 118, 768-75	59

1598	Papillary thyroid cancer: controversies in the management of neck metastasis. <b>2008</b> , 118, 2161-5	64
1597	BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. <b>2008</b> , 68, 618-34	95
1596	Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical <sup>131</sup> I ablation therapy for differentiated thyroid carcinoma. <b>2008</b> , 69, 957-62	22
1595	Recent advances in thyroid cancer. <b>2008</b> , 45, 156-250	53
1594	Standard and emerging therapeutic approaches for thyroid malignancies. <b>2008</b> , 35, 298-308	12
1593	Micrometastases in thyroid cancer. An important finding?. <b>2008</b> , 17, 253-8	101
1592	Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. <b>2008</b> , 7, 89	18
1591	Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. <b>2008</b> , 22, 1009-21	38
1590	[Transoral resection of thyroid cancer metastasis to retropharyngeal lymph node]. <b>2008</b> , 125, 309-12	9
1589	Postoperative management of thyroid carcinoma. <b>2008</b> , 17, 197-218, x	
1588	Utilisation de la thyreostimuline humaine recombinante dans la préparation au traitement par iode-131 des pathologies thyroïdiennes. <b>2008</b> , 32, 101-110	1
1587	Nuclear medicine in the assessment of differentiated thyroid cancer. <b>2008</b> , 63, 453-63	9
1586	Retrospective Analysis of Thyroid Cancer Patients. <b>2008</b> , 64, 7-10	
1585	Surgical approaches in thyroid cancer: what the radiologist needs to know. <b>2008</b> , 18, 491-504, viii	10
1584	Differentiated Thyroid Carcinoma: The Impact of Initial Surgical Therapy. <b>2008</b> , 3, 117-122	
1583	Medical management of persistent or recurrent differentiated thyroid carcinoma. <b>2008</b> , 41, 1241-60, xi-xii	1
1582	Impact of surgical treatment on outcomes for papillary thyroid cancer. <b>2008</b> , 42, 1-12	21
1581	Management of the neck in differentiated thyroid cancer. <b>2008</b> , 17, 157-73, ix	4

1580	Radioiodine imaging and treatment in thyroid disorders. <b>2008</b> , 18, 505-15, viii	12
1579	Outcomes in reoperative thyroid cancer. <b>2008</b> , 41, 1261-8, xii	10
1578	Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. <b>2008</b> , 18, 103-11	28
1577	Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. <b>2008</b> , 18, 411-8	260
1576	Prognostic factors in patients with papillary thyroid carcinoma. <b>2008</b> , 31, 1032-7	11
1575	Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. <b>2008</b> , 158, 551-60	140
1574	Molecular analysis of multifocal papillary thyroid carcinoma. <b>2008</b> , 41, 195-203	50
1573	Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. <b>2008</b> , 18, 853-64	61
1572	Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. <b>2008</b> , 36, 699-703	39
1571	Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2008</b> , 19 Suppl 2, ii99-101	15
1570	Refractory thyroid cancer: a paradigm shift in treatment is not far off. <b>2008</b> , 26, 4701-4	47
1569	RET/PTC Oncogene Expression in Papillary Thyroid Carcinoma and Its Correlation With Clinicopathologic Findings. <b>2008</b> , 18, 233-237	
1568	Postoperative surveillance of differentiated thyroid carcinoma: rationale, techniques, and controversies. <b>2008</b> , 249, 429-44	73
1567	Decision analysis of discordant thyroid nodule biopsy guideline criteria. <b>2008</b> , 93, 3037-44	17
1566	Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. <b>2008</b> , 18, 943-52	82
1565	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. <b>2008</b> , 93, 3943-9	416
1564	Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. <b>2008</b> , 18, 509-16	39
1563	Thyroid carcinoma in the United Arab Emirates: perspectives and experience of a tertiary care hospital. <b>2008</b> , 1, 14-21	15

1562	Prognosis and risk stratification in young papillary thyroid carcinoma patients. <b>2008</b> , 55, 269-75	7
1561	Practical management of well differentiated thyroid carcinoma in Korea. <b>2008</b> , 55, 1015-24	7
1560	Genome-wide gene expression profiles of thyroid carcinoma: Identification of molecular targets for treatment of thyroid carcinoma. <b>2008</b> ,	3
1559	Risk-adapted management of thyroid cancer. <b>2008</b> , 14, 764-74	63
1558	Radiologic and pathologic findings of nonpalpable thyroid carcinomas detected by ultrasonography in a medical screening center. <b>2008</b> , 27, 215-23	48
1557	Complications after the surgical treatment of malignant thyroid disease. <b>2008</b> , 173, 399-402	6
1556	Multi-targeted approach in the treatment of thyroid cancer. <b>2008</b> , 4, 935-47	15
1555	Long-term impact of initial surgical and medical therapy on young patients with papillary thyroid cancer and bilateral cervical metastases. <b>2008</b> , 121, 63-66	13
1554	Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. <b>2008</b> , 3, e1885	78
1553	Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. <b>2008</b> , 40, 475-80	15
1552	Utilidad de la detección de tiroglobulina en el aspirado de punción ganglionar cervical en el seguimiento de pacientes con cancer papilar de tiroides. <b>2008</b> , 136,	
1551	Article Commentary: The Treatment of Thyroid Cancer. <b>2008</b> , 74, 389-399	6
1550	131Iodine in Thyroid Cancer. <b>2009</b> , 1007-1023	
1549	Short-Term Outcomes after Unilateral versus Complete Thyroidectomy for Malignancy: A National Perspective. <b>2009</b> , 75, 20-24	14
1548	Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours. <b>2009</b> , 53, 65-71	6
1547	Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review. <b>2009</b> , 16, 23-31	5
1546	Thyroid and Parathyroid Glands. <b>2009</b> , 563-646	4
1545	Clinicopathologic Findings of Micropapillary Carcinomas, according to Tumor Size. <b>2009</b> , 76, 348	2

1544	Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. <b>2009</b> , 53, 884-7	112
1543	Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours. <b>2009</b> , 53, e8	10
1542	Prognostic factors in patients with multiple recurrences of well-differentiated thyroid carcinoma. <b>2009</b> , 2009, 650340	6
1541	Clinical behavior of radiation-induced thyroid cancer: factors related to recurrence. <b>2009</b> , 19, 479-85	44
1540	Axillary lymph node metastasis as a late manifestation of papillary thyroid carcinoma. <b>2009</b> , 19, 417-9	15
1539	Simplifying the TNM system for clinical use in differentiated thyroid cancer. <b>2009</b> , 27, 1872-8	17
1538	Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. <b>2009</b> , 160, 619-24	53
1537	Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. <b>2009</b> , 16, 1251-60	163
1536	Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?. <b>2009</b> , 19, 473-7	103
1535	Well-differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease. <b>2009</b> , 19, 487-94	16
1534	Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers 2009, 16, 201-10	45
1533	Contemporary management of papillary carcinoma of the thyroid gland. <b>2009</b> , 9, 317-29	42
1532	Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. <b>2009</b> , 47, 1001-4	25
1531	Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. <b>2009</b> , 50, 18-23	131
1530	124I-PET(/CT) bei differenzierten Schilddrüsenkarzinomen. <b>2009</b> , 32, 149-153	
1529	Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. <b>2009</b> , 94, 4171-9	69
1528	Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. <b>2009</b> , 20, 1728-35	110
1527	Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2009</b> , 20 Suppl 4, 143-6	31



1526	Contribution of gamma probe-guided surgery to lateral approach completion thyroidectomy. <b>2009</b> , 15, 213-9	2
1525	The association between serum TSH concentration and thyroid cancer. <b>2009</b> , 16, 1065-72	93
1524	The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels. <b>2009</b> , 30, 608-12	39
1523	Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. <b>2009</b> , 253, 854-60	104
1522	Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. <b>2009</b> , 160, 431-6	74
1521	Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?. <b>2009</b> , 145, 514-8	92
1520	Thyroid surgery in octogenarians is associated with higher complication rates. <b>2009</b> , 146, 913-21	42
1519	Autophagy: a new target for advanced papillary thyroid cancer therapy. <b>2009</b> , 146, 1208-14	43
1518	Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute. <b>2009</b> , 59, 359-67	43
1517	[Advantages of completion thyroidectomy as a second stage for differentiated thyroid cancer]. <b>2009</b> , 146, 520-1	
1516	Thyroid cancer in young adults. <b>2009</b> , 36, 258-74	20
1515	I-131 In the Management of Differentiated thyroid Cancer â An Update on Current Recommendations and Practices. <b>2009</b> , 6, 347-354	1
1514	Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. <b>2009</b> , 31, 782-8	28
1513	Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection. <b>2009</b> , 115, 251-8	108
1512	High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. <b>2009</b> , 115, 972-80	104
1511	The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. <b>2009</b> , 99, 186-8	77
1510	Short-term overt hypothyroidism affect on lipids after thyroxine-withdrawal in patients with differentiated thyroid carcinoma. <b>2009</b> , 8, 647-649	2
1509	Intraoperative gamma probe guidance with <sup>99m</sup> Tc-pertechnetate in the completion thyroidectomy. <b>2009</b> , 23, 421-6	7

1508	Targeted therapies in thyroid cancer. <b>2009</b> , 4, 275-85	2
1507	Controversies and challenges in the management of well-differentiated thyroid cancer. <b>2009</b> , 71, 299-307	2
1506	Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. <b>2009</b> , 36, 343-6	26
1505	Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. <b>2009</b> , 36, 886-93	91
1504	Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. <b>2009</b> , 33, 460-8	62
1503	Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. <b>2009</b> , 71, 291-7	43
1502	A comparison of prognostic classification systems for differentiated thyroid carcinoma. <b>2010</b> , 72, 830-8	28
1501	Short-term overt hypothyroidism induces discrete diastolic dysfunction in patients treated for differentiated thyroid carcinoma. <b>2009</b> , 39, 204-10	15
1500	Surgical management of advanced differentiated thyroid cancer -- introducing the concept of wide field total thyroidectomy: how we do it. <b>2009</b> , 34, 161-4	3
1499	Predictive factors of level IIb lymph node metastasis in patients with papillary thyroid carcinoma. <b>2009</b> , 16, 1344-7	36
1498	Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. <b>2009</b> , 16, 1348-55	98
1497	Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. <b>2009</b> , 19, 1167-214	5121
1496	BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. <b>2009</b> , 27, 2977-82	215
1495	The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. <b>2009</b> , 19, 683-9	197
1494	Sentinel lymph node biopsy in papillary thyroid cancer: comparison study of blue dye method and combined radioisotope and blue dye method in papillary thyroid cancer. <b>2009</b> , 35, 974-9	34
1493	Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. <b>2009</b> , 156, 167-72	319
1492	Le cancer de la thyroïde chez lâenfant (^ propos de 9 cas). <b>2009</b> , 33, 737-740	
1491	Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. <b>2009</b> , 9, 1261-75	6

1490	Adequate surgery for papillary thyroid cancer. <b>2009</b> , 7, 286-9	12
1489	[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice]. <b>2009</b> , 56, 176-86	12
1488	The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. <b>2009</b> , 19, 1381-91	122
1487	Role of ultrasound in the assessment of nodular thyroid disease. <b>2009</b> , 53, 177-87	48
1486	Surgical management of well-differentiated thyroid cancer: state of the art. <b>2009</b> , 89, 1171-91	19
1485	The Role of BRAFV600E Mutation in the Management of Thyroid Papillary Carcinoma. <b>2009</b> , 14, 231-235	3
1484	Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. <b>2009</b> , 249, 1023-31	76
1483	Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. <b>2009</b> , 249, 840-4	136
1482	Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. <b>2009</b> , 56, 177-92	114
1481	Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. <b>2009</b> , 250, 403-8	87
1480	Total thyroidectomy followed by postsurgical remnant ablation may improve cancer specific survival in differentiated thyroid carcinoma. <b>2010</b> , 35, 396-9	10
1479	Radioiodine Treatment of Differentiated Thyroid Carcinoma: The Experience at Seoul National University Hospital. <b>2010</b> , 6, 2-7	2
1478	Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer. <b>2010</b> , 31, 274-9	15
1477	BRAF Mutations in Papillary Thyroid Carcinoma. <b>2010</b> , 15, 121-125	
1476	Follicular variant of papillary thyroid carcinoma presenting as a toxic nodule by I-123 scintigraphy. <b>2010</b> , 35, 770-5	11
1475	Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. <b>2010</b> , 35, 6-11	12
1474	Thyroid carcinoma. <b>2010</b> , 8, 1228-74	172
1473	Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis. <b>2010</b> , 29, 419-25	44

1472	Initial management and follow-up of differentiated thyroid cancer in children. <b>2010</b> , 8, 1289-300	37
1471	Medullary carcinoma. <b>2010</b> , 8, 512-30	58
1470	Surgical Management of Thyroid Cancer. <b>2010</b> , 117-124	
1469	Medical Management of Thyroid Cancer. <b>2010</b> , 125-141	
1468	Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. <b>2010</b> , 17, 1101-5	49
1467	Prophylactic lymphadenectomy of neck level II in clinically node-positive papillary thyroid carcinoma. <b>2010</b> , 17, 1637-41	11
1466	The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. <b>2010</b> , 17, 3294-300	135
1465	Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence. <b>2010</b> , 40, 199-215	38
1464	Long-term outcome of differentiated thyroid carcinoma: experience in a developing country. <b>2010</b> , 34, 40-7	25
1463	Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern Thailand. <b>2010</b> , 34, 230-6	4
1462	Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. <b>2010</b> , 34, 1187-91	143
1461	Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: preliminary report. <b>2010</b> , 34, 2558-63	53
1460	[Minimally invasive follicular thyroid carcinoma : Not always total thyroidectomy]. <b>2010</b> , 81, 627-30, 632-5	16
1459	Regional metastatic pattern of papillary thyroid carcinoma. <b>2010</b> , 267, 437-41	25
1458	Management of thyroid cancers. <b>2010</b> , 1, 151-62	
1457	Differentiated thyroid cancer. <b>2010</b> , 37, 557-66	89
1456	Papillary thyroid cancer in children and adolescents does not differ in growth pattern and metastatic behavior. <b>2010</b> , 157, 648-52	39
1455	Occult lymph node metastases in neck level V in papillary thyroid carcinoma. <b>2010</b> , 147, 241-5	33

1454	Indeterminate thyroid nodules: a challenge for the surgical strategy. <b>2010</b> , 148, 516-25	18
1453	BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. <b>2010</b> , 148, 1139-45; discussion 1145-6	79
1452	Management of cervical nodal metastasis detected on I-131 scintigraphy after initial surgery of well-differentiated thyroid carcinoma. <b>2010</b> , 148, 1198-204; discussion 1204-6	4
1451	Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. <b>2010</b> , 148, 1100-6; discussion 1006-7	177
1450	Papillary cancer nodal surgery and the advisability of prophylactic central neck dissection: primum, non nocere. <b>2010</b> , 148, 1108-12	12
1449	Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. <b>2010</b> , 19, e57-70	68
1448	Occult contralateral central lymph node metastases in papillary thyroid carcinoma with unilateral lymph node metastasis in the lateral neck. <b>2010</b> , 210, 895-900	34
1447	Radioiodine ablation for differentiated thyroid cancer-none, one dose or two?. <b>2010</b> , 22, 131-5	1
1446	Contemporary post surgical management of differentiated thyroid carcinoma. <b>2010</b> , 22, 419-29	32
1445	Who should treat thyroid cancer? A UK surgical perspective. <b>2010</b> , 22, 413-8	1
1444	Thyroid cancer epidemiology and prognostic variables. <b>2010</b> , 22, 395-404	329
1443	Treatment and prognostic factors of papillary thyroid microcarcinoma. <b>2010</b> , 35, 118-24	60
1442	Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. <b>2010</b> , 101, 1731-7	121
1441	An Overview of the Management of Thyroid Cancer. <b>2010</b> , 104-116	1
1440	. <b>2010</b> ,	
1439	Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. <b>2010</b> , 25, 270	30
1438	An Evaluation of Lymph Node Yield and Lymph Node Ratio in Well-Differentiated Thyroid Carcinoma. <b>2010</b> , 76, 28-32	44
1437	Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: knowing when to stop. <b>2010</b> , 54, 807-12	7

1436	Folikulinio skydliaukė vėb ilgalaikio kompleksinio gydymo rezultatai. <b>2010</b> , 46, 268	
1435	Utility of the ultrasound elastographic systolic thyroid stiffness index in reducing fine-needle aspirations. <b>2010</b> , 29, 565-74	39
1434	Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trial. <b>2010</b> , 163, 637-44	28
1433	L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. <b>2010</b> , 17, 231-9	44
1432	Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. <b>2010</b> , 162, 1131-9	57
1431	Old and new insights in the treatment of thyroid carcinoma. <b>2010</b> , 2010, 279468	7
1430	Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysis. <b>2010</b> , 2010, 325602	26
1429	Tc-99m radio-guided completion thyroidectomy for differentiated thyroid carcinoma. <b>2010</b> , 25, 12-5	2
1428	Endocrine Neoplasia. <b>2010</b> ,	1
1427	Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. <b>2010</b> , 95, 2325-33	100
1426	Differentiated thyroid cancer with extrathyroidal extension: prognosis and the role of external beam radiotherapy. <b>2010</b> , 2010, 183461	25
1425	Papillary thyroid carcinoma: debate at rest. <b>2010</b> , 47, 206-16	9
1424	Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality. <b>2010</b> , 136, 692-6	29
1423	Fas ligand (FasL, Apo-1L/CD95L) expression and clinical outcome in papillary microcarcinoma and papillary thyroid carcinomas with diameter smaller than 1.5 centimeters. <b>2010</b> , 118, 537-43	2
1422	Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. <b>2010</b> , 95, 1516-27	167
1421	Langfristige Prognose des differenzierten Schilddr�senkarzinoms. <b>2010</b> , 33, 249-256	0
1420	Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. <b>2010</b> , 95, 4576-83	89
1419	Postoperative management of differentiated thyroid cancer. <b>2010</b> , 43, 329-51, viii-ix	5

1418	Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. <b>2010</b> , 20, 135-46	180
1417	Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. <b>2010</b> , 20, 147-52	145
1416	[Clinical endocrinologists' perception of the deleterious effects of TSH suppressive therapy in patients with differentiated thyroid carcinoma]. <b>2010</b> , 57, 350-6	1
1415	Surgery of well-differentiated thyroid carcinoma: the pendulum swings back in the central neck. <b>2010</b> , 16, 913-7	1
1414	Follicular thyroid carcinoma invades venous rather than lymphatic vessels. <b>2010</b> , 5, 8	18
1413	The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. <b>2010</b> , 20, 1235-45	115
1412	A new radioguided procedure for localization and surgical treatment of neck node metastasis of papillary thyroid cancer. <b>2010</b> , 33, 339-42	10
1411	Clinical efficacy of fine-needle aspiration biopsy of thyroid nodules in males. <b>2010</b> , 159, 645-50	11
1410	Prognostic utility of BRAF mutation in papillary thyroid cancer. <b>2010</b> , 321, 86-93	167
1409	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. <b>2010</b> , 322, 8-28	99
1408	BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. <b>2010</b> , 73, 113-28	94
1407	Reoperation for recurrent/persistent well-differentiated thyroid cancer. <b>2010</b> , 43, 353-63, ix	27
1406	miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. <b>2010</b> , 20, 489-94	183
1405	Considerations for personalized surgery in patients with papillary thyroid cancer. <b>2010</b> , 20, 771-6	18
1404	Thyroid function and human reproductive health. <b>2010</b> , 31, 702-55	677
1403	Thyroid cancer in older men. <b>2011</b> , 14, 91-8	13
1402	Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. <b>2011</b> , 21, 845-53	94
1401	Imaging surveillance of differentiated thyroid cancer. <b>2011</b> , 49, 473-87, vi	9

1400	Good practice guide for cervical ultrasound scan and echo-guided techniques in treating differentiated thyroid cancer of vesicular origin. <b>2011</b> , 72, 173-97	23
1399	[Best practices guideline for the use of neck ultrasonography and echo-guided techniques in the management of differentiated thyroid cancers of the follicular type. Société Française d'Endocrinologie. Groupe de Recherche sur la Thyroïde]. <b>2011</b> , 72, H1-26	3
1398	Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma. <b>2011</b> , 58, 75-83	5
1397	[Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma]. <b>2011</b> , 58, 75-83	6
1396	XB130, a novel adaptor protein, promotes thyroid tumor growth. <b>2011</b> , 178, 391-401	34
1395	Telomere length is related to alternative splice patterns of telomerase in thyroid tumors. <b>2011</b> , 179, 1415-24	18
1394	Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. <b>2011</b> , 201, 770-5	50
1393	SPECT-CT for Tumor Imaging. <b>2011</b> , 15-104	
1392	Radioiodine for remnant ablation and therapy of metastatic disease. <b>2011</b> , 7, 589-95	49
1391	Valeur pronostique du curage ganglionnaire prophylactique dans le cancer différencié de la thyroïde. <b>2011</b> , 35, 522-527	
1390	Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. <b>2011</b> , 96, E1719-26	137
1389	Molecular nuclear therapies for thyroid carcinoma. <b>2011</b> , 55, 230-7	8
1388	Metastatic carcinoma of maxilla secondary to primary follicular carcinoma of thyroid gland—case report. <b>2011</b> , 2, 30-32	2
1387	Prognostic evaluation of patients with multicentric papillary thyroid microcarcinoma. <b>2011</b> , 110, 511-7	10
1386	The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. <b>2011</b> , 32, 798-826	149
1385	An individualized approach to the child with thyroid cancer. <b>2011</b> , 6, 85-92	1
1384	Cancer thyroïdien. <b>2011</b> , 655-669	1
1383	Lymph node dissection in papillary thyroid carcinoma. <b>2011</b> , 41, 84-8	19



1382	Consensus-based management of differentiated thyroid cancer in a tertiary care set-up. <b>2011</b> , 9, 96-100	3
1381	CASE 98. <b>2011</b> ,	
1380	Metastatic Thyroid Cancer: Evaluation and Treatment. 382-386	
1379	Thyroid cancer: burden of illness and management of disease. <b>2011</b> , 2, 193-9	117
1378	Management of papillary and follicular (differentiated) thyroid carcinoma - an update. <b>2011</b> , 16, 126-130	
1377	Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer. <b>2011</b> ,	1
1376	The role of prophylactic central neck dissection in differentiated thyroid carcinoma: issues and controversies. <b>2011</b> , 2011, 127929	17
1375	Experience and analysis of level VII cervical lymph node metastases in patients with papillary thyroid carcinoma. <b>2011</b> , 80, 307-12	14
1374	Axillary lymph node metastasis and survival in breast cancer patients with concurrent cardio-cerebral-vascular disease. <b>2011</b> , 2, 12	2
1373	Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma. <b>2011</b> , 32, 954-9	28
1372	Central compartment dissection in thyroid papillary carcinoma. <b>2011</b> , 253, 123-30	30
1371	Insignificance of prophylactic upper mediastinal lymph node dissection by sternotomy for papillary thyroid carcinoma. <b>2011</b> , 58, 1093-8	6
1370	Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. <b>2011</b> , 58, 381-93	28
1369	Prognostic factors of a good response to initial therapy in children and adolescents with differentiated thyroid cancer. <b>2011</b> , 66, 281-6	25
1368	An analysis of factors predicting lateral cervical nodal metastases in papillary carcinoma of the thyroid. <b>2011</b> , 137, 1141-5	28
1367	Central neck dissection for papillary thyroid cancer. <b>2011</b> , 18, 83-8	58
1366	Recurrence of papillary thyroid carcinoma in a remnant pyramidal lobe. <b>2011</b> , 81, 304	12
1365	Pseudoangiomatous stromal hyperplasia of the breast: an unusual pathology necessitating bilateral mastectomy during pregnancy. <b>2011</b> , 81, 304-5	4

1364	Predictive factors related to the recurrence at US-guided fine needle aspiration in postoperative patients with differentiated thyroid cancer. <b>2011</b> , 74, 270-5	8
1363	Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. <b>2011</b> , 75, 112-9	135
1362	Use of sodium iodide symporter expression in differentiated thyroid carcinomas. <b>2011</b> , 75, 247-54	21
1361	A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. <b>2011</b> , 150, 1048-57	181
1360	The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. <b>2011</b> , 150, 1242-9	107
1359	Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. <b>2011</b> , 150, 1258-65	25
1358	Thyroid isthmusectomy for well-differentiated thyroid cancer. <b>2011</b> , 18, 767-70	42
1357	Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. <b>2011</b> , 18, 1312-8	78
1356	Contribution of computed tomography to ultrasound in predicting lateral lymph node metastasis in patients with papillary thyroid carcinoma. <b>2011</b> , 18, 1734-41	36
1355	Clinical implications of bilateral lateral cervical lymph node metastasis in papillary thyroid cancer: a risk factor for lung metastasis. <b>2011</b> , 18, 3486-92	25
1354	Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. <b>2011</b> , 18, 3566-71	49
1353	Psychological impact of thyroid surgery on patients with well-differentiated papillary thyroid cancer. <b>2011</b> , 20, 1411-7	13
1352	Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level. <b>2011</b> , 38, 1296-302	22
1351	Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. <b>2011</b> , 35, 111-21	138
1350	Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection. <b>2011</b> , 35, 1560-6	26
1349	The efficacy of lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma. <b>2011</b> , 35, 2675-82	20
1348	Prognostic factors and follow-up of patients with differentiated thyroid carcinoma with false negative or nondiagnostic FNAC before surgery. Comparison with a control group. <b>2011</b> , 40, 423-31	6
1347	Lobectomy versus total thyroidectomy in children with post-Chernobyl thyroid cancer: a 15 year follow-up. <b>2011</b> , 40, 432-6	5

1346	Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review. <b>2011</b> , 4, 9	9
1345	Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. <b>2011</b> , 33, 645-9	137
1344	Classification of papillary thyroid microcarcinoma according to size and fine-needle aspiration cytology: Behavior and therapeutic implications. <b>2011</b> , 33, 696-701	19
1343	Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. <b>2011</b> , 117, 4439-46	220
1342	The unexpected burden of hypomagnesaemia in gynae-oncology chemotherapy clinics. <b>2011</b> , 23, 373-4	2
1341	The recurrence rate for low-risk differentiated thyroid cancer is extremely low (0.5% after more than 5 years of follow-up). <b>2011</b> , 23, 374-5	1
1340	Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. <b>2011</b> , 32, 4840-8	65
1339	Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. <b>2011</b> , 96, 1237-45	74
1338	Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation. <b>2011</b> , 96, 3695-700	22
1337	[Indication and extent of cervical lymph node dissection in differentiated thyroid carcinoma]. <b>2011</b> , 136, 364-73	2
1336	Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. <b>2011</b> , 21, 391-9	28
1335	Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. <b>2011</b> , 21, 751-7	76
1334	Disease-related death in patients who were considered free of macroscopic disease after initial treatment of well-differentiated thyroid carcinoma. <b>2011</b> , 21, 501-4	18
1333	Historical note: TSH suppression for thyroid cancer. <b>2011</b> , 21, 1175-6	9
1332	Total en bloc spondylectomy for spinal metastases in thyroid carcinoma. <b>2011</b> , 14, 172-6	66
1331	Continuous re-evaluation in differentiated thyroid carcinoma. <b>2011</b> , 7, 127-8	4
1330	Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. <b>2011</b> , 12, 1-14	349
1329	Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. <b>2011</b> , 96, 1352-9	164

1328	Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. <b>2011</b> , 165, 441-6	186
1327	The need for a low-expense universally acceptable rhTSH protocol. <b>2011</b> , 52, 1166	1
1326	BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. <b>2011</b> , 49, 325-9	40
1325	Extent of surgery for differentiated thyroid cancer: recommended guideline. <b>2011</b> , 26, 56-8	4
1324	Molecular Therapies in Thyroid Cancer. <b>2011</b> , 4, 91-100	1
1323	Prognosis of thyroid cancer related to pregnancy: a systematic review. <b>2011</b> , 2011, 691719	22
1322	Thyroid carcinoma in children and adolescents-systematic review of the literature. <b>2011</b> , 2011, 845362	44
1321	Differentiated thyroid cancer in navarra (Spain): historic cohort results (1987-2003). <b>2011</b> , 2011, 560503	1
1320	The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. <b>2011</b> , 96, 2049-56	88
1319	Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma. <b>2011</b> , 2011, 308029	16
1318	Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer. <b>2011</b> , 21, 511-7	19
1317	Gender differences in thyroid cancer: a critical review. <b>2011</b> , 6, 215-243	30
1316	The first report of bilateral retropharyngeal lymph node metastasis from papillary thyroid carcinoma and review of the literature. <b>2011</b> , 131, 1341-8	17
1315	The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. <b>2011</b> , 52, 56-9	42
1314	The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. <b>2012</b> , 138, 44-9	22
1313	Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. <b>2012</b> , 97, 2706-13	100
1312	Durable effect of radioactive iodine in a patient with metastatic follicular thyroid carcinoma. <b>2012</b> , 2012, 231912	4
1311	BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. <b>2012</b> , 91, 274-286	207

1310	CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. <b>2012</b> , 25, 46-55	30
1309	Algorithmen für die Nachsorge des Schilddrüsenkarzinoms. <b>2012</b> , 35, 53-57	
1308	Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. <b>2012</b> , 97, E934-43	75
1307	Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?. <b>2012</b> , 97, 2748-53	110
1306	Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. <b>2012</b> , 22, 536-41	20
1305	Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. <b>2012</b> , 97, 1134-45	139
1304	Response to Kuru and Topgul. <b>2012</b> , 22, 226-227	1
1303	Undetectable serum thyroglobulin levels in patients with medullary thyroid carcinoma after total thyroidectomy without radioiodine ablation. <b>2012</b> , 22, 680-2	11
1302	The Effects of the Factors Related to the Patient and the Disease on the Performance of Ablation Therapy in Patients with Differentiated Thyroid Cancer who have Received I-131 Ablation Therapy. <b>2012</b> , 21, 103-9	4
1301	Surgical and pathological characteristics of papillary thyroid cancer in children and adolescents. <b>2012</b> , 2012, 125389	6
1300	Progress in gene therapy for prostate cancer. <b>2012</b> , 2, 172	25
1299	Large discrepancy in the results of sensitive measurements of thyroglobulin antibodies in the follow-up on thyroid cancer: a diagnostic dilemma. <b>2012</b> , 1, 193-7	8
1298	Prognostic Factors for Differentiated Thyroid Carcinoma and Review of the Literature. <b>2012</b> , 98, 233-237	12
1297	Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. <b>2012</b> , 33, 268-74	32
1296	Role of SPECT/CT in differentiated thyroid cancer. <b>2012</b> , 33, 787-98	23
1295	Correlation of clinicopathological features and expression of molecular markers with prognosis after $^{131}\text{I}$ treatment of differentiated thyroid carcinoma. <b>2012</b> , 37, e40-6	8
1294	[Treatment of thyroid cancer with radioactive iodine: indication and practice]. <b>2012</b> , 115, 204-5, 208	
1293	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review). <b>2012</b> , 6, 687-94	20

1292	Serum thyroglobulin level measured after thyroxine withdrawal is useful to predict further recurrence in whole body scan-negative papillary thyroid cancer patients after reoperation. <b>2012</b> , 59, 1021-30	5
1291	Papillary thyroid carcinoma involving cervical neck lymph nodes: correlations with lymphangiogenesis and ultrasound features. <b>2012</b> , 59, 941-8	14
1290	Imaging of thyroid cancer. <b>2012</b> , 33, 138-49	18
1289	Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. <b>2012</b> , 97, 2543-65	942
1288	Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer). <b>2012</b> , 22, 2246-54	20
1287	Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy. <b>2012</b> , 31, 328-31	4
1286	Differences in the diagnostic performances of staging US for thyroid malignancy according to experience. <b>2012</b> , 38, 568-73	26
1285	Analysis of prognostic factors in patients with multiple recurrences of papillary thyroid carcinoma. <b>2012</b> , 21, 185-90	21
1284	Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy. <b>2012</b> , 31, 328-331	
1283	Thyroid nodules. <b>2012</b> , 96, 329-49	114
1282	Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?. <b>2012</b> , 19, 3479-85	35
1281	Nuclear Endocrinology. <b>2012</b> , 163-190	
1280	BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. <b>2012</b> , 39, 198-203	44
1279	Thyroid microcarcinoma. <b>2012</b> , 26, 381-9	15
1278	Thyroid microcarcinoma. <b>2012</b> , 26, 421-9	20
1277	Should thyroxine treatment be discontinued for four weeks before 131I thyroid ablation?. <b>2012</b> , 59, 227-231	
1276	Radioiodine therapy of thyroid carcinoma following Pax-8 gene transfer. <b>2012</b> , 19, 435-42	5
1275	BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. <b>2012</b> , 10, 104	17

1274	Clinical predictors of right upper paraesophageal lymph node metastasis from papillary thyroid carcinoma. <b>2012</b> , 10, 164	27
1273	Spinal metastasis in thyroid cancer. <b>2012</b> , 4, 39	32
1272	Extensive Surgery for Thyroid Cancer. <b>2012</b> , 67-77	
1271	Update on thyroid cancer treatment. <b>2012</b> , 8, 1331-48	29
1270	Ablation Therapy with Radioiodine in Adults and Children with Differentiated Thyroid Cancer. <b>2012</b> , 245-258	
1269	Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. <b>2012</b> , 22, 905-10	82
1268	Papillary Thyroid Carcinoma. <b>2012</b> , 133-153	2
1267	French ENT Society (SFORL) practice guidelines for lymph-node management in adult differentiated thyroid carcinoma. <b>2012</b> , 129, 197-206	14
1266	TSH-suppressive treatment in differentiated thyroid cancer. A dogma under review. <b>2012</b> , 59, 125-130	5
1265	TSH-suppressive treatment in differentiated thyroid cancer. A dogma under review. <b>2012</b> , 59, 125-30	5
1264	[Should thyroxine treatment be discontinued for four weeks before I(131) thyroid ablation?]. <b>2012</b> , 59, 227-31	1
1263	A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry. <b>2012</b> , 152, 145-51	62
1262	Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?. <b>2012</b> , 152, 1096-105	58
1261	Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line. <b>2012</b> , 39, 1275-80	10
1260	Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. <b>2012</b> , 97, 3996-4003	71
1259	Clinical-pathological changes in differentiated thyroid cancer (DTC) over time (1997-2010): data from the University Hospital "Maggiore della Carit" in Novara. <b>2012</b> , 42, 382-90	15
1258	BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. <b>2012</b> , 42, 404-10	42
1257	Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer. <b>2012</b> , 26, 777-86	12

- 1256 Recommendation de la Société française d'oto-rhino-laryngologie et de chirurgie de la face et du cou pour la prise en charge ganglionnaire dans les cancers différenciés de souche folliculaire du corps thyroïde chez l'adulte. Recommandation pour la pratique clinique. **2012**, 129, 250-260
- 1255 Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin. **2012**, 19, 2951-7 42
- 1254 Imaging in Thyroid Cancer. **2012**, 621-631
- 1253 Management of well-differentiated thyroid cancer. **2012**, 45, 1163-79 14
- 1252 The impact of age and gender on papillary thyroid cancer survival. **2012**, 97, E878-87 127
- 1251 Reevaluating the prognostic significance of age in differentiated thyroid cancer. **2012**, 147, 221-6 37
- 1250 Thyroid Cancer. **2012**, 5
- 1249 Pediatric thyroid cancers: an Indian perspective. **2012**, 3, 166-72 4
- 1248 Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. **2012**, 53, 924-30 41
- 1247 To treat or not to treat: the role of adjuvant radioiodine therapy in thyroid cancer patients. **2012**, 2012, 707156 18
- 1246 Fine-needle aspiration biopsy of thyroid bed lesions in post-thyroidectomy patients: what is the importance of nondiagnostic biopsy results?. **2012**, 31, 1973-6 4
- 1245 MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report. **2012**, 56, 552-7 32
- 1244 Successful management of differentiated thyroid cancer in a community-based endocrine practice. **2012**, 18, 170-8 1
- 1243 Multifocal Micropapillary Thyroid Cancer: A New Indication for Total Thyroidectomy?. **2012**, 78, 1211-1214 12
- 1242 Two cases of papillary thyroid carcinoma with solitary lung metastasis. **2012**, 73, 2181-2185
- 1241 Alpha-Lipoic Acid Decreases Iodine Uptake in the Rat Thyroid Cell Line FRTL-5. **2012**, 5, 39
- 1240 Age and prognosis of papillary thyroid carcinoma: retrospective stratification into three groups. **2012**, 83, 259-66 19
- 1239 Clinical experience of thyroid carcinoma: a study of 178 cases. **2012**, 16, 218-22 2



1238	Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. <b>2012</b> , 19, 591-6	42
1237	Right paraesophageal lymph node dissection in papillary thyroid carcinoma. <b>2012</b> , 19, 996-1000	24
1236	Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. <b>2012</b> , 106, 357-62	63
1235	Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. <b>2012</b> , 122, 797-804	93
1234	Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. <b>2012</b> , 122, 1634-40	51
1233	The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. <b>2012</b> , 118, 1764-73	301
1232	$^{18}$ F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. <b>2012</b> , 39, 1373-80	50
1231	Well differentiated thyroid carcinoma: current treatment. <b>2012</b> , 13, 47-57	10
1230	Radioactive iodine ( $^{131}$ I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. <b>2012</b> , 26, 99-112	23
1229	Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas. <b>2012</b> , 18, 449-58	21
1228	Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer. <b>2012</b> , 36, 1255-61	19
1227	Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation exposure. <b>2012</b> , 36, 1241-6	58
1226	Prognostic factors in differentiated thyroid cancer--a 20-year surgical outcome study. <b>2012</b> , 397, 809-15	22
1225	Comparative analysis of therapeutic efficacy of $^{131}$ I in different clinical stages postoperative patients with papillary thyroid carcinoma. <b>2012</b> , 11, 399-402	
1224	Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment. <b>2012</b> , 76, 131-6	74
1223	Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation. <b>2012</b> , 24, 162-8	6
1222	Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. <b>2012</b> , 24, 159-61	43
1221	Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. <b>2012</b> , 151, 571-9	214

1220	Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. <b>2012</b> , 77, 139-45	18
1219	Clinical implication of elastography as a prognostic factor of papillary thyroid microcarcinoma. <b>2012</b> , 19, 2279-87	43
1218	Routine central compartment lymph node dissection for patients with papillary thyroid carcinoma. <b>2012</b> , 34, 260-3	35
1217	Study on the effective diffusion coefficient of nano-magnetic fluid and the geometrical factors in tumor tissues. <b>2012</b> , 48, 275-282	1
1216	S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. <b>2012</b> , 90, 163-74	46
1215	Fine-needle aspiration of metastatic papillary thyroid carcinoma found in the liver. <b>2013</b> , 41, 418-24	5
1214	Pattern and predictive factors of regional lymph node metastasis in papillary thyroid carcinoma: a prospective study. <b>2013</b> , 35, 40-5	27
1213	BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas. <b>2013</b> , 35, 548-53	16
1212	Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. <b>2013</b> , 35, 592-8	26
1211	Ultrasound-guided fine-needle aspiration biopsy of thyroid bed lesions from patients with thyroidectomy for thyroid carcinomas. <b>2013</b> , 121, 101-7	11
1210	Thyroid cancer: surgery for the primary tumor. <b>2013</b> , 49, 654-8	15
1209	Treatment of Thyroid Tumor. <b>2013</b> ,	7
1208	Nuclear Medicine Therapy. <b>2013</b> ,	3
1207	Quantitative shear wave elastography as a prognostic implication of papillary thyroid carcinoma (PTC): elasticity index can predict extrathyroidal extension (ETE). <b>2013</b> , 20, 2765-71	19
1206	Cancer: The effect of radioiodine therapy after total thyroidectomy. <b>2013</b> , 9, 511-2	2
1205	Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. <b>2013</b> , 37, 376-84	91
1204	Thyroid remnant ablation in differentiated thyroid carcinoma: when and how. <b>2013</b> , 1, 195-203	
1203	Effect of reoperation on outcomes in papillary thyroid cancer. <b>2013</b> , 154, 1354-61; discussion 1361-2	35

1202	Variations in clinicopathologic characteristics of thyroid cancer among racial ethnic groups: analysis of a large public city hospital and the SEER database. <b>2013</b> , 206, 632-40	18
1201	Prognostic nomograms to predict oncological outcome of thyroid cancers. <b>2013</b> , 98, 4768-75	26
1200	BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. <b>2013</b> , 20, 47-52	103
1199	A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. <b>2013</b> , 154, 1436-46; discussion 1446-7	173
1198	Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma. <b>2013</b> , 206, 586-93	44
1197	Level VII is an important component of central neck dissection for papillary thyroid cancer. <b>2013</b> , 20, 2261-5	16
1196	Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: a systematic review and meta-analysis. <b>2013</b> , 23, 583-92	65
1195	Indications of external beam radiation therapy in non-anaplastic thyroid cancer and impact of innovative radiation techniques. <b>2013</b> , 86, 52-68	24
1194	New developments in the diagnosis and treatment of thyroid cancer. <b>2013</b> , 63, 374-94	198
1193	DIRECT VISUALIZATION OF THERAPEUTIC RADIONUCLIDE DISTRIBUTION USING NUCLEAR MEDICINE IMAGING. <b>2013</b> , 426-431	
1192	Impact of lymph node ratio on survival in papillary thyroid cancer. <b>2013</b> , 20, 1906-11	101
1191	Usefulness of partial volume effect-corrected F-18 FDG PET/CT for predicting I-131 accumulation in the metastatic lymph nodes of patients with thyroid carcinoma. <b>2013</b> , 27, 873-9	6
1190	Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers. <b>2013</b> , 23, 529-42	12
1189	Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?. <b>2013</b> , 44, 426-33	24
1188	Ernest L. Mazzaferri, MD, MACP (1936-2013). <b>2013</b> , 23, 917-23	0
1187	Thyroid and Parathyroid Tumors. <b>2013</b> , 297-361	
1186	Radioiodine Therapy of Differentiated Thyroid Cancer. <b>2013</b> , 133-153	
1185	Prophylactic central neck dissection for papillary thyroid cancer. <b>2013</b> , 100, 410-8	189

1184	Morbidity of enlargement of the central compartment in differentiated thyroid cancer. <b>2013</b> , 130, 250-254	
1183	Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. <b>2013</b> , 39, 191-6	88
1182	Recurrent well-differentiated thyroid carcinoma. <b>2013</b> , 49, 689-94	18
1181	18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin. <b>2013</b> , 23, 1003-9	14
1180	Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. <b>2013</b> , 54, 1230-6	41
1179	Morbidity of central compartment dissection for differentiated thyroid carcinoma of the follicular epithelium. <b>2013</b> , 130, 245-9	7
1178	Increasing incidence of thyroid cancer: controversies explored. <b>2013</b> , 9, 178-84	113
1177	An easy schedule for postsurgical radioiodine administration in newly diagnosed differentiated thyroid carcinoma patients. <b>2013</b> , 78, 145-51	2
1176	Lymph node ratio predicts recurrence in papillary thyroid cancer. <b>2013</b> , 18, 157-62	65
1175	Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. <b>2013</b> , 98, 636-42	199
1174	Pitfalls in the staging of cancer of thyroid. <b>2013</b> , 23, 123-45	4
1173	Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. <b>2013</b> , 168, 675-81	39
1172	Thyroid Neoplasia. <b>2013</b> , 319-336	
1171	CQ17. Does Total (or Near Total) Thyroidectomy Improve the Prognosis of Papillary Carcinoma Patients Compared to Lobectomy or Lobectomy Isthmectomy?. <b>2013</b> , 107-110	
1170	CQ24. Does Total Thyroidectomy with Radioactive Iodine Ablation and TSH Suppression Therapy Improve Patient Prognosis with Widely Invasive Follicular Carcinoma Compared to Only Limited Thyroidectomy?. <b>2013</b> , 149-151	
1169	CQ40. What Are Applications and Roles of Ablation?. <b>2013</b> , 231-233	
1168	Column 13. Comments on RAI Therapy Including the Actual Situation in Japan. <b>2013</b> , 247-249	
1167	Progress in molecular-based management of differentiated thyroid cancer. <b>2013</b> , 381, 1058-69	378

1166	Remnant uptake as a postoperative oncologic quality indicator. <b>2013</b> , 23, 1269-76	29
1165	The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. <b>2013</b> , 23, 683-94	60
1164	Molekulare Bildgebung und pathologische Diagnostik. <b>2013</b> , 19, 809-820	
1163	Influence of human immune cells on cancer: studies at the University of Colorado. <b>2013</b> , 55, 22-33	11
1162	Radioiodine Remnant Ablation: A Critical Review. <b>2013</b> , 289-300	2
1161	Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. <b>2013</b> , 2, 57-64	26
1160	Management of differentiated thyroid cancer in the presence of resistance to thyroid hormone and TSH-secreting adenomas: a report of four cases and review of the literature. <b>2013</b> , 98, 2210-7	29
1159	Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer. <b>2013</b> , 9, 921-3	0
1158	Preoperative ultrasonographic features of papillary thyroid carcinoma predict biological behavior. <b>2013</b> , 98, 1476-82	56
1157	Estrogen Induces Metastatic Potential of Papillary Thyroid Cancer Cells through Estrogen Receptor and $\beta$ -catenin. <b>2013</b> , 2013, 941568	38
1156	A case of concurrent several forms of thyroid cancer. <b>2013</b> , 54, 351-3	8
1155	Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry. <b>2013</b> , 52, 249-58	90
1154	Limited adequacy of thyroid cancer patient follow-up at a Canadian tertiary care centre. <b>2013</b> , 56, 385-92	5
1153	Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. <b>2013</b> , 347, f4706	187
1152	Recurrence of differentiated thyroid cancer in the elderly. <b>2013</b> , 168, 549-56	25
1151	Thyroid cancer in pediatric age group: an institutional experience and review of the literature. <b>2013</b> , 35, 93-7	27
1150	Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. <b>2013</b> , 37, 1586-91	39
1149	Long-term follow-up of patients with differentiated thyroid cancer who had negative <sup>131</sup> I whole-body scan at first evaluation after treatment. <b>2013</b> , 38, 765-9	8

1148	Differentiated thyroid carcinoma: defining new paradigms for postoperative management. <b>2013</b> , 20, R141-54	33
1147	Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. <b>2013</b> , 20, 13-22	38
1146	Life expectancy is reduced in differentiated thyroid cancer patients ≥45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. <b>2013</b> , 98, 172-80	127
1145	Factors influencing morbidity after surgical management of malignant thyroid disease. <b>2013</b> , 122, 398-403	10
1144	Changes of regulatory T and B cells in patients with papillary thyroid carcinoma after 131I radioablation: a preliminary study. <b>2013</b> , 2013, 683768	0
1143	Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma. <b>2013</b> , 23, 566-74	27
1142	The clinical and economic burden of a sustained increase in thyroid cancer incidence. <b>2013</b> , 22, 1252-9	164
1141	Surgical extent of central lymph node dissection in clinically node-negative papillary thyroid cancer. <b>2013</b> , 35, 1616-20	19
1140	BRAF: a tool in the decision to perform elective neck dissection?. <b>2013</b> , 23, 1541-6	25
1139	Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma. <b>2013</b> , 62, 578-88	14
1138	Preoperative detection and predictors of level V lymph node metastasis in patients with papillary thyroid carcinoma. <b>2013</b> , 100, 497-503	29
1137	BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy. <b>2013</b> , 114, 1174-82	9
1136	Preoperative detection and predictors of level V lymph node metastasis in patients with papillary thyroid carcinoma (Br J Surg 2013; 100: 497-503). <b>2013</b> , 100, 503-4	3
1135	Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas. <b>2013</b> , 78-92	
1134	CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. <b>2013</b> , 23, 1561-8	38
1133	Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings. <b>2013</b> , 60, 291-7	12
1132	The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. <b>2013</b> , 42, 1858-68	49
1131	A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer. <b>2013</b> , 2, 195-202	14

1130	Stunning phenomenon after a radioactive iodine- $^{131}\text{I}$ diagnostic whole-body scan: Is it really a point of clinical consideration?. <b>2013</b> , 34, 771-6	5
1129	Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. <b>2013</b> , 38, 25-8	63
1128	Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. <b>2013</b> , 60, 415-421	34
1127	Role of Surgery in a Multidisciplinary Approach. <b>2013</b> , 909-916	
1126	The usefulness and accuracy of sentinel lymph node biopsy using single photon emission computed tomography/computed tomography with $^{99\text{m}}\text{Tc}$ phytate to detect locoregional lymph node metastases in patients with papillary thyroid carcinoma. <b>2013</b> , 84, 195-201	9
1125	A. Endocrine Neoplasms of the Head and Neck: Management of High-Risk Thyroid Cancer. <b>2013</b> ,	
1124	Regional differences in thyroid cancer presentation and survival: a SEER study. <b>2013</b> , 19, 998-1006	6
1123	Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size. <b>2013</b> , 52, 71-80	7
1122	[Changes in quality of life and related factors in thyroid cancer patients with radioactive iodine remnant ablation]. <b>2013</b> , 43, 801-11	9
1121	Cerebral metastases from thyroid carcinoma: complete remission following radioiodine treatment. <b>2013</b> , 110, 861-6	9
1120	Recent advances in the surgical treatment of differentiated thyroid cancer: a comprehensive review. <b>2013</b> , 2013, 425-136	8
1119	Bilateral versus unilateral papillary thyroid microcarcinoma: predictive factors and associated histopathological findings following total thyroidectomy. <b>2013</b> , 12, 529-36	13
1118	. <b>2013</b> ,	0
1117	Peace of mind for patients with differentiated thyroid cancer?. <b>2013</b> , 52, 115-20	12
1116	Regional Lymph Node Metastasis in Papillary Thyroid Cancer. <b>2014</b> , 7, 129	2
1115	Management of Recurrent Differentiated Thyroid Carcinoma. <b>2014</b> , 7, 40	
1114	Multikinase inhibitors use in differentiated thyroid carcinoma. <b>2014</b> , 8, 281-91	18
1113	Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation. <b>2014</b> , 29, 33-9	10

1112	Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma. <b>2014</b> , 9, e114511	6
1111	Measuring Quality in Thyroid Cancer Surgery. <b>2014</b> , 2014, 1-6	6
1110	BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients. <b>2014</b> , 21, e740-7	5
1109	The Use of Low Dose in Radioiodine Ablation of Well-Differentiated Thyroid Cancer. <b>2014</b> , 04,	
1108	Transfection with Sodium Iodine Symporter Gene (NIS) and Future Applications with Radioiodine Treatment. <b>2014</b> , 03,	
1107	Evolution in the profile of thyroid cancer cases treated in an oncology reference service: what changed in the last 20 years. <b>2014</b> , 41, 320-4	5
1106	Pathologic spectrum of lymphocytic infiltration and recurrence of papillary thyroid carcinoma. <b>2014</b> , 55, 879-85	7
1105	Secular trends in the prognostic factors for papillary thyroid cancer. <b>2014</b> , 171, 667-75	21
1104	Improving the quality of thyroid cancer care: how does the Thyroid Cancer Care Collaborative cross the Institute of Medicine's Quality Chasm?. <b>2014</b> , 24, 615-24	12
1103	Factors related to mortality in patients with papillary and follicular thyroid cancer in long-term follow-up. <b>2014</b> , 37, 1195-200	15
1102	Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma. <b>2014</b> , 48, 255-61	23
1101	Dosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment. <b>2014</b> , 9, 247	2
1100	Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib. <b>2014</b> , 7, 343-8	11
1099	Novel therapies for thyroid cancer. <b>2014</b> , 15, 2641-52	9
1098	The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. <b>2014</b> , 155, 1222-34	21
1097	Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer. <b>2014</b> , 3, 207-14	14
1096	Adjuvant radioactive iodine use among differentiated thyroid cancer patients in the military health system. <b>2014</b> , 179, 1043-50	
1095	Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review. <b>2014</b> , 21, R473-84	30



1094	Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases. <b>2014</b> , 84, 240-4	15
1093	Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. <b>2014</b> , 99, 4487-96	65
1092	Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population. <b>2014</b> , 24, 689-94	21
1091	SPET/CT in thyroid cancer: a systematic review. <b>2014</b> , 2, 459-475	2
1090	Minimally Invasive and Robotic Thyroid and Parathyroid Surgery. <b>2014</b> ,	
1089	Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. <b>2014</b> , 33, 5397-404	22
1088	Terapia empírica del cáncer de tiroides con I-131 como estrategia diagnóstica para identificar lesiones ocultas en pacientes con tiroglobulina elevada sin enfermedad estructural identificable. <b>2014</b> , 18, 157-165	
1087	Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective. <b>2014</b> , 24, 975-86	12
1086	No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer. <b>2014</b> , 80, 911-7	11
1085	Intrathyroidal tumors presenting with extranodal extension: what are we missing?. <b>2014</b> , 25, 385-9	3
1084	Number of tumor foci predicts prognosis in papillary thyroid cancer. <b>2014</b> , 14, 914	39
1083	A review of the Fukushima nuclear reactor accident: radiation effects on the thyroid and strategies for prevention. <b>2014</b> , 21, 384-93	41
1082	Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. <b>2014</b> , 39, 142-6	12
1081	Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer. <b>2014</b> , 26, 31-5	7
1080	Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement. <b>2014</b> , 170, 837-46	26
1079	Analysis of the prognostic significance of lymph node related characteristics in papillary thyroid carcinoma patients presenting with pre- or intra-operative evidence of cervical lymph node metastases. <b>2014</b> , 128, 284-8	2
1078	The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. <b>2014</b> , 41, 2281-90	25
1077	A bulky mass in the neck. <b>2014</b> , 140, 879-80	1

1076	The effect of scoring systems for predicting locoregional recurrence in patients with differentiated thyroid cancer. <b>2014</b> , 56, 138	
1075	Thyroid cancer. <b>2014</b> , 38, 48-74	30
1074	Pathological characteristics and clinical perspectives of papillary thyroid cancer: study of 714 patients. <b>2014</b> , 271, 141-8	2
1073	Number of central lymph node metastasis for predicting lateral lymph node metastasis in papillary thyroid microcarcinoma. <b>2014</b> , 36, 101-6	30
1072	Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin. <b>2014</b> , 21, 1647-52	13
1071	Pathologic reporting of lymph node metastases in differentiated thyroid cancer: a call to action for the College of American Pathologists. <b>2014</b> , 25, 214-8	9
1070	Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. <b>2014</b> , 46, 285-91	14
1069	Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma: do involved lymph nodes mandate completion thyroidectomy?. <b>2014</b> , 38, 872-7	16
1068	The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. <b>2014</b> , 40, 665-74	44
1067	Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES). <b>2014</b> , 399, 165-84	46
1066	Nodal recurrence in the lateral neck after total thyroidectomy with prophylactic central neck dissection for papillary thyroid cancer. <b>2014</b> , 399, 237-44	32
1065	Scattered psammomatous calcifications around papillary thyroid carcinoma. <b>2014</b> , 38, 1738-42	7
1064	Prognostic biomarkers in thyroid cancer. <b>2014</b> , 464, 333-46	42
1063	Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer. <b>2014</b> , 46, 300-8	10
1062	Prognostic significance of the number of metastatic lymph nodes to stratify the risk of recurrence. <b>2014</b> , 38, 858-62	55
1061	Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer. <b>2014</b> , 28, 676-82	27
1060	Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma. <b>2014</b> , 53, 516-23	41
1059	Surgical complications and recurrence after central neck dissection in cN0 papillary thyroid carcinoma. <b>2014</b> , 41, 63-8	15

1058	The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. <b>2014</b> , 68, 413-7	27
1057	Laminin-5 $\beta$ 2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. <b>2014</b> , 99, E62-72	40
1056	Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. <b>2014</b> , 99, 510-6	81
1055	MicroRNA Targeted Cancer Therapy. <b>2014</b> ,	1
1054	Thyroid cancer. <b>2014</b> , 65, 125-37	181
1053	Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. <b>2014</b> , 38, 68-79	214
1052	A preoperative nomogram for the prediction of ipsilateral central compartment lymph node metastases in papillary thyroid cancer. <b>2014</b> , 24, 675-82	54
1051	Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. <b>2014</b> , 24, 27-34	472
1050	Clinical and pathological characteristics of incidental and nonincidental papillary thyroid microcarcinoma in 339 patients. <b>2014</b> , 36, 564-70	30
1049	Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES). <b>2014</b> , 399, 141-54	51
1048	Concepts in Thyroid, Parathyroid, and Adrenal Surgery. <b>2014</b> , 1043-1049	
1047	Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. <b>2014</b> , 36, 191-202	98
1046	Lymph node distribution in the central compartment of the neck: an anatomic study. <b>2014</b> , 36, 1425-30	13
1045	E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features. <b>2014</b> , 156, 1550-7; discussion 1557-8	3
1044	SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas. <b>2014</b> , 156, 1542-8; discussion 1548-9	11
1043	Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. <b>2014</b> , 24, 820-5	47
1042	Clinical, pathologic, and immunohistochemical prognostic factors in dogs with thyroid carcinoma. <b>2014</b> , 28, 1805-13	32
1041	Molecular approaches to thyroid cancer diagnosis. <b>2014</b> , 21, T301-13	39

1040	Computer-assisted three-dimensional analysis of multifocal/multicentric prostate cancer. <b>2014</b> , 32, 303-10	2
1039	Endocrine scintigraphy with hybrid SPECT/CT. <b>2014</b> , 35, 717-46	10
1038	Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. <b>2014</b> , 99, 2674-82	40
1037	Differentiated thyroid cancer-personalized therapies to prevent overtreatment. <b>2014</b> , 10, 563-74	23
1036	Cancer of the thyroid gland in geriatric age: a single center retrospective study with a 10-year post-operative follow-up. <b>2014</b> , 12 Suppl 2, S103-S107	6
1035	Clinician-performed thyroid ultrasound. <b>2014</b> , 47, 491-507	8
1034	The prognostic implications from molecular testing of thyroid cancer. <b>2014</b> , 47, 595-607	8
1033	Modulation of sodium iodide symporter in thyroid cancer. <b>2014</b> , 5, 363-73	20
1032	MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. <b>2014</b> , 24, 1375-84	11
1031	Guidelines for the management of thyroid cancer. <b>2014</b> , 81 Suppl 1, 1-122	692
1030	Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. <b>2014</b> , 21, 1374-8	31
1029	Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. <b>2014</b> , 21, 1379-83	26
1028	Risk factors for recurrence after therapeutic lateral neck dissection for primary papillary thyroid cancer. <b>2014</b> , 21, 1884-90	38
1027	The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers. <b>2014</b> , 24, 511-9	24
1026	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. <b>2014</b> , 32, 2718-26	449
1025	Significance of Salivary Gland Radioiodine Retention on Post-ablation (131)I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma. <b>2014</b> , 48, 203-11	8
1024	Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. <b>2014</b> , 37, 709-714	2
1023	Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. <b>2014</b> , 11, 1939-54	70

1022	Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. <b>2014</b> , 99, 3263-74	32
1021	Redefining classification of central neck dissection in differentiated thyroid cancer. <b>2014</b> , 36, 286-90	7
1020	BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity. <b>2014</b> , 131, 7-13	19
1019	Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. <b>2014</b> , 155, 689-95	22
1018	La mutation BRAF dans le carcinome papillaire de la thyroïde : intff dans le pronostic ^long terme et dans lâbdosensibilit. <b>2014</b> , 131, 5-9	
1017	Treatment with thyroid hormone. <b>2014</b> , 35, 433-512	150
1016	Management of recurrent cervical papillary thyroid cancer. <b>2014</b> , 43, 565-72	6
1015	Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up. <b>2014</b> , 156, 147-57	20
1014	Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma. <b>2014</b> , 192, 487-93	16
1013	The impact of nodal status on outcome in older patients with papillary thyroid cancer. <b>2014</b> , 156, 137-46	71
1012	How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. <b>2014</b> , 43, 331-44	14
1011	Surgery for thyroid cancer. <b>2014</b> , 43, 443-58	16
1010	Initial radioiodine administration: when to use it and how to select the dose. <b>2014</b> , 43, 385-400	0
1009	Update on differentiated thyroid cancer staging. <b>2014</b> , 43, 401-21	108
1008	Controversy over radioiodine ablation in thyroid cancer: who benefits?. <b>2014</b> , 94, 573-86	1
1007	ACR Appropriateness Criteria <sup>®</sup> thyroid carcinoma. <b>2014</b> , 50, 577-86	8
1006	Thyrotropin in the development and management of differentiated thyroid cancer. <b>2014</b> , 43, 367-83	20
1005	Prognostic significance of young age in papillary thyroid carcinoma: analysis of 5,733 patients with 150 months' median follow-up. <b>2014</b> , 61, 491-7	17

1004	Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF- $\beta$ in thyroid cancer cells. <b>2014</b> , 31, 153-60	11
1003	Low-risk papillary thyroid cancer: times are changing. <b>2014</b> , 9, 9-18	9
1002	Therapeutic strategy for low-risk thyroid cancer in Kanaji Thyroid Hospital. <b>2014</b> , 61, 1-12	9
1001	Lymphatic drainage, regional metastases and surgical management of papillary thyroid carcinoma arising in pyramidal lobe--a single institution experience. <b>2014</b> , 61, 55-9	15
1000	Prognosis and growth activity depend on patient age in clinical and subclinical papillary thyroid carcinoma. <b>2014</b> , 61, 205-13	32
999	Static and dynamic prognostic factors of papillary thyroid carcinoma. <b>2014</b> , 61, 1145-51	18
998	Adequate Surgery for Low-Risk Papillary Thyroid Cancer--The Debate Rages On. <b>2014</b> , 26, 281-284	
997	Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. <b>2014</b> , 36, 1695-700	32
996	Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer. <b>2014</b> , 2, 1331-1340	4
995	GLI1 Transcription Factor Affects Tumor Aggressiveness in Patients With Papillary Thyroid Cancers. <b>2015</b> , 94, e998	12
994	Follicular cell-derived thyroid cancer. <b>2015</b> , 1, 15077	55
993	Anaplastic Thyroid Carcinoma, Version 2.2015. <b>2015</b> , 13, 1140-50	68
992	Comparing the effectiveness of stimulation using rhTSH and thyroid hormone withdrawal in the treatment of thyroid cancer. <b>2015</b> , 8, A16	2
991	Clinicopathological features of recurrent papillary thyroid cancer. <b>2015</b> , 10, 96	16
990	Cost-effectiveness analysis of papillary thyroid cancer surveillance. <b>2015</b> , 121, 4132-40	31
989	Differentiated thyroid cancer in people aged 85 and older. <b>2015</b> , 63, 932-7	13
988	Number of tumor foci as predictor of lateral lymph node metastasis in papillary thyroid carcinoma. <b>2015</b> , 37, 650-4	17
987	Voice outcomes following reoperative central neck dissection for recurrent/persistent thyroid cancer. <b>2015</b> , 125, 2621-5	7

986	Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer. <b>2015</b> , 128, 1058-64	16
985	Predictive factors of central lymph node metastasis in papillary thyroid carcinoma. <b>2015</b> , 88, 63-8	31
984	The Prognostic Significance of the Metastatic Lymph Node Ratio in Patients with Papillary Thyroid Carcinoma. <b>2015</b> , 15, 67	
983	Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer. <b>2015</b> , 30, 543-50	8
982	Low Dose versus High Dose Radioiodine Therapy. <b>2015</b> , 8, 14	
981	The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer. <b>2015</b> , 10, e0133852	20
980	Risk Factors for Central Lymph Node Metastasis in CNO Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. <b>2015</b> , 10, e0139021	79
979	Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. <b>2015</b> , 59, 347-50	2
978	The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients. <b>2015</b> , 2015, 642046	11
977	What Is the Optimal Treatment of Papillary Thyroid Cancer?. <b>2015</b> , 49, 79-93	17
976	Comparative effectiveness in thyroid cancer: key questions and how to answer them. <b>2015</b> , 164, 67-87	3
975	Multifocality and bilaterality of papillary thyroid microcarcinoma. <b>2015</b> , 8, 174-8	51
974	Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study. <b>2015</b> , 42, 499-504	20
973	PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. <b>2015</b> , 3, 620-30	53
972	Efficacy and Safety of Radiofrequency Ablation for Treatment of Locally Recurrent Thyroid Cancers Smaller than 2 cm. <b>2015</b> , 276, 909-18	78
971	MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. <b>2015</b> , 32, 521-30	62
970	Preoperative imaging modalities to predict the risk of regional nodal recurrence in well-differentiated thyroid cancers. <b>2015</b> , 19, 116-20	4
969	Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation. <b>2015</b> , 94, e760	14

968	Identification of occult tumors by whole-specimen mapping in solitary papillary thyroid carcinoma. <b>2015</b> , 22, 679-86	7
967	Treatment of Thyroid Follicular Carcinoma. <b>2015</b> , 93, 611-618	
966	Strong Neck Accumulation of <sup>131</sup> I is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone. <b>2015</b> , 94, e1490	
965	A Quantitative Evaluation of Hepatic Uptake on I-131 Whole-Body Scintigraphy for Postablative Therapy of Thyroid Carcinoma. <b>2015</b> , 94, e1191	2
964	The Significance of Cervical Lymph Nodes in Well-Differentiated Thyroid Cancer. <b>2015</b> , 15-27	
963	Treatment of thyroid follicular carcinoma. <b>2015</b> , 93, 611-8	2
962	Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study. <b>2015</b> , 10, 1749-1754	5
961	The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy. <b>2015</b> , 6, 24-33	
960	Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma. <b>2015</b> , 144, 35-41	1
959	Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer. <b>2015</b> , 25, 1291-6	9
958	Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. <b>2015</b> , 25, 15-27	79
957	Lateral neck recurrence from papillary thyroid carcinoma: Predictive factors and prognostic significance. <b>2015</b> , 125, 2226-31	15
956	Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. <b>2015</b> , 100, 1529-36	128
955	Sorafenib for the treatment of thyroid cancer: an updated review. <b>2015</b> , 16, 573-83	25
954	The discovery and development of sorafenib for the treatment of thyroid cancer. <b>2015</b> , 10, 427-39	28
953	BRAF mutation in fine-needle aspiration specimens as a potential predictor for persistence/recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area. <b>2015</b> , 37, 1432-8	8
952	Papillary thyroid carcinoma in Denmark, 1996-2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. <b>2015</b> , 25, 78-84	44
951	The evolving use of radioiodine therapy in differentiated thyroid cancer. <b>2015</b> , 88, 247-56	10



950	Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. <b>2015</b> , 127, 337-44	12
949	Lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma, is it really necessary? A randomized, controlled study. <b>2015</b> , 157, 518-25	13
948	Comparison of differentiated thyroid carcinoma staging systems in a Spanish population. <b>2015</b> , 62, 152-160	
947	Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros. <b>2015</b> , 50, 61-6	20
946	Percutaneous Irreversible Electroporation for Recurrent Thyroid Cancer--A Case Report. <b>2015</b> , 26, 1180-2	3
945	Low Recurrence Rates in a Cohort of Differentiated Thyroid Carcinoma Patients: A Referral Center Experience. <b>2015</b> , 25, 883-9	13
944	Characteristics and significance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma. <b>2015</b> , 51, 759-63	44
943	Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. <b>2015</b> , 158, 1500-11	30
942	Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer. <b>2015</b> , 25, 1026-32	19
941	Use of vemurafenib in anaplastic thyroid carcinoma: a case report. <b>2015</b> , 16, 1430-3	31
940	Factors affecting survival in 43 consecutive patients after surgery for spinal metastases from thyroid carcinoma. <b>2015</b> , 23, 419-28	30
939	Management of Thyroid Cancer. <b>2015</b> ,	1
938	THERAPY OF ENDOCRINE DISEASE: Central neck dissection: a step forward in the treatment of papillary thyroid cancer. <b>2015</b> , 173, R199-206	13
937	Risk factor analysis for central nodal metastasis in papillary thyroid carcinoma. <b>2015</b> , 9, 103-107	19
936	KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer. <b>2015</b> , 54, 115-24	7
935	[Clinical guideline for management of patients with low risk differentiated thyroid carcinoma]. <b>2015</b> , 62, e57-72	5
934	[Comparison of differentiated thyroid carcinoma staging systems in a Spanish population]. <b>2015</b> , 62, 152-60	
933	Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2. <b>2015</b> , 6, 100-6	4

932	Factors Affecting the Locoregional Recurrence of Conventional Papillary Thyroid Carcinoma After Surgery: A Retrospective Analysis of 3381 Patients. <b>2015</b> , 22, 3543-9	44
931	Impact of tumor size on subclinical central lymph node metastasis in papillary thyroid microcarcinoma depends on age. <b>2015</b> , 13, 88	21
930	Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low-Risk Papillary Thyroid Cancer. <b>2015</b> , 25, 797-803	10
929	Cervical lymph node metastasis in differentiated thyroid carcinoma: does it have an impact on disease-related morbid events?. <b>2015</b> , 36, 120-4	5
928	Nonoperative management of low-risk differentiated thyroid carcinoma. <b>2015</b> , 27, 15-20	56
927	Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation. <b>2015</b> , 100, 1561-7	23
926	Optimal differentiated thyroid cancer management in the elderly. <b>2015</b> , 32, 283-94	8
925	Risk Factors for Re-recurrence After First Reoperative Surgery for Locoregional Recurrent/Persistent Papillary Thyroid Carcinoma. <b>2015</b> , 39, 1943-50	22
924	Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. <b>2015</b> , 42, 2045-55	13
923	Drug safety evaluation of lenvatinib for thyroid cancer. <b>2015</b> , 14, 1935-43	13
922	Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer. <b>2015</b> , 173, 873-81	9
921	The Management of Recurrent/Persistent Well-Differentiated Thyroid Cancer in the Central Compartment. <b>2015</b> , 51-60	
920	Is There Justification for Total Thyroidectomy in Low-Risk Papillary Thyroid Carcinoma? A Decision-Analysis Model. <b>2015</b> , 39, 2707-17	4
919	Reply to C. Bal et al. <b>2015</b> , 33, 2483-4	1
918	Follicular Thyroid Carcinoma: How Have Histologic Diagnoses Changed in the Last Half-Century and What Are the Prognostic Implications?. <b>2015</b> , 25, 1209-16	44
917	Postoperative simultaneous integrated boost-intensity modulated radiation therapy for patients with locoregionally advanced papillary thyroid carcinoma: preliminary results of a phase II trial and propensity score analysis. <b>2015</b> , 100, 1009-17	11
916	How do liquid-based preparations of thyroid fine-needle aspiration compare with conventional smears? An analysis of 5475 specimens. <b>2015</b> , 25, 308-13	24
915	Administration of Radioactive Iodine Therapy Within 1 Year After Total Thyroidectomy Does Not Affect Vocal Function. <b>2015</b> , 56, 1480-6	4

914	Bone Marrow Function After (131)I Therapy in Patients With Differentiated Thyroid Carcinoma. <b>2015</b> , 100, 3911-7	21
913	Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis. <b>2015</b> , 17, 274-80	10
912	Recurrence in regional lymph nodes after total thyroidectomy and neck dissection in patients with papillary thyroid cancer. <b>2015</b> , 51, 164-9	15
911	[18F]-fluorodeoxyglucose-positron emission tomography/computed tomography in malignancies of the thyroid and in head and neck squamous cell carcinoma: a review of the literature. <b>2015</b> , 10, 75-88	5
910	Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. <b>2015</b> , 25, 300-7	94
909	Noncolorectal, Nonneuroendocrine Liver Metastases. <b>2015</b> ,	
908	Shear wave elastography in evaluation of cervical lymph node metastasis of papillary thyroid carcinoma: elasticity index as a prognostic implication. <b>2015</b> , 22, 111-6	40
907	[Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma]. <b>2015</b> , 144, 35-41	1
906	Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative. <b>2015</b> , 37, 605-14	55
905	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. <b>2015</b> , 33, 42-50	345
904	CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. <b>2015</b> , 83, 246-53	32
903	Adjuvant therapy with 131-iodine in patients with elevated serum thyroglobulin after reoperation due to papillary thyroid carcinoma lymph node metastases. <b>2015</b> , 49, 279-82	7
902	Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. <b>2015</b> , 48, 264-71	30
901	Medical Management of Thyroid Disease. <b>2016</b> ,	
900	2016 Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. <b>2016</b> , 9, 59	54
899	Expression of Notch 1 receptor associated with tumor aggressiveness in papillary thyroid carcinoma. <b>2016</b> , 9, 1519-23	3
898	Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma. <b>2016</b> , 60, 348-54	3
897	BRAFV600ETest for Suspicious Lateral Lymph Nodes in Papillary Thyroid Cancer. <b>2016</b> , 16, 36	1

- 896 Can We Omit Prophylactic Central Lymph Node Dissection in Patients with Clinically LN Negative Papillary Thyroid Microcarcinoma?. **2016**, 16, 79
- 895 Outcome of Well-Differentiated Thyroid Carcinoma Patients Receiving a Cumulative Doses of ? 600 mCi (22GBq) of I-131. **2016**, 17, 114-119
- 894 Comparison between Three Promising Emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease. **2016**, 6, 1611-8 50
- 893 124I PET: Pretherapeutic Staging, Detection of Recurrent Thyroid Cancer and Dosimetry. **2016**,
- 892 Risk of Thyroid Cancer in Euthyroid Asymptomatic Patients with Thyroid Nodules with an Emphasis on Family History of Thyroid Cancer. **2016**, 17, 255-63 5
- 891 Development of Tracheoesophageal Fistula after the Use of Sorafenib in Locally Advanced Papillary Thyroid Carcinoma: a Case Report. **2016**, 9, 210 2
- 890 Prognostic Value of Extranodal Extension in Thyroid Cancer: A Meta-Analysis. **2016**, 57, 1324-8 14
- 889 9 Thyroid diseasesmalignant diseases, thyroid glandMalignant diseasesDiseases, thyroidmalignant diseases, thyroid glandMalignant Disease of the Thyroid Gland. **2016**,
- 888 10 Thyroid diseasesmolecular advances, diagnosis and treatmentMolecular advancesModern day technologymolecular advancesDiseases, thyroidmolecular advances, diagnosis and treatmentCancersmolecular advances inMolecular Advances in the Diagnosis and Treatment of Thyroid Cancer. **2016**,
- 887 18 Thyroid diseasesurgical management ofcancer, anaplasticSurgical managementof thyroid diseasesesthroid cancer, anaplasticDiseases, thyroidsurgical management ofcancer, anaplasticCancersanaplastic thyroid (ATCs)surgical management ofCancersanaplastic thyroid (ATCs)Malignant thyroid (ATC) surgical management ofMalignant thyroid (ATC) surgical management of thyroid cancer, anaplastic. **2016**,
- 886 20 Thyroid diseasesurgical management oflateral neckThyroid diseasesurgical management ofcancer, lateral neckSurgical managementof thyroid diseasesesthroid cancer, lateral neckSurgical managementof thyroid diseasesof lateral neckLateral neck metastasesDiseases, thyroidsurgical management oflateral neckDiseases, thyroidsurgical management ofcancer, lateral
- 885 Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. **2016**, 7, 32318-28 105
- 884 External Beam Radiation in Differentiated Thyroid Carcinoma. **2016**, 7, 2
- 883 A Randomized Controlled Trial for the Effectiveness of Aromatherapy in Decreasing Salivary Gland Damage following Radioactive Iodine Therapy for Differentiated Thyroid Cancer. **2016**, 2016, 9509810 9
- 882 Two thyroid cancer patients who received lenvatinib. **2016**, 26, 259-263 2
- 881 Molecular mechanisms in differentiated thyroid cancer. **2016**, 21, 119-29 15
- 880 Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer. **2016**, 2016, 1680464 42
- 879 Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. **2016**, 17, 370-95 486

878	Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up. <b>2016</b> , 55, 99-103	8
877	CLINICALLY UNDETECTABLE OCCULT THYROID PAPILLARY CARCINOMA PRESENTING WITH CERVICAL LYMPH NODE METASTASIS. <b>2016</b> , 12, 72-76	
876	Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma. <b>2016</b> , 7,	7
875	BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma. <b>2016</b> , 23, 244-71	10
874	Impact of patient age on the iodine/FDG "flip-flop" phenomenon in lung metastasis from thyroid cancer. <b>2016</b> , 30, 518-24	5
873	Differentiated thyroid cancer in patients $\leq 5$ years: Histopathological features and results of surgical treatment. <b>2016</b> , 33 Suppl 1, S159-63	8
872	Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas. <b>2016</b> , 38, 1772-1779	3
871	Risk factors for persistent disease in papillary thyroid carcinoma with lymph node metastasis. <b>2016</b> , 37, 721-6	
870	Carbon nanoparticle-guided central lymph node dissection in clinically node-negative patients with papillary thyroid carcinoma. <b>2016</b> , 38, 840-5	30
869	Prognostic role of the Bethesda System for conventional papillary thyroid carcinoma. <b>2016</b> , 38, 1509-14	5
868	Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog" From Puppies. <b>2016</b> , 117, 1491-6	6
867	Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis. <b>2016</b> , 85, 299-305	31
866	Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study. <b>2016</b> , 85, 466-74	19
865	Prophylactic neck dissection for low-risk differentiated thyroid cancers: Risk-benefit analysis. <b>2016</b> , 38, 1091-6	4
864	Comparison of differentiated thyroid cancer in children and adolescents ( $\leq 20$ years) with young adults. <b>2016</b> , 84, 571-7	28
863	Revision neural monitored surgery for recurrent thyroid cancer: Safety and thyroglobulin response. <b>2016</b> , 126, 1020-5	14
862	Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence. <b>2016</b> , 38 Suppl 1, E1172-6	16
861	The Role of SPECT/CT Lymphoscintigraphy and Radioguided Sentinel Lymph Node Biopsy in Managing Papillary Thyroid Cancer. <b>2016</b> , 142, 834-41	18

860	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <b>2016</b> , 38, 493-8	46
859	ACTIVE SURVEILLANCE FOR PAPILLARY THYROID MICROCARCINOMA: NEW CHALLENGES AND OPPORTUNITIES FOR THE HEALTH CARE SYSTEM. <b>2016</b> , 22, 602-11	41
858	Metastatic Papillary Thyroid Carcinoma Presenting as Abducens Palsy Complicated by Ocular Neuromyotonia. <b>2016</b> , 40, 97-101	2
857	Klotho inhibits human follicular thyroid cancer cell growth and promotes apoptosis through regulation of the expression of stanniocalcin-1. <b>2016</b> , 35, 552-8	19
856	[Usefulness and Limitation of Thyroglobulin Measurement in Fine Needle Aspirates (FNA-Tg) for Diagnosis of Neck Lymph Node Metastasis from Thyroid Carcinoma]. <b>2016</b> , 119, 721-6	6
855	Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1 $\beta$ /VEGF signaling pathway. <b>2016</b> , 12, 5217-5222	9
854	Re: Long-term recurrence and chronic pain after repair for small umbilical or epigastric hernias: a regional cohort study. <b>2016</b> , 211, 305-6	1
853	'Incidental' and 'non-incidental' thyroid papillary microcarcinomas are two different entities. <b>2016</b> , 174, 813-20	5
852	Long-term follow-up ultrasonography after lobectomy in papillary thyroid microcarcinoma patients: A single-center study. <b>2016</b> , 41, 213-7	9
851	Low iodine diet in differentiated thyroid cancer: a review. <b>2016</b> , 84, 3-12	21
850	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. <b>2016</b> , 2, 1023-9	895
849	Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma. <b>2016</b> , 40, 2123-30	3
848	Surgical Oncology Manual. <b>2016</b> ,	
847	Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. <b>2016</b> , 21, 862-868	9
846	New therapies in thyroid cancer. <b>2016</b> , 146, 324-329	
845	Application of molecular biology of differentiated thyroid cancer for clinical prognostication. <b>2016</b> , 23, R499-R515	21
844	The role of lateral neck ultrasound in detecting single or multiple lymph nodes in papillary thyroid cancer. <b>2016</b> , 212, 1147-1153	17
843	The Management of Thyroid and Parathyroid Cancer. <b>2016</b> , 673-692	

842	Routine Level 2b Dissection may be Recommended Only in N1b Papillary Thyroid Carcinoma with Three- or Four-Level Lateral Lymph Node Metastasis. <b>2016</b> , 23, 694-700	6
841	Stage II differentiated thyroid cancer: A mixed bag. <b>2016</b> , 113, 94-7	2
840	Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-Up. <b>2016</b> , 26, 1472-1479	10
839	Risk factors for level V lymph node metastases in solitary papillary thyroid carcinoma with clinically lateral lymph node metastases. <b>2016</b> , 5, 2161-8	17
838	B-Raf mutation and papillary thyroid carcinoma patients. <b>2016</b> , 11, 2699-2705	7
837	The Role of Adjuvant Radiation Therapy for Locoregionally Advanced Papillary Thyroid Carcinoma. <b>2016</b> , 90, 209-14	14
836	Risk Factors of I-Induced Salivary Gland Damage in Thyroid Cancer Patients. <b>2016</b> , 101, 4085-4093	13
835	Changing trends in the management of well-differentiated thyroid carcinoma in Korea. <b>2016</b> , 63, 515-21	6
834	WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?. <b>2016</b> , 23, T109-T121	18
833	Efficacy of lenvatinib in treating thyroid cancer. <b>2016</b> , 17, 1683-91	7
832	Clinical implications of the extent of BRAF alleles in patients with papillary thyroid carcinoma. <b>2016</b> , 62, 72-77	7
831	Management of the Central and Lateral Neck in Patients with Differentiated Thyroid Cancer. <b>2016</b> , 4, 1	
830	Solitary Firm Abdominal Nodule in a 70-Year-Old Woman. <b>2016</b> , 38, 557-8	
829	Treatment of Metastatic Lymph Nodes in the Neck from Papillary Thyroid Carcinoma with Percutaneous Laser Ablation. <b>2016</b> , 39, 1023-30	82
828	Pin1 is related with clinical stage of papillary thyroid carcinoma. <b>2016</b> , 14, 95	3
827	Comparing a thyroid prognostic nomogram to the existing staging systems for prediction risk of death from thyroid cancers. <b>2016</b> , 42, 1491-6	3
826	Common Diagnostic Pitfalls in Thyroid Cytopathology. <b>2016</b> ,	3
825	Thyroid Cancer in Pediatrics. <b>2016</b> , 45, 359-404	11

824	ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. <b>2016</b> , 175, R185-202	35
823	Thyroid Cancer. <b>2016</b> , 317-334	
822	Minimally invasive video-assisted lateral neck lymphadenectomy for the papillary thyroid carcinoma with cervical lymph nodes metastasis. <b>2016</b> , 46, 635-41	1
821	Correlation Between Surgical Extent and Prognosis in Node-Negative, Early-Stage Papillary Thyroid Carcinoma Originating in the Isthmus. <b>2016</b> , 40, 344-9	19
820	BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma. <b>2016</b> , 38 Suppl 1, E1203-9	11
819	Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. <b>2016</b> , 54, 467-475	20
818	Selenium Increases Thyroid-Stimulating Hormone-Induced Sodium/Iodide Symporter Expression Through Thioredoxin/Apurinic/Apyrimidinic Endonuclease 1-Dependent Regulation of Paired Box 8 Binding Activity. <b>2016</b> , 24, 855-66	15
817	Increased rates of advanced thyroid cancer in California. <b>2016</b> , 201, 244-52	6
816	ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. <b>2016</b> , 41, 106-17	1
815	Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines. <b>2016</b> , 46, 147-64	41
814	Novel Approaches to Thyroid Cancer Treatment and Response Assessment. <b>2016</b> , 46, 109-18	23
813	Dose Deposits from <sup>90</sup> Y, <sup>177</sup> Lu, <sup>111</sup> In, and <sup>161</sup> Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy. <b>2016</b> , 57, 759-64	62
812	BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. <b>2016</b> , 54, 1531-9	12
811	Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. <b>2016</b> , 43, 1001-5	67
810	Cost-Effectiveness of Diagnostic Lobectomy Versus Observation for Thyroid Nodules >4 cm. <b>2016</b> , 26, 271-9	8
809	Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. <b>2016</b> , 11, 21	41
808	Head and Neck and Endocrine Surgery. <b>2016</b> ,	1
807	Risk factors and indication for dissection of right paraesophageal lymph node metastasis in papillary thyroid carcinoma. <b>2016</b> , 42, 81-6	17



806	Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. <b>2016</b> , 159, 163-70	17
805	Surgery of the Thyroid Glands. <b>2016</b> , 225-333	
804	Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid. <b>2016</b> , 159, 1390-5	13
803	Association between GWAS-Derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer. <b>2016</b> , 22, 1111-9	21
802	Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma. <b>2016</b> , 37, 4689-97	3
801	[New therapies in thyroid cancer]. <b>2016</b> , 146, 324-9	
800	Prophylactic Central Neck Dissection Might Not Be Necessary in Papillary Thyroid Carcinoma: Analysis of 11,569 Cases from a Single Institution. <b>2016</b> , 222, 853-64	32
799	Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma. <b>2016</b> , 23, 367-76	15
798	Nodal metastases in thyroid cancer: prognostic implications and management. <b>2016</b> , 12, 981-94	37
797	A Prospective Study Showing an Excellent Response of Patients with Low-Risk Differentiated Thyroid Cancer Who Did Not Undergo Radioiodine Remnant Ablation after Total Thyroidectomy. <b>2016</b> , 5, 44-9	7
796	A Patient with Papillary Thyroid Carcinoma and Biochemical Evidence of Disease at Follow-Up Visits and Increasing Serum Tg Values at the Follow-Up Assessments. <b>2016</b> , 135-143	
795	A Papillary Thyroid Cancer with Minimal Extra-thyroidal Extension. <b>2016</b> , 61-72	
794	Prognostic Value of the Number of Retrieved Lymph Nodes in Pathological Nx or N0 Classical Papillary Thyroid Carcinoma. <b>2016</b> , 40, 2043-50	11
793	Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients. <b>2016</b> , 32, 201-8	44
792	Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer. <b>2016</b> , 37, 8783-9	17
791	Current Guidelines for Postoperative Treatment and Follow-Up of Well-Differentiated Thyroid Cancer. <b>2016</b> , 25, 41-59	10
790	Quantification of lymph nodes in the central compartment of the neck: a cadaveric study. <b>2016</b> , 273, 2773-8	4
789	Thyroid Cancer. <b>2016</b> ,	1

788	MECHANISMS IN ENDOCRINOLOGY: Impact of isolated TSH levels in and out of normal range on different tissues. <b>2016</b> , 174, R29-41	10
787	Same thyroid cancer, different national practice guidelines: When discordant American Thyroid Association and National Comprehensive Cancer Network surgery recommendations are associated with compromised patient outcome. <b>2016</b> , 159, 41-50	22
786	Risk factors for central lymph node metastasis in papillary thyroid carcinoma: A National Cancer Data Base (NCDB) study. <b>2016</b> , 159, 31-9	33
785	Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma. <b>2016</b> , 38 Suppl 1, E1256-63	18
784	Prognostic significance of papillary thyroid carcinoma presentation: long-term follow-up is mandatory. <b>2016</b> , 211, 306-7	
783	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <b>2016</b> , 26, 1-133	6910
782	Surgery of the Thyroid. <b>2016</b> , 1666-1692.e4	0
781	The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer. <b>2016</b> , 84, 284-291	21
780	Lymph node characteristics for predicting locoregional recurrence of papillary thyroid cancer in adolescents and young adults. <b>2017</b> , 66, 22-27	9
779	Should Age at Diagnosis Be Included as an Additional Variable in the Risk of Recurrence Classification System in Patients with Differentiated Thyroid Cancer. <b>2017</b> , 6, 160-166	6
778	A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study. <b>2017</b> , 39, 767-771	4
777	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <b>2017</b> , 27, 512-517	81
776	Is Male Gender a Prognostic Factor for Papillary Thyroid Microcarcinoma?. <b>2017</b> , 24, 1958-1964	29
775	The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing. <b>2017</b> , 70, 260-265	17
774	Patterns, Predictive Factors, and Prognostic Impact of Contralateral Lateral Lymph Node Metastasis in N1b Papillary Thyroid Carcinoma. <b>2017</b> , 24, 1943-1950	2
773	Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option. <b>2017</b> , 44, 918-925	13
772	Ultrasound of the Thyroid and Soft Tissues of the Neck. <b>2017</b> , 23-45	
771	The role of ablative treatment in differentiated thyroid cancer management. <b>2017</b> , 12, 109-116	2

770	The utility of intra-operative frozen section for the evaluation of microscopic extrathyroidal extension in papillary thyroid carcinoma. <b>2017</b> , 42, 1167-1171	3
769	Management of Thyroid Nodules and Differentiated Thyroid Cancer. <b>2017</b> ,	3
768	1.5-2 cm tumor size was not associated with distant metastasis and mortality in small thyroid cancer: A population-based study. <b>2017</b> , 7, 46298	6
767	Patients with Multifocal Macroscopic Papillary Thyroid Carcinoma Have a Low Risk of Recurrence at Early Follow-Up after Total Thyroidectomy and Radioactive Iodine Treatment. <b>2017</b> , 6, 31-39	4
766	Alternative Means of Estimating I Maximum Permissible Activity to Treat Thyroid Cancer. <b>2017</b> , 58, 1588-1595	0
765	Radioguided occult lesion localization for locally recurrent thyroid carcinoma. <b>2017</b> , 274, 2915-2919	11
764	Clinical Features of Early and Late Postoperative Hypothyroidism After Lobectomy. <b>2017</b> , 102, 1317-1324	38
763	Thyroid Cancer. <b>2017</b> , 318-334	
762	ANALYSIS OF POSTOPERATIVE ULTRASONOGRAPHY SURVEILLANCE AFTER HEMITHYROIDECTOMY IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA: A MULTICENTER STUDY. <b>2017</b> , 23, 794-802	5
761	Development of a New Clinical Severity Staging System for Patients With Nonmetastatic Papillary Thyroid Carcinoma. <b>2017</b> , 143, 1173-1180	7
760	Patterns of Initial Recurrence in Completely Resected Papillary Thyroid Carcinoma. <b>2017</b> , 27, 908-914	37
759	Rationale for the Evaluation of Cervical Lymph Nodes in the Setting of Thyroid Cancer. <b>2017</b> , 197-206	
758	The Effect of Prophylactic Central Neck Dissection on Locoregional Recurrence in Papillary Thyroid Cancer After Total Thyroidectomy: A Systematic Review and Meta-Analysis : pCND for the Locoregional Recurrence of Papillary Thyroid Cancer. <b>2017</b> , 24, 2189-2198	50
757	The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation. <b>2017</b> , 35, 505-510	10
756	Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. <b>2017</b> , 87, 566-571	10
755	Controversies in the Management of Low-Risk Differentiated Thyroid Cancer. <b>2017</b> , 38, 351-378	42
754	Endocrine and Neuroendocrine Surgery. <b>2017</b> ,	1
753	Risk factors and the preoperative assessment of right para-oesophageal lymph node metastasis in right lobe papillary thyroid carcinoma: A case series. <b>2017</b> , 42, 123-127	3

752	Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro. <b>2017</b> , 92, 403-411	19
751	Advances in small molecule therapy for treating metastatic thyroid cancer. <b>2017</b> , 18, 1049-1060	10
750	Nonanaplastic follicular cell-derived thyroid carcinoma: mitosis and necrosis in long-term follow-up. <b>2017</b> , 274, 2541-2548	3
749	Non-parametric intravoxel incoherent motion analysis of the thyroid gland. <b>2017</b> , 3, e00239	4
748	Prognostic indicators for papillary thyroid carcinoma. <b>2017</b> , 12, 101-108	4
747	Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1-4 cm: Preliminary results. <b>2017</b> , 87, 80-86	20
746	Follicular and Hürthle Cell Carcinoma. <b>2017</b> , 379-393	
745	Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. <b>2017</b> , 143, 1555-1562	28
744	Targeting the TSH receptor in thyroid cancer. <b>2017</b> , 24, R191-R202	26
743	Managing tyrosine kinase inhibitors side effects in thyroid cancer. <b>2017</b> , 12, 117-127	8
742	Patterns, predictive factors and prognostic impact of multilevel metastasis in N1b papillary thyroid carcinoma. <b>2017</b> , 104, 857-867	11
741	Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation. <b>2017</b> , 27, 531-536	10
740	A novel thyroid cancer nodal map classification system to facilitate nodal localization and surgical management: The A to D map. <b>2017</b> , 127, 2429-2436	11
739	Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer. <b>2017</b> , 38, 1036-1040	3
738	Traitement par iode 131 des cancers thyroïdiens différenciés: recommandations 2017 des sociétés françaises SFMN/SFE/SFP/SFBC/AFCE/SFORL. <b>2017</b> , 41, S1-S22	2
737	Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a). <b>2017</b> , 42, 842-846	8
736	Predictors of lymph nodes posterior to the right recurrent laryngeal nerve metastasis in patients with papillary thyroid carcinoma: A retrospective study. <b>2017</b> , 96, e7908	11
735	High Expression of Angiopoietin-1 is Associated with Lymph Node Metastasis and Invasiveness of Papillary Thyroid Carcinoma. <b>2017</b> , 41, 3128-3138	4

734	Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study. <b>2017</b> , 27, 1164-1170	30
733	Blue plaque on the chest: A sign of systemic disease. <b>2017</b> , 3, 151-153	
732	Disease Severity at Presentation in Patients with Disease-Related Mortality from Differentiated Thyroid Cancer: Implications for the 2015 ATA Guidelines. <b>2017</b> , 27, 1171-1176	4
731	AEG-1 associates with metastasis in papillary thyroid cancer through upregulation of MMP2/9. <b>2017</b> , 51, 812-822	38
730	Only a Rapid Complete Biochemical Remission After 131I-Therapy is Associated with an Unimpaired Life Expectancy in Differentiated Thyroid Cancer. <b>2017</b> , 49, 860-868	3
729	Automated MicroSPECT/MicroCT Image Analysis of the Mouse Thyroid Gland. <b>2017</b> , 27, 1433-1440	
728	Reactivity of thyroid papillary carcinoma cells to thyroid stimulating hormone-dominated endocrine therapy. <b>2017</b> , 14, 7405-7409	2
727	BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. <b>2017</b> , 7, 4666	28
726	Deep convolutional neural networks for classifying head and neck cancer using hyperspectral imaging. <b>2017</b> , 22, 60503	112
725	Diagnosis and Management of Small Thyroid Nodules: A Comparative Study with Six Guidelines for Thyroid Nodules. <b>2017</b> , 283, 560-569	43
724	Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma. <b>2017</b> , 27, 261-270	7
723	Should Level V Be Routinely Dissected in N1b Papillary Thyroid Carcinoma?. <b>2017</b> , 27, 253-260	21
722	Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: Analysis of 8,676 patients at a single institution. <b>2017</b> , 161, 485-492	43
721	Differentiated thyroid carcinoma: Incremental diagnostic value of I SPECT/CT over planar whole body scan after radioiodine therapy. <b>2017</b> , 56, 551-559	20
720	Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?. <b>2017</b> , 44, 183-184	9
719	Clinicopathological features of thyroid cancer in the elderly compared to younger counterparts: single-center experience. <b>2017</b> , 40, 471-479	4
718	Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. <b>2017</b> , 161, 127-133	40
717	Second Radioactive Iodine Treatment Alone Is of Little Benefit in Treating Patients with Locoregional Persistent Differentiated Thyroid Carcinoma Who Previously Have Been Treated with Total Thyroidectomy and Ablative Radioactive Iodine. <b>2017</b> , 29, 468-471	

7 <sup>16</sup>	Disparities in the Care of Differentiated Thyroid Cancer in the United States: Exploring the National Cancer Database. <b>2017</b> , 83, 739-746	6
7 <sup>15</sup>	Using Ultrasonography to Evaluate the Relationship between Capsular Invasion or Extracapsular Extension and Lymph Node Metastasis in Papillary Thyroid Carcinomas. <b>2017</b> , 130, 1309-1313	2
7 <sup>14</sup>	Feasibility of sentinel lymph node dissection using Tc-99m phytate in papillary thyroid carcinoma. <b>2017</b> , 93, 240-245	9
7 <sup>13</sup>	[Differentiated thyroid cancer in children and adolescents: about 22 cases]. <b>2017</b> , 28, 71	
7 <sup>12</sup>	Differentiated Thyroid Cancer-Treatment: State of the Art. <b>2017</b> , 18,	68
7 <sup>11</sup>	The Role of Central Neck Lymph Node Dissection in the Management of Papillary Thyroid Cancer. <b>2017</b> , 7, 122	21
7 <sup>10</sup>	Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study. <b>2017</b> , 32, 434-441	24
7 <sup>09</sup>	Predictive factors of right paraesophageal lymph node metastasis in papillary thyroid carcinoma: Single center experience and meta-analysis. <b>2017</b> , 12, e0177956	6
7 <sup>08</sup>	Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma. <b>2017</b> , 56, 211-218	1
7 <sup>07</sup>	Clinical laboratory verification of thyroglobulin concentrations in the presence of autoantibodies to thyroglobulin: comparison of EIA, radioimmunoassay and LC MS/MS measurements in an Urban Hospital. <b>2017</b> , 10, 725	7
7 <sup>06</sup>	Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation. <b>2018</b> , 39, 338-348	16
7 <sup>05</sup>	Surgical Treatment Guidelines for Patients with Differentiated Thyroid Cancer: The Korean Association of Thyroid and Endocrine Surgeons (KATES) Guidelines Taskforce. <b>2017</b> , 17, 1	4
7 <sup>04</sup>	Clinical and histopathological characteristics of patients with incidental and nonincidental thyroid cancer. <b>2017</b> , 13, 390-395	9
7 <sup>03</sup>	Deaths related to differentiated thyroid cancer: a rare but real event. <b>2017</b> , 61, 222-227	11
7 <sup>02</sup>	A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. <b>2017</b> , 8, 16690-16703	12
7 <sup>01</sup>	Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation. <b>2017</b> , 8, 596-609	16
7 <sup>00</sup>	The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea. <b>2017</b> , 35, 112-120	8
6 <sup>99</sup>	Autocrine activation of platelet-derived growth factor receptor $\beta$ in metastatic papillary thyroid cancer. <b>2018</b> , 75, 146-153	4

698	Is the ratio superior to the number of metastatic lymph nodes in addressing the response in patients with papillary thyroid cancer?. <b>2018</b> , 97, e9664	1
697	A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. <b>2018</b> , 53, 73-78	20
696	High Serum Thyrotropin Concentrations within the Reference Range: A Predictor of Malignancy in Nodular Thyroid Disease. <b>2018</b> , 27, 272-277	4
695	CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer. <b>2018</b> , 45, 1590-1602	6
694	Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis. <b>2018</b> , 42, 2846-2857	59
693	Radiofrequency ablation for treatment of locally recurrent thyroid cancer presenting as a metastatic lymph node with dense macrocalcification: A case report and literature review. <b>2018</b> , 97, e0003	4
692	Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients. <b>2018</b> , 89, 100-109	22
691	Thyroid Disorders in the Elderly: An Overall Summary. <b>2018</b> , 34, 259-277	3
690	The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7. <b>2018</b> , 88, 950-956	9
689	EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines. <b>2018</b> , 15, 6763-6769	3
688	Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease. <b>2018</b> , 103, 469-476	10
687	Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer. <b>2018</b> , 59, 565-572	15
686	Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients: an Asian survey. <b>2018</b> , 39, 283-289	6
685	Differentiated Thyroid Cancer: Diagnosis, Therapy, and Follow-Up. <b>2018</b> , 51-64	
684	Philosophy on Neck Dissection in Thyroid Cancer-Current Controversies and Consensus. <b>2018</b> , 9, 2-5	
683	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <b>2018</b> , 110, 362-370	42
682	Revision central neck dissection. <b>2018</b> , 29, 24-29	1
681	Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence. <b>2018</b> , 88, 1193-1197	2

680	A survival analysis of songs on digital music platform. <b>2018</b> , 35, 1675-1686	7
679	Most Recurrences of Thyroid Cancer Represent Persistent Rather Than Recurrent Disease. <b>2018</b> , 30, 108-111	3
678	Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015. <b>2018</b> , 103, 1095-1101	17
677	Long term outcomes of simple clinical risk stratification in management of differentiated thyroid cancer. <b>2018</b> , 16, 283-291	5
676	Extent of Thyroidectomy in Differentiated Thyroid Cancers-Review of Evidence. <b>2018</b> , 9, 90-96	4
675	Post-treatment surveillance of thyroid cancer. <b>2018</b> , 44, 357-366	9
674	Thyroid diseases and bone health. <b>2018</b> , 41, 99-109	78
673	Management of the central compartment in differentiated thyroid carcinoma. <b>2018</b> , 44, 327-331	5
672	A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better. <b>2018</b> , 28, 187-192	10
671	The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes. <b>2018</b> , 28, 96-103	32
670	Capsaicin inhibits the metastasis of human papillary thyroid carcinoma BCPAP cells through the modulation of the TRPV1 channel. <b>2018</b> , 9, 344-354	30
669	Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?. <b>2018</b> , 163, 118-123	47
668	Prognostic markers in well differentiated papillary and follicular thyroid cancer (WDTC). <b>2018</b> , 44, 286-296	32
667	Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancers. <b>2018</b> , 117, 488-496	2
666	Macrometastasis in Papillary Thyroid Cancer Patients is Associated with Higher Recurrence in Lateral Neck Nodes. <b>2018</b> , 42, 123-129	19
665	Efficacy of F-fluorodeoxyglucose PET/CT for Detecting Lymph Node Metastasis in Papillary Thyroid Carcinoma. <b>2018</b> , 2, 2473974X18788545	2
664	Thyroid Carcinoma. <b>2018</b> , 573-585	2
663	Thyroid follicular adenomas and carcinomas: molecular profiling provides evidence for a continuous evolution. <b>2018</b> , 9, 10343-10359	20



662	Radioiodine Treatment of Well-Differentiated Thyroid Cancer: Balancing Risks and Benefits. <b>2018</b> , 36, 1785-1787	4
661	Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer. <b>2018</b> , 97, e12675	13
660	Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis. <b>2019</b> , 17, 2308-2316	3
659	Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma. <b>2018</b> , 84, 637-643	3
658	THE ASSOCIATION BETWEEN LYMPH NODE METASTASIS AND MOLECULAR MARKERS IN DIFFERENTIATED THYROID CANCER. <b>2018</b> , 14, 55-65	2
657	A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma. <b>2018</b> , 87, 158-164	30
656	Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways. <b>2018</b> , 7, 85	16
655	Critical Issues in Head and Neck Oncology. <b>2018</b> ,	1
654	Low-Dose Radioiodine Ablation Is Equally Effective as High-Dose Ablation in Patients with Low-Risk Thyroid Cancer on Long-Term Follow-up. <b>2018</b> , 30, 511-515	
653	Efficacy and Affecting Factors of I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma. <b>2018</b> , 8, 640	1
652	Be Aware of the Patient With Benign Follicular Thyroid Lesion Histology and Rising Thyroglobulin Level. <b>2018</b> , 24, 740-745	7
651	Utility of routine ultrasonography follow-up after total thyroidectomy in patients with papillary thyroid carcinoma: a single-center study. <b>2018</b> , 18, 12	2
650	Nodal disease predicts recurrence whereas other traditional factors affect survival in a cohort of South African patients with differentiated thyroid carcinoma. <b>2018</b> , 3, 10	1
649	Pattern of urine iodine excretion with low iodine diet during preparation for radioactive iodine ablation in patients with thyroid cancer. <b>2019</b> , 41, 381-387	1
648	Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age. <b>2018</b> , 33, 459-465	4
647	Differentiated thyroid cancer theranostics: radioiodine and beyond. <b>2018</b> , 91, 20180136	34
646	Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR-103/GPER1 axis. <b>2018</b> , 79, 324-331	14
645	Differentiated Thyroid Cancer: How Do Current Practice Guidelines Affect Management?. <b>2018</b> , 7, 319-326	3

644	Radioiodine Therapy for Well-Differentiated Thyroid Cancer. <b>2018</b> , 109-120	
643	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. <b>2018</b> , 9, 590	3
642	Interplay between Body Size Measures and Thyroid Cancer Aggressiveness: A Retrospective Analysis. <b>2018</b> , 2018, 2089471	1
641	Identifying risk factors for recurrence of papillary thyroid cancer in patients who underwent modified radical neck dissection. <b>2018</b> , 16, 205	8
640	Integrated analysis of long noncoding RNA interactions reveals the potential role in progression of human papillary thyroid cancer. <b>2018</b> , 7, 5394-5410	13
639	Risk factors for contralateral central lymph node metastasis in unilateral cN0 papillary thyroid carcinoma: A meta-analysis. <b>2018</b> , 59, 90-98	17
638	Predictive Value of BRAF Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis. <b>2018</b> , 38, 785-797	13
637	Understanding Malignancies of the Thyroid Gland: Institutional Experience. <b>2018</b> , 70, 482-489	2
636	Persistent/Recurrent Differentiated Thyroid Cancer: Clinical and Radiological Characteristics of Persistent Disease and Clinical Recurrence Based on Computed Tomography Analysis. <b>2018</b> , 28, 1490-1499	5
635	Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low-intermediate risk differentiated thyroid cancer. <b>2018</b> , 6, 347-355	2
634	Refining definitions within low-risk differentiated thyroid cancers. <b>2018</b> , 43, 1195-1200	2
633	Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. <b>2018</b> , 13, e0198896	8
632	Follow-up of differentiated thyroid cancer - what should (and what should not) be done. <b>2018</b> , 14, 538-551	48
631	Increased Numbers of Circulating Tumor Cells in Thyroid Cancer Patients. <b>2018</b> , 50, 602-608	14
630	Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER. <b>2018</b> , 9, 361-370	13
629	The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. <b>2018</b> , 11, 3551-3560	12
628	Age greater than 60 years portends a worse prognosis in patients with papillary thyroid cancer: should there be three age categories for staging?. <b>2018</b> , 18, 316	16
627	Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer. <b>2018</b> , 13, e0202644	6

626	Deep Learning-Based Computer-Aided Diagnosis System for Localization and Diagnosis of Metastatic Lymph Nodes on Ultrasound: A Pilot Study. <b>2018</b> , 28, 1332-1338	21
625	To Use or Not to Use 131I in Thyroid Cancer. <b>2018</b> , 43, 670-671	3
624	Patients with Differentiated Thyroid Cancer Who Undergo Reoperation for Recurrence Have Increased Mortality. <b>2018</b> , 30, 361-363	1
623	Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer. <b>2018</b> , 153, 1098-1104	5
622	A favorable tumor size to define papillary thyroid microcarcinoma: an analysis of 1176 consecutive cases. <b>2018</b> , 10, 899-906	8
621	Neck Ultrasound in Patients with Follicular Thyroid Carcinoma. <b>2018</b> , 9, 433-439	8
620	Impact of Nodule Size on Malignancy Risk Differs according to the Ultrasonography Pattern of Thyroid Nodules. <b>2018</b> , 19, 534-541	27
619	An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma. <b>2018</b> , 103, 2199-2206	23
618	Temperature-dependent cell death patterns induced by functionalized gold nanoparticle photothermal therapy in melanoma cells. <b>2018</b> , 8, 8720	114
617	Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?. <b>2018</b> , 179, 135-142	31
616	Evidence-Based Practice: Management of Well-Differentiated Thyroid Cancer. <b>2018</b> , 175-184	
615	The Prognostic Impact of Tumor Size in Papillary Thyroid Carcinoma is Modified by Age. <b>2018</b> , 28, 991-996	29
614	The University of Florida Department of Radiation Oncology Guidelines for Treatment of Differentiated Thyroid Cancer With I-131 or External-beam Radiotherapy. <b>2019</b> , 42, 92-98	3
613	Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?. <b>2019</b> , 32, 1223-1240	5
612	Efficacy of hemithyroidectomy in papillary thyroid carcinoma with minimal extrathyroidal extension. <b>2019</b> , 276, 3435-3442	5
611	Long non-coding RNA H19 may be a marker for prediction of prognosis in the follow-up of patients with papillary thyroid cancer. <b>2019</b> , 26, 203-207	9
610	Palliative Viszeralchirurgie. <b>2019</b> ,	1
609	Predictive value of LN metastasis detected by F-FDG PET/CT in patients with papillary thyroid cancer receiving iodine-131 radiotherapy. <b>2019</b> , 18, 1641-1648	1

608	Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like. <b>2019</b> , 104, 3557-3575	24
607	Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer. <b>2019</b> , 10,	40
606	Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma. <b>2019</b> , 10, 3543-3552	3
605	Predictive Significance of Serum MMP-9 in Papillary Thyroid Carcinoma. <b>2019</b> , 14, 275-287	1
604	Superior Located Papillary Thyroid Microcarcinoma is a Risk Factor for Lateral Lymph Node Metastasis. <b>2019</b> , 26, 3992-4001	21
603	The extent of extrathyroidal extension is a key determinant of prognosis in T4a papillary thyroid cancer. <b>2019</b> , 120, 1016-1022	8
602	Thyroid hormone therapy in differentiated thyroid cancer. <b>2019</b> , 66, 43-50	33
601	Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach. <b>2019</b> , 49, 1391-1403	1
600	Does microscopic positive tumor margin in papillary thyroid cancer really matter?. <b>2019</b> , 166, 1160-1167	5
599	Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma. <b>2019</b> , 24, 7-17	1
598	Investigation of the clonal origin of multifocal papillary thyroid carcinoma according to the X-chromosome inactivation pattern. <b>2019</b> , 17, 4695-4700	1
597	Impact of the change from the seventh to eighth edition of the AJCC TNM classification of malignant tumours and comparison with the MACIS prognostic scoring system in non-medullary thyroid cancer. <b>2019</b> , 3, 623-628	6
596	Predictive Factors of Recurrence in Patients with Differentiated Thyroid Carcinoma: A Retrospective Analysis on 579 Patients. <b>2019</b> , 11,	12
595	Expression of PDK-1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance. <b>2019</b> , 18, 2819-2824	3
594	Development of a personalized and realistic educational thyroid cancer phantom based on CT images: An evaluation of accuracy between three different 3D printers. <b>2019</b> , 113, 103393	12
593	Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients . <b>2019</b> , 104, 4941-4948	1
592	Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma. <b>2019</b> , 53, 320-327	6
591	Re-treatment With Adjuvant Radioactive Iodine Does Not Improve Recurrence-Free Survival of Patients With Differentiated Thyroid Cancer. <b>2019</b> , 10, 671	1

590	Contemporary Debates in Adult Papillary Thyroid Cancer Management. <b>2019</b> , 40, 1481-1499	31
589	Thyroid Anatomy. <b>2019</b> ,	
588	Impact of tumor-associated macrophages and BRAF mutation on clinical outcomes in patients with various thyroid cancers. <b>2019</b> , 41, 686-691	8
587	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocyctic features. <b>2019</b> , 64, 97-108	20
586	Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer. <b>2019</b> , 55, 20-24	4
585	Does every classical type of well-differentiated thyroid cancer have excellent prognosis? A case series and literature review. <b>2019</b> , 11, 2441-2448	4
584	Radioiodine Therapy of Thyroid Cancer. <b>2019</b> , 35-42	
583	Thyroid core needle biopsy: patients' pain and satisfaction compared to fine needle aspiration. <b>2019</b> , 65, 365-370	5
582	Loss of nuclear localization of thyroid transcription factor 1 and adverse outcomes in papillary thyroid cancer. <b>2019</b> , 91, 36-42	3
581	Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence. <b>2019</b> , 94, 106-110	16
580	In-Depth Proteomics Analysis to Identify Biomarkers of Papillary Thyroid Cancer Patients Older Than 45 Years with Different Degrees of Lymph Node Metastases. <b>2019</b> , 13, e1900030	5
579	Efficacy of posttreatment radioiodine scanning in patients with differentiated thyroid cancer. <b>2019</b> , 41, 3235-3240	2
578	Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy. <b>2019</b> , 3, 299-304	14
577	Nuclear Medicine Therapy. <b>2019</b> ,	1
576	Lobectomy Compared to Total Thyroidectomy for Low-Risk Papillary Thyroid Cancer: A Systematic Review. <b>2019</b> , 242, 244-251	32
575	Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer. <b>2019</b> , 14, e0215948	7
574	Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis. <b>2019</b> , 26, 51-60	18
573	Radioguided occult lesion localization in patients with recurrent thyroid cancer. <b>2019</b> , 276, 1757-1766	6

572	Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: a single-center propensity score matching study. <b>2019</b> , 36, 359-367	26
571	Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature. <b>2019</b> , 38, 195-203	1
570	PD-1-expressing B cells suppress CD4 and CD8 T cells via PD-1/PD-L1-dependent pathway. <b>2019</b> , 109, 20-26	56
569	Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose. <b>2019</b> , 65, 132-137	6
568	Expression of activator protein-1 in papillary thyroid carcinoma and its clinical significance. <b>2019</b> , 17, 25	6
567	Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma. <b>2019</b> , 21, 1482-1491	26
566	Thyroid Cancer Benefits the Prognosis of Ovarian Cancer: A SEER-Based Study. <b>2019</b> , 36, 1211-1220	5
565	Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Follow-Up. <b>2019</b> , 29, 802-808	27
564	The Role of TSH Suppression in the Management of Differentiated Thyroid Cancer. <b>2019</b> , 711-720	
563	Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer. <b>2019</b> , 2, e187754	10
562	Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature. <b>2019</b> , 38, 195-203	4
561	Differentiated Thyroid Carcinoma and Late Onset of Lung Distant Metastasis. A Case Report. <b>2019</b> , 2, 6	
560	Differentiated Thyroid Cancer and Radioactive Iodine: Past, Present and Future. <b>2019</b> , 12, 71	1
559	Diagnostic Accuracy and Scope of Intraoperative Transoral Ultrasound and Transoral Ultrasound-Guided Fine-Needle Aspiration of Retropharyngeal Masses. <b>2019</b> , 40, 1960-1964	2
558	Relationship between Initial Thyroid Operation and the Location of Locoregional Recurrence in Papillary Thyroid Cancer: a Single Tertiary Center Experience. <b>2019</b> , 19, 116	
557	Prognostic Parameters in Differentiated Thyroid Carcinomas. <b>2019</b> , 12, 883-900	9
556	Molecular Predictors for Advanced Papillary Thyroid Carcinoma Recurrence. <b>2019</b> , 10, 839	5
555	Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?. <b>2019</b> , 98, e18437	

554	Current trends in the features of male thyroid cancer: Retrospective evaluation of their prognostic value. <b>2019</b> , 98, e15559	7
553	Predictive factors for non-small-volume central lymph node metastases (more than 5 or $\geq$ mm) in clinically node-negative papillary thyroid carcinoma. <b>2019</b> , 98, e14028	7
552	Differentiated thyroid carcinoma: a 5-years survival study at a referral hospital in Brazil. <b>2019</b> , 53, 106	3
551	The impact of the number of harvested central lymph nodes on the lymph node ratio. <b>2019</b> , 46, 267-271	0
550	Preoperative predictors and prognosis of bilateral multifocal papillary thyroid carcinomas. <b>2019</b> , 28, 145-149	3
549	Long-Term Outcome after Hemithyroidectomy for Papillary Thyroid Cancer: A Comparative Study and Review of the Literature. <b>2018</b> , 11,	9
548	Thyroid Nodule: Current Evaluation and Management. <b>2019</b> , 493-516	1
547	Staging and Prognosis of Thyroid Cancer. <b>2019</b> , 595-610	
546	Radioiodine Therapy in Differentiated Thyroid Carcinoma. <b>2019</b> , 611-632	2
545	Implications of Na/I Symporter Transport to the Plasma Membrane for Thyroid Hormonogenesis and Radioiodide Therapy. <b>2019</b> , 3, 222-234	15
544	Antitumor Effect of Various Phytochemicals on Diverse Types of Thyroid Cancers. <b>2019</b> , 11,	24
543	A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na <sup>+</sup> /I <sup>-</sup> Symporter. <b>2019</b> , 160, 156-168	12
542	Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan. <b>2019</b> , 8, 90-95	5
541	BRAF mutation in papillary thyroid cancer-Prevalence and clinical correlation in a South-East Asian cohort. <b>2019</b> , 44, 114-123	7
540	The Need for Completion Thyroidectomy in Cases of Differentiated Thyroid Cancer. <b>2019</b> , 71, 82-87	1
539	Temporal analysis of thyroid cancer management in a Melbourne tertiary centre. <b>2019</b> , 89, 38-42	3
538	Investigating the prevalence of risk factors of papillary thyroid carcinoma recurrence and disease-free survival after thyroidectomy and central neck dissection in Iranian patients. <b>2020</b> , 120, 173-178	5
537	MALAT1 rs619586 polymorphism functions as a prognostic biomarker in the management of differentiated thyroid carcinoma. <b>2020</b> , 235, 1700-1710	3

536	Usefulness of a 3D-Printed Thyroid Cancer Phantom for Clinician to Patient Communication. <b>2020</b> , 44, 788-794	8
535	Targeted Radionuclide Therapy: A Historical and Personal Review. <b>2020</b> , 50, 87-97	26
534	Cancer of the Endocrine System. <b>2020</b> , 1074-1107.e11	1
533	Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer. <b>2020</b> , 34, 144-151	4
532	Prognostic factors and the effect of radioiodine on patients with locally advanced differentiated thyroid cancer. <b>2020</b> , 8, 928	2
531	Lymphovascular invasion of papillary thyroid carcinoma revisited in the era of active surveillance. <b>2020</b> , 46, 1814-1819	7
530	Lymphovascular invasion and risk of recurrence in papillary thyroid carcinoma. <b>2020</b> , 90, 1727-1732	3
529	Reoperations for structurally persistent or recurrent disease after thyroidectomy: analysis via preoperative CT. <b>2020</b> , 10, 12376	3
528	The Molecular Function and Clinical Role of Thyroid Stimulating Hormone Receptor in Cancer Cells. <b>2020</b> , 9,	8
527	The Impact of the Extent of Surgery on the Long-Term Outcomes of Patients with Low-Risk Differentiated Non-Medullary Thyroid Cancer: A Systematic Meta-Analysis. <b>2020</b> , 9,	5
526	Global Burden of Thyroid Cancer From 1990 to 2017. <b>2020</b> , 3, e208759	52
525	Clinical Image-Guided Ablation for Thyroid Malignancy with Proposed Thyroid Segmentation System. <b>2020</b> , 2, 139-150	0
524	Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. <b>2020</b> , 12,	9
523	Predictive factors of contralateral occult carcinoma in patients with papillary thyroid carcinoma: a retrospective study. <b>2020</b> , 9, 872-878	2
522	Prognostic lncRNA, miRNA, and mRNA Signatures in Papillary Thyroid Carcinoma. <b>2020</b> , 11, 805	2
521	Clinical Course from Diagnosis to Death in Patients with Well-Differentiated Thyroid Cancer. <b>2020</b> , 12,	6
520	In Vivo Computing Strategies for Tumor Sensitization and Targeting. <b>2020</b> , PP,	0
519	Pattern of Nodal Metastasis in Relation to Size of the Primary Tumour in Well-Differentiated Thyroid Carcinoma. <b>2020</b> , 1	



518	A Retrospective Study of Lymph Node Yield in Lateral Neck Dissection for Papillary Thyroid Carcinoma. <b>2020</b> , 145561320967339	
517	Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?. <b>2020</b> , 41, 416-425	1
516	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. <b>2020</b> , 10, 8031	3
515	Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States. <b>2020</b> , 37, 2841-2852	13
514	Salvage surgery for structural local recurrence of papillary thyroid cancer: recurrence patterns and surgical outcome. <b>2020</b> , 67, 949-956	3
513	Total thyroidectomy with therapeutic level II-IV neck dissection for papillary thyroid carcinoma: level VI recurrence patterns. <b>2020</b> , 277, 3449-3455	1
512	Lymphocyte-to-monocyte ratio prior to radioiodine ablation in low- and intermediate-risk, papillary thyroid cancer. <b>2020</b> , 70, 364-371	3
511	Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice. <b>2020</b> , 11, 1124	8
510	The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer. <b>2020</b> , 15, e0234843	6
509	African Head and Neck Society Clinical Practice guidelines for thyroid nodules and cancer in developing countries and limited resource settings. <b>2020</b> , 42, 1746-1756	7
508	Patient Report of Recurrent and Persistent Thyroid Cancer. <b>2020</b> , 30, 1297-1305	4
507	Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a I-SPECT/CT study. <b>2020</b> , 20, 239	9
506	Wolf in Sheep's Clothing: Papillary Thyroid Microcarcinoma in the US. <b>2020</b> , 230, 484-491	13
505	Prophylactic Central Lymph Node Dissection Improves Disease-Free Survival in Patients with Intermediate and High Risk Differentiated Thyroid Carcinoma: A Retrospective Analysis on 399 Patients. <b>2020</b> , 12,	11
504	Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. <b>2020</b> , 59, 1064-1071	0
503	Metastasis of Papillary Thyroid Carcinoma to the Maxillary Sinus: Case Report and Review of the Literature. <b>2020</b> , 2020, 4056901	0
502	Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma-Do They Exist?. <b>2020</b> , 21,	2
501	Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma. <b>2020</b> , 122, 906-913	2

500	Simultaneous occurrence of follicular and papillary thyroid carcinomas in same thyroid lobe: A case series of six patients from Qatar. <b>2020</b> , 73, 65-70	1
499	Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma. <b>2020</b> , 107, 687-694	11
498	The rise and fall of surgical aggressiveness for known or suspected differentiated thyroid cancer. <b>2020</b> , 128, 435-439	2
497	Does the TT Variant of the rs966423 Polymorphism in Affect the Stage and Clinical Course of Papillary Thyroid Cancer?. <b>2020</b> , 12,	2
496	The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. <b>2020</b> , 271, e21-e93	115
495	Prognostic value of tumor size and minimal extrathyroidal extension in papillary thyroid carcinoma. <b>2020</b> , 220, 925-931	6
494	Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma. <b>2020</b> , 15, e0228968	14
493	Identifying risk factors for metastasis to the level VII lymph node in papillary thyroid carcinoma patients. <b>2020</b> , 20, 13	3
492	TUMOR SIZE IS AN INDEPENDENT PREDICTOR OF MORTALITY RISK IN DIFFERENTIATED THYROID CANCER PATIENTS WITH T4 DISEASE. <b>2020</b> , 26, 499-507	2
491	Predictive Risk-scoring Model For Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma. <b>2020</b> , 10, 710	13
490	Risk factors for posttreatment recurrence in patients with intermediate-risk papillary thyroid carcinoma. <b>2020</b> , 220, 642-647	1
489	Lymph node metastasis in the space between the right carotid artery and jugular vein in papillary thyroid carcinoma. <b>2020</b> , 48, 300060520920036	1
488	GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy. <b>2020</b> , 11, 269	6
487	Cystic Lateral Lymph Node Metastases From Papillary Thyroid Cancer Patients. <b>2020</b> , 130, E976-E981	3
486	Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation. <b>2020</b> , 128, 204-210	1
485	MicroRNA-574-5p directly targets FOXN3 to mediate thyroid cancer progression via Wnt/βcatenin signaling pathway. <b>2020</b> , 216, 152939	5
484	LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway. <b>2020</b> , 52, 382-389	14
483	Unusual metastasis of papillary thyroid cancer to the pancreas, liver, and diaphragm: a case report with review of literature. <b>2020</b> , 20, 82	4

482	Surgical Outcomes and Efficacy of Isthmusectomy in Single Isthmic Papillary Thyroid Carcinoma: A Preliminary Retrospective Study. <b>2021</b> , 34, 1129-1134	2
481	Efficiency of intraoperative frozen section analysis of central neck lymph node dissection in patients with papillary thyroid carcinoma. <b>2021</b> , 3, 67	1
480	Papillary Thyroid Microcarcinoma. <b>2021</b> , 194-198.e2	
479	FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with Gene Mutations or Fusions. <b>2021</b> , 27, 2130-2135	25
478	Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer. <b>2021</b> , 33, 68-74	1
477	Principles in Thyroid Surgery. <b>2021</b> , 272-293.e5	0
476	Current practice in patients with differentiated thyroid cancer. <b>2021</b> , 17, 176-188	40
475	Thyroid Cancer. <b>2021</b> ,	
474	Efficacy of radiofrequency ablation for recurrent thyroid cancer invading the airways. <b>2021</b> , 31, 2153-2160	9
473	Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. <b>2021</b> , 94, 504-512	1
472	Treating papillary and follicular thyroid cancer in children and young people: Single UK-center experience between 2003 and 2018. <b>2021</b> , 56, 534-539	4
471	Voice Outcome of Total Thyroidectomy in Comparison With Administration of Recombinant Human TSH. <b>2021</b> , 35, 317-322	0
470	Lateral Neck Dissection: Indications and Technique. <b>2021</b> , 379-385.e2	
469	Reoperative Thyroid Surgery. <b>2021</b> , 461-471.e3	
468	Current Understanding of Papillary Thyroid Carcinoma. <b>2021</b> , 10, 184-221	0
467	Korean Thyroid Imaging Reporting and Data System: Current Status, Challenges, and Future Perspectives. <b>2021</b> , 22, 1569-1578	3
466	Papillary Thyroid Cancer. <b>2021</b> , 186-193.e5	
465	Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma. <b>2021</b> , 21, 8	3

- 464 Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. **2021**, 9, 71-80 1
- 463 Incidence of the Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma. **2021**, 13, 3
- 462 Surgery for Locally Advanced Thyroid Cancer: Larynx, Tracheal Invasion, and Esophageal. **2021**, 360-371.e2
- 461 Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review. **2020**, 45, 306-317 4
- 460 Contributions of Airway Stent for Long-term Outcome in Patients With Malignant Central Airway Stenosis or Obstruction. **2021**, 28, 228-234 4
- 459 Prognostic Assessment of BRAF Mutation in Preoperative Thyroid Fine-Needle Aspiration Specimens. **2021**, 156, 100-108 0
- 458 Long-Term Oncological Outcome Comparison between Intermediate- and High-Dose Radioactive Iodine Ablation in Patients with Differentiated Thyroid Carcinoma: A Propensity Score Matching Study. **2021**, 2021, 6642971 0
- 457 The role of the size in thyroid cancer risk stratification. **2021**, 11, 7303
- 456 Enemy Beyond the Wall: Clinicopathological Features of Intrathyroidal Papillary Thyroid Carcinoma (T1-T3a) That Metastasize to Lymph Nodes Without Extrathyroidal Extension. **2021**, 39, 401-408
- 455 Time to Surgery and Thyroid Cancer Survival in the United States. **2021**, 28, 3556-3565 3
- 454 Optimal Timing of Initiating Dynamic Risk Stratification During the Early Postoperative Period in Patients with Differentiated Thyroid Carcinoma After Thyroidectomy and Radioactive Iodine Remnant Ablation. **2021**, 28, 6580-6589
- 453 Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?. **2021**, 11,
- 452 Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer. **2021**, 3
- 451 Lateral Neck Dissection for Well-Differentiated Thyroid Carcinoma: Is Prophylactic Level V Neck Dissection Necessary? A Retrospective Cohort Study. **2021**, 1455613211003805 0
- 450 Evaluation of thyroid nodules by shear wave elastography: a review of current knowledge. **2021**, 44, 2043-2056 3
- 449 Metastases of papillary radioiodine-refractory thyroid cancer in the parapharyngeal lymph node: clinical case. **2021**, 11, 115-121
- 448 Diagnostic values of F-18 FDG PET or PET/CT, CT, and US for Preoperative Lymph Node Staging in Thyroid Cancer: A Network Meta-Analysis. **2021**, 94, 20201076 3
- 447 Immune Landscape of Thyroid Cancers: New Insights. **2020**, 11, 637826 3

446	Clinical Perspectives of Theranostics. <b>2021</b> , 26,	7
445	Benefits and harms of hemithyroidectomy, total or near-total thyroidectomy in 1-4 cm differentiated thyroid cancer. <b>2021</b> , 95, 668-676	1
444	Investigating F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review. <b>2021</b> , 11, 648658	1
443	Editorial: Time to Surgery and Thyroid Cancer Survival in the United States. <b>2021</b> , 28, 3459-3460	0
442	The advantages of carbon nanoparticles in level VII lymph node dissection in patients with papillary thyroid cancer. <b>2021</b> , 10, 2028-2036	1
441	Histone Deacetylase Inhibitors and Papillary Thyroid Cancer. <b>2021</b> , 27, 2199-2208	4
440	Papillary thyroid microcarcinoma: Is active surveillance always enough?. <b>2021</b> , 95, 811-817	4
439	Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population. <b>2021</b> , 1	0
438	Role of indocyanine green combined with radiotracer-Technetium 99m in neck surgery for primary and recurrent head and neck cancer: preliminary results of a tertiary cancer center. <b>2021</b> , 1	0
437	Less extensive surgery for low-risk papillary thyroid cancers post 2015 American Thyroid Association guidelines in an Australian tertiary centre. <b>2021</b> , 47, 2781-2787	1
436	A Prediction Model for Contralateral Central Neck Lymph Node Metastases in Unilateral Papillary Thyroid Cancer. <b>2021</b> , 2021, 6621067	
435	Application of competing risk model in the prognostic prediction study of patients with follicular thyroid carcinoma. <b>2021</b> , 1	
434	THE UTILITY OF COMBINED WWOX, HBME-1 AND CK34β12 AS A DIAGNOSTIC PANEL IN THYROID PAPILLARY CARCINOMA. <b>2021</b> , 72-74	
433	Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review. <b>2021</b> , 31, 1523-1530	2
432	Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study. <b>2021</b> , 11, 14908	5
431	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <b>2021</b> , 106, 3228-3238	8
430	Surgical Skills and Technological Advancements to Avoid Complications in Lateral Neck Dissection for Differentiated Thyroid Cancer. <b>2021</b> , 13,	0
429	Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <b>2021</b> , 127, 4161-4170	0

428	Ultrasound-guided implantation of radioactive I seed in radioiodine refractory differentiated thyroid carcinoma. <b>2021</b> , 21, 834	0
427	Translational Utility of Liquid Biopsies in Thyroid Cancer Management. <b>2021</b> , 13,	3
426	Comparison of the abilities of staging and risk stratification systems to predict the long-term structural recurrence in patients with differentiated thyroid carcinoma after total thyroidectomy and radioactive iodine remnant ablation. <b>2021</b> , 10, 2200-2210	0
425	Should Contralateral Nodules Be an Indication of Total or Completion Thyroidectomy for Patients With Unilateral Papillary Thyroid Carcinoma?. <b>2021</b> , 12, 723631	0
424	Ultrasound-Guided Thermal Ablation of Bethesda IV Thyroid Nodules: A Pilot Study. <b>2021</b> , 12, 674970	
423	Polymorphisms at the IL17A and IL17RA genes are associated with prognosis of papillary thyroid carcinoma. <b>2021</b> ,	0
422	Nanoemulsion of Mentha arvensis Essential Oil as an Anticancer Agent in Anaplastic Thyroid Cancer Cells and as an Antibacterial Agent in Staphylococcus aureus. 1	1
421	Advances in Functional Imaging of Differentiated Thyroid Cancer. <b>2021</b> , 13,	1
420	Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015. <b>2021</b> , 12, 718833	1
419	MicroRNA-Based Risk Score for Predicting Tumor Progression Following Radioactive Iodine Ablation in Well-Differentiated Thyroid Cancer Patients: A Propensity-Score Matched Analysis. <b>2021</b> , 13,	4
418	Is Delayed Papillary Thyroid Cancer Surgery Associated with Higher Mortality Risk?. <b>2021</b> , 33, 400-402	
417	Spinal metastases from thyroid cancer: Some prognostic factors. <b>2021</b> ,	1
416	Diagnostic performance of the modified Korean Thyroid Imaging Reporting and Data System for thyroid malignancy according to nodule size: a comparison with five society guidelines. <b>2021</b> , 40, 474-485	9
415	Na <sup>+</sup> /I <sup>-</sup> symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy. <b>2021</b> , 28, T167-T177	1
414	External Beam Radiation Therapy in pT4 Well-Differentiated Thyroid Cancer: A Population-Based Study of 405 Patients. <b>2021</b> , 111, 468-478	2
413	Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors. <b>2021</b> , 28, 107327482110297263	
412	Diagnostic Performance of the Modified Korean Thyroid Imaging Reporting and Data System for Thyroid Malignancy: A Multicenter Validation Study. <b>2021</b> , 22, 1579-1586	2
411	Thyroidal iodide transport and thyroid cancer. <b>2004</b> , 122, 221-36	8

410	External Beam Radiotherapy. <b>2005</b> , 139-161	4
409	Schilddrüsenkarzinom. <b>2006</b> , 3421-3466	1
408	Thyroid. <b>2010</b> , 87-96	39
407	Evaluation of the thyroid nodule. <b>2010</b> , 153, 23-34	4
406	Thyroid. <b>2014</b> , 99-129	1
405	Thyroid Cancer: Impact of Therapeutic Modalities on Prognosis. <b>1998</b> , 255-284	5
404	Thyroid carcinoma. <b>1997</b> , 90, 149-69	12
403	Thyroid. <b>2002</b> , 77-87	15
402	Recombinant Human Thyrotropin. <b>2000</b> , 163-178	1
401	An Approach to the Management of Patients with Scan Negative, Thyroglobulin Positive, Differentiated Thyroid Carcinoma. <b>2000</b> , 251-261	8
400	Recombinant Human Thyrotropin. <b>2006</b> , 103-113	1
399	Papillary Carcinoma. <b>2006</b> , 253-260	2
398	Prescribed Activity for Radioiodine Ablation. <b>2006</b> , 273-282	3
397	Determinants of Prognosis in Papillary Thyroid Cancer. <b>2006</b> , 375-376	1
396	Thyroid Carcinoma. <b>2006</b> , 497-508	3
395	Staging of Thyroid Cancer. <b>2006</b> , 87-95	2
394	Modulation of Deregulated MicroRNAs for Target Therapy in Thyroid Cancer. <b>2014</b> , 219-237	1
393	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. <b>2017</b> , 545-583	1

392	Lymph Node Dissection for Differentiated Thyroid Cancer. <b>2017</b> , 153-169	2
391	Considerations in Thyrotropin-Stimulating Hormone Suppression in Individuals with Differentiated Thyroid Cancer. <b>2017</b> , 223-232	1
390	Surveillance Strategies After Initial Treatment of Differentiated Thyroid Cancer. <b>2017</b> , 281-311	1
389	Clinical Presentation and Diagnosis of Papillary Thyroid Cancer. <b>2017</b> , 79-91	2
388	Surgery for the Solitary Thyroid Nodule. <b>2007</b> , 91-100	1
387	Thyroid Cancer. <b>2007</b> , 259-270	2
386	Sentinel lymph node dissection for thyroid malignancy. <b>2000</b> , 157, 201-5	32
385	Thyroid Cancer. <b>2015</b> , 353-388	1
384	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. <b>2018</b> , 59, 143-150	37
383	Management of Thyroid Neoplasms. <b>2010</b> , 1750-1772	4
382	Cancer of the Endocrine System. <b>2008</b> , 1271-1305	1
381	Cancer of the Thyroid. <b>2010</b> , 726-736	1
380	Cancer of the Endocrine System. <b>2014</b> , 1112-1142.e7	2
379	Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. <b>2006</b> , 060118075408001	7
378	Thyroid Cancer. <b>2006</b> , 975-994	46
377	Follicular carcinoma of the thyroid gland: prognostic factors, treatment, and survival. <b>2000</b> , 23, 1-5	31
376	Clinicopathological significance of poorly differentiated thyroid carcinoma. <b>1999</b> , 23, 205-11	105
375	Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. <b>1996</b> , 223, 472-8; discussion 478-80	209



374	Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. <b>1998</b> , 227, 912-21	62
373	Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. <b>1996</b> , 21, 780-2	43
372	Lymphoscintigraphy and gamma probe-guided surgery in papillary thyroid carcinoma: the sentinel lymph node concept in thyroid carcinoma. <b>1999</b> , 24, 744-6	24
371	Thyroid nodules: risk stratification for malignancy with ultrasound and guided biopsy. <b>2011</b> , 11, 209-23	49
370	Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer. <b>2003</b> , 56, 162-6	29
369	Management of papillary and follicular thyroid cancer. <b>2002</b> , 95, 325-6	8
368	Analysis of Risk Factors Contributing to Recurrence of Papillary Thyroid Carcinoma in Chinese Patients Who Underwent Total Thyroidectomy. <b>2016</b> , 22, 1274-9	12
367	The assessment of prognostic histopathological parameters depending on histological patterns of papillary thyroid carcinoma. <b>2014</b> , 40, 37-41	2
366	Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study. <b>2015</b> , 10, e0120184	3
365	Thyroid fine-needle aspiration biopsy and thyroid cancer diagnosis: a nationwide population-based study. <b>2015</b> , 10, e0127354	13
364	Scoring System for Mortality in Patients Diagnosed with and Treated Surgically for Differentiated Thyroid Carcinoma with a 20-Year Follow-Up. <b>2015</b> , 10, e0128620	6
363	2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells. <b>2015</b> , 10, e0130959	15
362	Fine-Needle Aspiration Biopsy as a Preoperative Procedure in Patients with Malignancy in Solitary and Multiple Thyroid Nodules. <b>2016</b> , 11, e0146883	13
361	The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence. <b>2016</b> , 11, e0153242	16
360	POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer. <b>2020</b> , 9, 923-932	2
359	[Treatment of papillary microcarcinoma of the thyroid]. <b>2004</b> , 48, 855-60	5
358	5 mCi pretreatment scanning does not cause stunning when the ablative dose is administered within 72 hours. <b>2005</b> , 49, 420-4	9
357	Managing thyroid cancer without thyroxine withdrawal. <b>2006</b> , 50, 91-6	3

356	Clinical prognosis in BRAF-mutated PTC. <b>2007</b> , 51, 736-47	15
355	[Clinical repercussion of the 6th edition TNM staging system classification on differentiated thyroid carcinoma]. <b>2007</b> , 51, 825-31	3
354	The Prognostic Significance of the Metastatic Lymph Node Ratio in Patients with Papillary Thyroid Carcinoma. <b>2015</b> , 15, 67	1
353	Surgical Treatment Guidelines for Patients with Differentiated Thyroid Cancer: The Korean Association of Thyroid and Endocrine Surgeons (KATES) Guidelines Taskforce. <b>2017</b> , 17, 1	1
352	Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition. <b>2016</b> , 7, 83684-83700	24
351	Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations. <b>2017</b> , 8, 108946-108957	12
350	Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer. <b>2020</b> , 26, 3812-3827	3
349	[Identification of sentinel lymph nodes in thyroid carcinoma]. <b>2003</b> , 50, 103-6	1
348	[Influence of lymphocytic thyroiditis on prognostic outcome differentiated thyroid carcinoma]. <b>2010</b> , 57, 85-94	2
347	Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma. <b>2019</b> , 63, 253-257	3
346	Total versus hemithyroidectomy for microscopic papillary thyroid cancer. <b>2012</b> , 35, 464-8	5
345	The pituitary tumor transforming gene in thyroid cancer. <b>2012</b> , 35, 425-33	7
344	Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma?. <b>2008</b> , 1, 41-5	38
343	Expression of Bcl-2, Bax and p27 in Patients with Papillary Thyroid Cancer with or without Lymph Node Metastasis. <b>2010</b> , 53, 153	0
342	Clinical Characteristics of Papillary Thyroid Microcarcinoma. <b>2010</b> , 53, 166	2
341	Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. <b>2011</b> , 54, 8	17
340	Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. <b>2011</b> , 64, 389	8
339	Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early. <b>2015</b> , 54, 151-7	1

338	Comparison of Different Staging Systems for Predicting Recurrence of Papillary Thyroid Carcinoma. <b>2011</b> , 26, 53	10
337	Association between Serum Thyroid Stimulating Hormone Level and Papillary Thyroid Microcarcinoma in Korean Euthyroid Patients. <b>2011</b> , 26, 297	1
336	Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer. <b>2019</b> , 34, 150-157	17
335	Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer. <b>2020</b> , 35, 435-442	2
334	Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. <b>2007</b> , 22, 157	25
333	Mutations of the promoter are associated with aggressiveness and recurrence/distant metastasis of papillary thyroid carcinoma. <b>2020</b> , 20, 50	4
332	Neck circumference correlates with tumor size and lateral lymph node metastasis in men with small papillary thyroid carcinoma. <b>2013</b> , 28, 62-71	6
331	The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma. <b>2013</b> , 2, 196-205	16
330	Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India. <b>2015</b> , 30, 227-32	3
329	Radioiodine Remnant Ablation: A Critical Review. <b>2015</b> , 14, 144-55	7
328	Surgical outcomes of thyroid cancer patients in a tertiary cancer center in India. <b>2018</b> , 55, 23-32	2
327	An Interesting Case of Retropharyngeal Lymph Nodal Metastases in a Case of Iodine-Refractory Thyroid Cancer. <b>2018</b> , 33, 125-127	1
326	AACE/AAES MEDICAL/SURGICAL Guidelines for Clinical Practice: Management of Thyroid Carcinoma. <b>2001</b> , 7, 202-220	219
325	Clinical Significance of p53, Ki-67 and Galectin-3 Expressions in Papillary Thyroid Carcinoma. <b>2009</b> , 77, 29	5
324	Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography. <b>2016</b> , 8, 635-55	10
323	Is Prophylactic Central Compartment Lymph Node Dissection Necessary for Papillary Thyroid Carcinoma?. <b>2010</b> , 2, 1-7	1
322	The current pattern of thyroid surgery in Saudi Arabia and how to improve it. <b>2002</b> , 22, 256-7	5
321	High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission. <b>2008</b> , 28, 277-81	5

320	Controversies in the management of papillary thyroid cancer revisited. <b>2011</b> , 2011, 303128	12
319	Salivary gland function in thyroid cancer patients with radioiodine administration history. <b>2020</b> , 164, 277-283	1
318	Emerging Therapeutics for Radioiodide-Refractory Thyroid Cancer. <b>2016</b> , 5, 75-86	2
317	Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. <b>2012</b> , 67, 483-8	40
316	Threshold primary tumour sizes for nodal and distant metastases in papillary and follicular thyroid cancers. <b>2012</b> , 13, 2473-6	4
315	Shorter distance between the nodule and capsule has greater risk of cervical lymph node metastasis in papillary thyroid carcinoma. <b>2014</b> , 15, 855-60	19
314	Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. <b>2015</b> , 12, 53-9	22
313	Value of Dedicated Head and Neck F-FDG PET/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative I Whole-body Scan. <b>2016</b> , 4, 12-18	4
312	Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013. <b>2019</b> , 11, e4127	33
311	A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study). <b>2021</b> , 21, 208	0
310	Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer. <b>2021</b> , 11, 705929	1
309	Papillary Thyroid Cancer Affecting Multiple Family Members: A Case Report and Literature Review of Familial Nonmedullary Thyroid Cancer. <b>2021</b> , 2021, 3472000	
308	The Use of F-FDG PET/CT in Patients with Recurrent Differentiated Thyroid Cancer. <b>2021</b> , 30, 137-143	
307	Clinical Management of End-Stage Renal Disease Patients on Dialysis Receiving Radioactive Iodine Treatment. <b>2021</b> , 46, 977-982	0
306	Cost-Effectiveness of Follow-up Ultrasound for Incidental Thyroid Nodules on CT. <b>2021</b> ,	0
305	Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers. <b>2021</b> , 57,	0
304	Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine. <b>2021</b> , 10, 7610-7619	1
303	Radioiod- und TSH-suppressive Schilddr�senhormon-Therapie beim differenzierten Schilddr�senkarzinom. <b>2000</b> , 359-364	

302 Papillary Carcinoma. **2000**, 185-192

301 Schilddrüse. **2000**, 27-202

300 Papillary Thyroid Cancer. **2000**, 263-265

299 Radioiodine Therapy of Thyroid Cancer. **2000**, 147-153

2

298 Differentiated Thyroid Carcinoma. **2000**, 213-220

297 Clinical Aspects of Miscellaneous and Unusual Types of Thyroid Cancers. **2000**, 421-451

296 Thyroid Cancer: Treatment with Thyroid Hormone. **2001**, 131-138

295 Histopathology, Immunohistochemistry, and Molecular Biology. **2001**, 27-53

294 Thyroid. **2001**, 879-895

1

293 Radioiodine Therapy for Thyroid Cancer. **2001**, 93-120

1

292 Surgical Diseases of the Thyroid and Parathyroid Glands. **2001**, 281-300

291 Schilddrüse. **2001**, 103-154

290 Tireoidectomia unilateral no carcinoma diferenciado da tireóide de baixo risco: uma cirurgia inadequada. **2001**, 28, 181-187

289 The sentinel lymph node concept in thyroid carcinoma: Preliminary results. **2002**, 10, 197-198

0

288 Metastatic Bone Disease. **2002**, 695-715

287 [Principles of lymph node surgery in differentiated thyroid carcinoma]. **2003**, 50, 97-102

286 Principles of surgery for thyroid carcinoma. **2003**, 11, 175-177

285 Papillary thyroid carcinoma. **2003**, 50, 78-83

- 284 Prognostic factors in differentiated thyroid carcinoma. **2003**, 11, 181-182
- 283 Thyroid Malignancies. **2003**, 609-625
- 282 Surgery for Differentiated Thyroid Cancer. **2003**,
- 281 Postoperative Adjuvant Therapy and Follow-Up of Thyroid Carcinoma. **2004**, 47, 1183
- 280 Recent Trends in the Surgical Treatment of Thyroid Cancer. **2004**, 47, 1152
- 279 Thyroid Cancer. **2005**, 431-444
- 278 Levothyroxine Therapy and Thyrotropin Suppression. **2006**, 293-296
- 277 Miscellaneous and Unusual Types of Thyroid Tumors. **2006**, 553-569
- 276 Schilddrüsenkarzinom. **2006**, 41-65
- 275 Low Iodine Diets. **2006**, 677-681
- 274 Thyroid Nodules and Cancer Risk. **2006**, 247-250
- 273 A Model for Predicting Outcomes in Patients With Differentiated Thyroid Cancer and Model Performance in Comparison With Other Classification Systems. **2006**, 2006, 277-283
- 272 External Radiation Therapy of Papillary Cancer. **2006**, 485-489
- 271 Alternative Options and Future Directions for Thyroid Cancer Therapy. **2006**, 665-670
- 270 Ultrasonic Imaging and Identification of Metastases in Cervical Lymph Nodes. **2006**, 351-358
- 269 Surgical Approach to Papillary Carcinoma. **2006**, 261-262
- 268 External Radiation Therapy of Follicular Carcinoma. **2006**, 545-548
- 267 Thyroid Diseases in the Elderly. **2006**, 491-500

- 266 Cancers thyroïdiens différenciés : comment optimiser les résultats à long terme ? À propos des résultats à 25 ans d'une série de 850 opérés. **2006**, 190, 89-109
- 265 Stunning Is Not a Problem. **2006**, 346-348
- 264 Differentiated Thyroid Cancer. **2007**, 53-91 0
- 263 Treatment of Differentiated Thyroid Carcinoma. **2007**, 45-75
- 262 Subsection Reports. **2007**, 92, s8-s47
- 261 Thyroid. **2008**, 1211-1228
- 260 THYROID GLAND. **2008**, 1074-1082
- 259 The Use of Lithium as an Adjuvant in Radioactive Iodine Treatment of Thyroid Cancer. **2009**, 1001-1006
- 258 Papillary Thyroid Carcinoma. **2009**, 361-381
- 257 Thyroid Cancer. **2009**, 117-124
- 256 Thyroid Cancer. **2009**, 623-629
- 255 The usefulness of 131I radioiodine to thyroid papillary carcinoma with extra thyroidal extension. **2009**, 35, 43-47
- 254 Follicular Carcinoma. **2009**, 383-397
- 253 Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer. **2009**, 1, 13-18 1
- 252 Clinical Analysis of Risk Factors Related to Recurrent Well Differentiated Thyroid Carcinoma. **2009**, 52, 431
- 251 Clinical Behavior of Papillary Thyroid Carcinoma Smaller than 1.5 cm. **2009**, 52, 599
- 250 Differentiated Thyroid Carcinoma. **2009**, 237-295
- 249 Differentiated thyroid cancers of follicular cell origin. **2010**, 153, 35-56 1

- 248 Thyroid Neoplasia. **2010**, 1668-1701 o
- 247 Nuclear Medicine in Oncology. **2010**, 30-59
- 246 Surgery of the Thyroid. **2010**, 1760-1782
- 245 Solitary Thyroid Nodule. **2010**, 223-236
- 244 Thyroid. **2010**, 111-122
- 243 Prognostic Factors and Therapeutic Strategies of Thyroid Carcinomas Originating from Follicular Cells. **2010**, 2, 53-62
- 242 PET-CT of Thyroid Cancer. **2011**, 209-225
- 241 Surgical Disorders of the Thyroid in the Elderly. **2011**, 421-437
- 240 Analysis of Papillary Thyroid Carcinoma with Multicentric Intraglandular Microscopic Lesions. **2011**, 104, 727-732
- 239 Cancer of the Thyroid. **2011**, 331-353 1
- 238 METASTATIC RISK FACTORS AND THERAPEUTIC STRATEGIES IN FOLLICULAR THYROID CARCINOMA. **2011**, 72, 555-559
- 237 Management of Thyroid and Parathyroid Cancers. **2011**, 555-568
- 236 Radioactive Iodine Therapy. **2012**, 243-270
- 235 The Thyroid Gland. **2012**, 53-163
- 234 Nonoperative Ablative Procedures for Recurrent Cancer. **2012**, 367-381
- 233 Postoperative Surveillance for Recurrent Malignant Disease. **2012**, 339-351
- 232 Systemic Treatment for Unresectable Thyroid Carcinoma: Comprehensive Approach. **2012**, 383-397
- 231 A case of pulmonary metastasis from papillary thyroid carcinoma resected 55 years earlier. **2012**, 26, 444-447



230 Surgery for Solitary Thyroid Nodule Including Differentiated Thyroid Cancer. **2012**, 207-214

229 Evaluation of Thyroid Nodules. **2012**, 59-76

228 Schilddrüse. **2013**, 29-227

227 CLINICAL STUDY OF THYROID MALIGNACIES AND THE ROLE OF SERUM TSH IN PREDICTING MALIGNANCIES. **2013**, 2, 8386-8392

1

226 Conservative Central Neck Dissection. **2014**, 85-92

225 Long-term Prognosis of Differentiated Thyroid Carcinoma. **2014**, 65, 234-240

2

224 Thyroid Disorders. **1997**, 491-510

223 Schilddrüsenkarzinome. **1998**, 476-495

222 The Role of Medical Imaging in the Diagnosis and Follow-Up of Recurrent or Metastatic Thyroid Cancer. **1998**, 207-232

221 Surgical Management of Thyroid Cancer. **1998**, 233-254

220 Thyroid Malignancies. **1999**, 977-1000

219 Thyroid Cancer. **1999**, 129-142

218 PECULIARITIES AND CHARACTERISTICS OF INDICATORS OF THYROID CANCER AMONG RESIDENTS OF TOMSK AND TOMSK REGION. **2014**, 13, 74-81

217 Liver Metastases in Thyroid Cancer. **2015**, 159-173

216 Observation of Papillary Thyroid Microcarcinoma Patient Treated with Acupuncture Alone. **2014**, 19, 53-59

1

215 Well-Differentiated Thyroid Cancer: Papillary, Follicular, and Oncocytic (Hürthle) Cell Cancer. **2015**, 83-97

214 A Study on Prognostic Factors of Papillary Thyroid Carcinoma. **2015**, 108, 213-220

213 Surgical Experience in the Management of 125 Patients with Thyroid Masses in Kashmir. **2015**, 04, 381-393

- 212 The evolving field of thyroid cancer: refinement of old and creation of new paradigms. **2015**, 59, 283-4
- 211 External Radiation Therapy for Follicular Carcinoma. **2016**, 807-810
- 210 Papillary Carcinoma: Clinical Aspects. **2016**, 359-370
- 209 Staging of Thyroid Cancer. **2016**, 105-117
- 208 Safety and Prognostic Impact of Prophylactic Level VII Lymph Node Dissection for Papillary Thyroid Carcinoma. **2015**, 16, 8425-30
- 207 Radioiodine Ablation as a Post-operative Adjuvant Therapy for Thyroid Cancer. **2016**, 77, 2875-2880
- 206 One-stage thyroidectomy with complete sternal removal and anterior chest wall resection for metastatic thyroid cancer. **2016**, 5, 47
- 205 Thyroid Hormone Therapy and Thyrotropin Suppression. **2016**, 427-432
- 204 Radionuclide Therapy of Thyroid Tumors. **2016**, 1-47
- 203 Low-Iodine Diets. **2016**, 1015-1019
- 202 Stunning Is Not a Problem. **2016**, 237-241
- 201 Evaluation of Thyroid Bed Sampling. **2016**, 323-337
- 200 External Radiation Therapy for Papillary Carcinoma. **2016**, 709-715
- 199 Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. **2016**, 1-40 1
- 198 Miscellaneous and Unusual Tumors of the Thyroid Gland. **2016**, 825-843
- 197 Prognosis in Papillary Thyroid Cancer. **2016**, 539-542
- 196 Utility of Second Surgery for Lymph Node Metastases. **2016**, 545-550
- 195 Custo-efetividade do uso da tomografia de emissão de pósitrons na detecção de recorrência do câncer diferenciado de tireoide. **2016**, 26, 331-356

- 194 Malignant tumors of the thyroid gland by oncologist - systemic treatment. **2016**, 10, 181-184
- 193 The Perceptual and Consonant Analysis for the Voice with Hypothyroidism. **2016**, 27, 95-101
- 192 Differentiated Thyroid Cancer: Prognostic and Risk Assessment Systems. **2017**, 189-204
- 191 Extradural Vertebral Tumors in the Elderly. **2017**, 247-276
- 190 The Thyroid Gland. **2017**, 61-177
- 189 Central Neck Dissection for Medullary Thyroid Carcinoma. **2017**, 91-109
- 188 Radionuclide Therapy of Thyroid Tumors. **2017**, 1197-1241 o
- 187 Surveillance of Treated Thyroid Cancer Patients and Thyroid Hormone Replacement and Suppression. **2017**, 331-350
- 186 Local and Systemic Treatment of Unresectable Disease. **2017**, 263-280
- 185 Cancer papillaire de la thyroïde : vers une d'escalade th'apeutique. **2017**, 201, 699-706
- 184 Thyroid carcinomas: the present view on diagnostics and therapy. **2017**, 63, 572-579 1
- 183 Management of Locally Advanced Thyroid Cancer. **2018**, 85-95
- 182 The Relationship of Age and Clinicopathologic Pattern to the Aggressiveness of Thyroid Cancer. **2018**, 09, 755-766
- 181 Surgical Approach to Thyroid Cancer. **2018**, 319-337
- 180 [Clinical, morphological, and prognostic features of papillary thyroid carcinoma with different BRAF mutational status assessed by immunohistochemistry]. **2018**, 80, 19-25 o
- 179 Evaluation of Ultrasonography Results in Terms of Involvement of Lymph Nodes before Thyroidectomy and Its Comparison with Pathologic Results after Thyroidectomy in Non-Medullary Thyroid Carcinoma Patients. **2018**, 18, 43-51
- 178 CLINICAL CASES OF THE EFFICACY OF THERAPY MULTIKINASE INHIBITORS OF METASTATIC RADIOID-REFRACTORY DIFFERENTIATED THYROID CANCER. **2018**, 12, 81-88
- 177 The Effect of Positive Surgical Margins After Thyroidectomy on Patient Prognosis in Cases with Differentiated Thyroid Carcinoma. **2019**, 263-268

- 176 Conservative surgery and the total thyroidectomy in well-Differentiated thyroid cancer. **2018**, 7,
- 175 Unusual loco-regional presentation in papillary carcinoma of thyroid: A case series. **2019**, 56, 325-329 1
- 174 Palliative Chirurgie maligner Schilddrüsentumoren. **2019**, 275-293
- 173 Thyroid Cancer. **2019**, 08, 217-270 4
- 172 Hybrid Imaging and Radionuclide Therapy for Thyroid Disorders. **2019**, 707-747
- 171 Level V lymph node metastasis in N1b papillary thyroid carcinoma patients: contributing factors and pattern of metastasis. **2019**, 32,
- 170 Central neck lymph node dissection for papillary thyroid cancer. **2019**, 9, 27-34 1
- 169 Selective use of radioactive iodine justifying "greater latitude to offer hemithyroidectomy" - 'Putting the cart before the horse'. **2019**, 45, 1750-1751
- 168 The Cause of Cervical Lymph Node Recurrence after the Initial Surgery of Papillary Thyroid Carcinoma. **2019**, 35, 11-17
- 167 Small Thyroid Nodule but Big Impact. **2020**, 9, 23 1
- 166 Tumors of the Thyroid Gland. **2020**, 505-514
- 165 Thyroid Cancer. **2020**, 345-456
- 164 Is the Internal Jugular Node Dissection without Level V Sufficient in Patients with Papillary Thyroid Carcinoma with Lateral Neck Node Metastasis?. **2020**, 20, 31
- 163 Diagnostic Accuracy of Ultrasound for the Evaluation of Lateral Compartment Lymph Nodes in Papillary Thyroid Carcinoma. **2020**, 16, 459-465
- 162 Treatment of a patient with differentiated thyroid carcinoma - a case report.. **2020**, 14, 92-97
- 161 Deep Learning in Thyroid Ultrasonography to Predict Tumor Recurrence in Thyroid Cancers. **2020**, 81, 1164 1
- 160 A Case of Cardiotoxicity Developed Under the Administration of Lenvatinib in a Thyroid Cancer Patient. **2020**, 113, 309-314
- 159 A Patient with Papillary Thyroid Carcinoma and Biochemical Evidence of Disease at Follow-Up Visits and Increasing Serum Tg Values at Follow-Up Assessments. **2021**, 119-129

- 158 Thyroid neoplasm in Makkah region, Saudi Arabia. A retrospective epidemiological study. **2020**, 41, 1330-1335 ○
- 157 BRAF V600E mutation correlates with aggressive clinico-pathological features but does not influence tumor recurrence in papillary thyroid carcinoma-10-year single-center results. **2020**, 9, 1902-1913 ○
- 156 Papillary Thyroid Cancer with Microscopic Extra-thyroidal Extension. **2021**, 41-53 2
- 155 2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations. **2021**, 22, 2094-2123 10
- 154 Thyroglobulin Measurement in Needle Aspiration for Detection of Recurrences and Neck Metastases in Patients with Differentiated Thyroid Carcinoma: Significance of Anti-Tg Antibodies. **2020**, 59, 9-17
- 153 Application of Ultrasonography in the Diagnosis and Management of Papillary Thyroid Microcarcinoma. **2020**, 4, 284 2
- 152 PET in Head and Neck Cancer. **2020**, 585-596
- 151 Differentiated Thyroid Cancer: Radioiodine Therapy. **2020**, 831-844 1
- 150 Association between BRAF mutation and the clinicopathological features in incidental papillary thyroid microcarcinoma: A single-center study in Turkish patients. **2020**, 7, 321-328 1
- 149 Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment. **2020**, 67, 1193-1198 1
- 148 Treatment for Recurrent Differentiated Thyroid Cancer: A Canadian Population Based Experience. **2020**, 12, e7122 2
- 147 Neck Lymph Node Metastasis Detection in Patients with Differentiated Thyroid Carcinoma (DTC) in Long-Term Follow-up: a <sup>125</sup>I-SPECT/CT Study.
- 146 Optimization of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9-12 months after treatment. **2021**, 5,
- 145 Neck Lymph Node Metastasis Detection in Patients with Differentiated Thyroid Carcinoma (DTC) in Long-Term Follow-up: a <sup>125</sup>I-SPECT/CT Study.
- 144 Tiroid Hastalıkları ve Erektile Disfonksiyon. ○
- 143 Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer. **2020**, 64, 115-123
- 142 Revision Thyroid Surgery.. **2022**, 13, 199-207
- 141 Surgery of Well-Differentiated Thyroid Carcinoma: The Pendulum Swings Back in the Central Neck. **2010**, 16, 913-917

140 Thyroid Neoplasms. **2003**, 74-85

139 Thyroid Disorders. **2003**, 695-717

1

138 Factors that Predict Cancer Recurrence and Death from Differentiated Thyroid Cancer. **2005**, 131-140

137 Effects of Suppressing Thyrotropin on Tumor Growth and Recurrence. **2005**, 263-266

136 Initial Thyroid Surgery for Patient with Differentiated Thyroid Carcinoma. **2006**, 135-147

135 Fertility Following Treatment with Iodine-131 for Thyroid Cancer. **2006**, 193-197

134 The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations. **2006**, 31-38

133 Histopathology, Immunohistochemistry, and Molecular Biology. **2005**, 29-56

132 The Current Surgical Approach to Non-Medullary Thyroid Cancer. **2005**, 83-92

0

131 Thyroid Cancer: Treatment with Thyroid Hormone. **2005**, 163-170

130 Medical Management of Thyroid Cancer. **2006**, 157-164

129 Papillary Thyroid Cancer. **2008**, 109-119

128 BRAFV600E Test for Suspicious Lateral Lymph Nodes in Papillary Thyroid Cancer. **2016**, 16, 36

127 Can We Omit Prophylactic Central Lymph Node Dissection in Patients with Clinically LN Negative Papillary Thyroid Microcarcinoma?. **2016**, 16, 79

126 Schilddrüsenkarzinom. 524-537

125 Diagnostic Imaging of the Thyroid and Radioiodine Therapy. **2007**, 31-44

124 Evaluation of Thyroid Nodules. **2007**, 45-60

123 Thyroid Cancer. **2008**, 95-107

122	The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer. <b>2013</b> , 2, 206-11	5
121	Recombinant thyrotropin for detection of recurrent thyroid cancer. <b>2002</b> , 113, 21-30	8
120	Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. <b>2002</b> , 113, 241-60	128
119	Presentation of problem-specific, text-based medical knowledge: XML and related technologies. <b>2001</b> , 259-63	
118	Analysis of medical-decision making and the use of standards of care in oncology. <b>2000</b> , 364-8	1
117	Differentiated thyroid cancer long-term impact of initial therapy. <b>1995</b> , 106, 151-68; discussion 168-70	32
116	Role of prophylactic central neck dissection in cN0 papillary thyroid cancer. <b>2009</b> , 29, 61-9	45
115	Current concepts and future directions in differentiated thyroid cancer. <b>2010</b> , 31, 9-19	17
114	<sup>99</sup> Tc nanocolloid sentinel node procedure in papillary thyroid carcinoma: our mono-institutional experience on a large series of patients. <b>2009</b> , 29, 321-5	11
113	Multi-targeted approach in the treatment of thyroid cancer. <b>2010</b> , 65, 59-69	17
112	BRAF mutation in papillary thyroid carcinoma. <b>2012</b> , 5, 310-5	30
111	Central neck dissection in differentiated thyroid cancer: technical notes. <b>2014</b> , 34, 9-14	12
110	The pros and cons of routine central compartment neck dissection for clinically nodal negative (cN0) papillary thyroid cancer. <b>2013</b> , 2, 186-95	13
109	Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. <b>2014</b> , 7, 5393-403	50
108	The expression of twist in differentiated thyroid carcinomas. <b>2014</b> , 40, 184-9	1
107	Radioactive Iodine Therapy and Glucose Tolerance. <b>2017</b> , 19, 184-193	3
106	CD44v8-10 and CD44s Are Age-dependently Expressed in Primary Cultured Papillary Thyroid Carcinoma Cells and Are Associated with Cell Proliferation. <b>2019</b> , 65, E1-E9	2
105	High expression of HAX-1 protein is associated with tumor growth in papillary thyroid carcinoma. <b>2018</b> , 11, 2080-2087	

104	Concurrent Anaplastic and Papillary Thyroid Carcinomas: A Case Report. <b>2020</b> , 8, 202-205	2
103	The Effect of BRAF Mutation on Lymph Node Involvement in Papillary Thyroid Cancer. <b>2020</b> , 36, 249-255	1
102	Imaging of Treated Thyroid and Parathyroid Disease. <b>2022</b> , 32, 145-157	0
101	Patterns of Occult Metastasis to Level Va and Vb in Clinically Lateral Node-Positive Papillary Thyroid Carcinoma. <b>2021</b> , 1	1
100	Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with -Mutant Advanced Papillary Thyroid Carcinoma. <b>2021</b> , 13,	2
99	Theranostische Liganden: Aktuelle und zukünftige Anwendungen. <b>2021</b> , 44, 369-374	
98	Noncoding RNAs in Papillary Thyroid Cancer: Interaction with Cancer-Associated Fibroblasts (CAFs) in the Tumor Microenvironment (TME) and Regulators of Differentiation and Lymph Node Metastasis. <b>2021</b> , 1350, 145-155	0
97	Radioguided surgery for intraoperative detection of occult lesions. <b>2021</b> ,	
96	The Effect of BRAF V600E Mutation on Lymph Node Involvement in Papillary Thyroid Cancer. <b>2020</b> , 36, 249-255	1
95	Papillary Thyroid Carcinoma. <b>2021</b> , 107-129	
94	Methylation-Driven Gene PLAU as a Potential Prognostic Marker for Differential Thyroid Carcinoma.. <b>2022</b> , 10, 819484	1
93	KSNM60 in Nuclear Endocrinology: from the Beginning to the Future.. <b>2022</b> , 56, 17-28	1
92	Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers.. <b>2022</b> , 13, 810681	0
91	Long-Term Efficacy of Ethanol Ablation as Treatment of Metastatic Lymph Nodes from Papillary Thyroid Carcinoma.. <b>2021</b> ,	0
90	[The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors]. <b>2008</b> , 59, 123-30	
89	Dosimetry of <sup>131</sup> I treatment in differentiated thyroid cancer. <b>2022</b> ,	
88	Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.. <b>2021</b> ,	5
87	Bone-density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy.. <b>2022</b> ,	1



- 86 Long-Term Outcome of Differentiated Thyroid Cancer Patients-Fifty Years of Croatian Thyroid Disease Referral Centre Experience.. **2022**, 12, 0
- 85 Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.. **2022**, 51, 9 0
- 84 Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis.. **2022**, 14, 1
- 83 Risk Factors and Prognosis for Metastatic Follicular Thyroid Cancer.. **2022**, 13, 791826 1
- 82 Teranóstica: conceptos y aplicaciones. **2022**, 33, 119-124
- 81 How Many Nodes to Take? Lymph Node Ratio Below 1/3 Reduces Papillary Thyroid Cancer Nodal Recurrence.. **2022**, 0
- 80 Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis.. **2021**, 14, 9707-9718
- 79 Prognostic significance of patient age in papillary thyroid carcinoma with no high-risk features.. **2022**, 1
- 78 FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.. **2022**, 1
- 77 Role of STAT3 Expression in Thyroid Cancer: A Meta-Analysis and Systematic Review Based on the Chinese Population.. **2022**, 2022, 1116535
- 76 Table\_1.DOCX. **2019**,
- 75 Data\_Sheet\_1.PDF. **2020**,
- 74 Data\_Sheet\_2.PDF. **2020**,
- 73 Table\_1.DOCX. **2020**,
- 72 Image\_1.TIF. **2020**,
- 71 Image\_2.TIF. **2020**,
- 70 Image\_3.TIF. **2020**,
- 69 Table\_1.XLSX. **2020**,

68	Table_2.XLSX. 2020,	
67	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. 2022, 1-40	
66	Radionuclide Therapy of Thyroid Tumors. 2022, 1-50	
65	Outcomes and Trends of Treatments in High-Risk Differentiated Thyroid Cancer.. 2022, 1945998221095720	
64	Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer.. 2022,	
63	The Cost and Financial Burden of Thyroid Cancer on Patients in the US: A Review and Directions for Future Research.. 2022,	2
62	Hepatopulmonary metastases from papillary thyroid microcarcinoma: A case report. 2022, 10, 4661-4668	
61	Is Gross Extrathyroidal Extension to Strap Muscles (T3b) Only a Risk Factor for Recurrence in Papillary Thyroid Carcinoma? A Propensity Score Matching Study. 2022, 14, 2370	0
60	Management of thyroid cancer. 34-45	2
59	Thyroid nodules: When to biopsy. 8-18	2
58	Long-term follow-up ultrasonography surveillance in a large cohort of patients with papillary thyroid carcinoma.. 2022,	0
57	Post-operative radioactive iodine administration in patients with low-risk thyroid cancer.	
56	Prognostic Utility of Tumor Stage versus American Thyroid Association Risk Class in Thyroid Cancer.	
55	Construction of an expression classifier based on an immune-related ten-gene panel for rapid diagnosis of papillary thyroid carcinoma risks. 2022, 17,	
54	A Narrative Review of Preventive Central Lymph Node Dissection in Patients With Papillary Thyroid Cancer -A Necessity or an Excess. 12,	1
53	Targeting Autophagy in Thyroid Cancer: EMT, Apoptosis, and Cancer Stem Cells. 10,	1
52	Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis. 13,	0
51	Patterns of Cyclin E, Retinoblastoma Protein, and p21Cip1/WAF1 Immunostaining in the Oncogenesis of Papillary Thyroid Carcinoma. 2005, 11, 1037-1043	2

50	Outcomes of reoperation for locoregional recurrence in radioactive-iodine refractory papillary thyroid carcinoma patients: a single-institution experience. <b>2022</b> , 30, 67-73	
49	Active surveillance of small metastatic lymph nodes as an alternative to surgery in selected patients with low risk papillary thyroid cancer: A retrospective cohort study.	0
48	Tumor mutation burden-assisted risk stratification for papillary thyroid cancer.	0
47	Strategies for Radioiodine Treatment: What's New. <b>2022</b> , 14, 3800	1
46	National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019. <b>2022</b> , 12,	1
45	Electrical based cancer therapy for solid tumours - Theranostics approach. <b>2022</b> , 11, 100214	
44	Radionuclide Therapy of Thyroid Tumors. <b>2022</b> , 1381-1429	0
43	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. <b>2022</b> , 643-682	0
42	A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence. <b>2022</b> , 14, 4128	1
41	Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.	0
40	Lymph Node Metastasis in Differentiated Thyroid Cancers.	0
39	Chronology of Thyroid Cancer.	0
38	Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma.	0
37	ENST00000438158 aids ultrasound for predicting lymph node metastasis and inhibits migration and invasion of papillary thyroid carcinoma cells. <b>2022</b> ,	0
36	Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers. <b>2022</b> , 12, 2381	0
35	Donafenib in Locally Advanced/Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (DIRECTION).	0
34	Radiologist versus Non-Radiologist Detection of Lymph Node Metastasis in Papillary Thyroid Carcinoma by Ultrasound: A Meta-Analysis. <b>2022</b> , 10, 2575	0
33	MEG3 Expression Indicates Lymph Node Metastasis and Presence of Cancer-Associated Fibroblasts in Papillary Thyroid Cancer. <b>2022</b> , 11, 3181	0

- 32 Papillary Thyroid Carcinoma Metastatic to the Frontal Sinus and Frontal Recess: Case Report. 014556132211294
- 31 Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine. ○
- 30 Predictive Value and Dynamic Risk Stratification of High Sensitive Basal or Stimulated Thyroglobulin Assay in a Long-term Thyroid Carcinoma Cohort. ○
- 29 High RPMB predicts poor disease-free survival of male N1 papillary thyroid cancer after adjuvant radioiodine therapy. **2022**, e11783 ○
- 28 Using particle swarm optimization and genetic algorithms for optimal control of non-linear fractional-order chaotic system of cancer cells. **2023**, 206, 538-560 3
- 27 The Association of Socioeconomic Factors and Well-Differentiated Thyroid Cancer. **2023**, 283, 973-981 ○
- 26 Prognostic Factors of Insular versus Papillary/Follicular Thyroid Carcinoma. **2004**, 70, 461-466 1
- 25 Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center. ○
- 24 The effect of thymectomy during central neck dissection in papillary thyroid carcinoma: a case-controlled study. ○
- 23 Bibliometric analysis of scientific publications of surgical procedures for papillary thyroid cancer. ○
- 22 Urinary Exosomal Tissue TIMP and Angiopoietin-1 Are Preoperative Novel Biomarkers of Well-Differentiated Thyroid Cancer. **2023**, 11, 24 ○
- 21 Role of 131I in low-risk differentiated thyroid cancer. **2022**, ○
- 20 Papel del 131I en el cáncer diferenciado de tiroides de bajo riesgo. **2022**, ○
- 19 Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up. ○
- 18 Optimal thyrotropin level for low-risk papillary thyroid carcinoma after ultrasound-guided radiofrequency ablation. **2023**, 40, ○
- 17 The efficacy of adjuvant radioactive iodine after reoperation in patients with persistent or recurrent differentiated thyroid cancer: a systematic review. **2024**, 408, ○
- 16 Screening and treatment of brain metastasis from papillary thyroid carcinoma: a case series. **2023**, 16, ○
- 15 Papillary Thyroid Carcinoma and Pregnancy: What Impact on Prognosis?. **2023**, 12, 22-29 ○

- 14 Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma. **2023**, 16,
- 13 Rare Columnar Cell Variant Papillary Thyroid Carcinoma with Metastasis to Pancreas and Lungs at Initial Presentation: A Case Report and Review of Literature.
- 12 A Novel Pyroptosis-Related Gene Signature for Prediction of Disease-Free Survival in Papillary Thyroid Carcinoma. **2023**, 13, 85
- 11 Clinical Application of the 2021 Korean Thyroid Imaging Reporting and Data System (K-TIRADS). **2023**, 84, 92
- 10 Clinical Significance of the Lymph Node Ratio of the Second Operation to Predict Re-Recurrence in Thyroid Carcinoma. **2023**, 15, 624
- 9 Management of Recurrent Well-Differentiated Thyroid Carcinoma in the Neck: A Comprehensive Review. **2023**, 15, 923
- 8 Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer (DTC). **2023**,
- 7 Prognostic factors for recurrence in patients with papillary thyroid carcinoma. 014556132311587
- 6 Predictive value and dynamic risk stratification of high sensitive basal or stimulated thyroglobulin assay in a long-term thyroid carcinoma cohort.
- 5 A Nod to the Nodes. **2023**, 32, 383-398
- 4 The preliminary study on the microwave ablation of multifocal papillary thyroid microcarcinoma.
- 3 The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer. 14,
- 2 Level II in lateral neck dissection for papillary thyroid carcinoma: A retrospective cohort study. **2023**,
- 1 Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response. 14,